<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">80273</article-id><article-id pub-id-type="doi">10.7554/eLife.80273</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Transient regulation of focal adhesion via Tensin3 is required for nascent oligodendrocyte differentiation</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-279743"><name><surname>Merour</surname><given-names>Emeric</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-279744"><name><surname>Hmidan</surname><given-names>Hatem</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="pa1">‡</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-279745"><name><surname>Marie</surname><given-names>Corentine</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-279746"><name><surname>Helou</surname><given-names>Pierre-Henri</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-279747"><name><surname>Lu</surname><given-names>Haiyang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-279748"><name><surname>Potel</surname><given-names>Antoine</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-279749"><name><surname>Hure</surname><given-names>Jean-Baptiste</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-279750"><name><surname>Clavairoly</surname><given-names>Adrien</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-279751"><name><surname>Shih</surname><given-names>Yi Ping</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-279752"><name><surname>Goudarzi</surname><given-names>Salman</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-279753"><name><surname>Dussaud</surname><given-names>Sebastien</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5365-8338</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-279754"><name><surname>Ravassard</surname><given-names>Philippe</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-279755"><name><surname>Hafizi</surname><given-names>Sassan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4539-0888</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-279756"><name><surname>Lo</surname><given-names>Su Hao</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2675-9387</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-1762"><name><surname>Hassan</surname><given-names>Bassem A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9533-4908</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-143163"><name><surname>Parras</surname><given-names>Carlos</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0248-1752</contrib-id><email>carlos.parras@icm-institute.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02en5vm52</institution-id><institution>Paris Brain Institute, Sorbonne Université, Inserm U1127, CNRS UMR 7225, Hôpital Pitié‐Salpêtrière</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05rrcem69</institution-id><institution>Department of Biochemistry and Molecular Medicine, University of California, Davis</institution></institution-wrap><addr-line><named-content content-type="city">Davis</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03ykbk197</institution-id><institution>School of Pharmacy and Biomedical Sciences, University of Portsmouth</institution></institution-wrap><addr-line><named-content content-type="city">Portsmouth</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Nave</surname><given-names>Klaus-Armin</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a7f6w43</institution-id><institution>Max Planck Institute of Experimental Medicine</institution></institution-wrap><country>Germany</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Cheah</surname><given-names>Kathryn Song Eng</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02zhqgq86</institution-id><institution>University of Hong Kong</institution></institution-wrap><country>Hong Kong</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="present-address" id="pa1"><label>‡</label><p>Physiology and Pharmacology Department, College of Medicine, Al‐Quds University, Jerusalem, Palestine</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>10</day><month>10</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e80273</elocation-id><history><date date-type="received" iso-8601-date="2022-05-15"><day>15</day><month>05</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-06-27"><day>27</day><month>06</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-02-27"><day>27</day><month>02</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.02.25.481980"/></event></pub-history><permissions><copyright-statement>© 2022, Merour, Hmidan et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Merour, Hmidan et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-80273-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-80273-figures-v2.pdf"/><abstract><p>The differentiation of oligodendroglia from oligodendrocyte precursor cells (OPCs) to complex and extensive myelinating oligodendrocytes (OLs) is a multistep process that involves large-scale morphological changes with significant strain on the cytoskeleton. While key chromatin and transcriptional regulators of differentiation have been identified, their target genes responsible for the morphological changes occurring during OL myelination are still largely unknown. Here, we show that the regulator of focal adhesion, Tensin3 (Tns3), is a direct target gene of Olig2, Chd7, and Chd8, transcriptional regulators of OL differentiation. Tns3 is transiently upregulated and localized to cell processes of immature OLs, together with integrin-β1, a key mediator of survival at this transient stage. Constitutive <italic>Tns3</italic> loss of function leads to reduced viability in mouse and humans, with surviving knockout mice still expressing Tns3 in oligodendroglia. Acute deletion of <italic>Tns3</italic> in vivo, either in postnatal neural stem cells (NSCs) or in OPCs, leads to a twofold reduction in OL numbers. We find that the transient upregulation of Tns3 is required to protect differentiating OPCs and immature OLs from cell death by preventing the upregulation of p53, a key regulator of apoptosis. Altogether, our findings reveal a specific time window during which transcriptional upregulation of Tns3 in immature OLs is required for OL differentiation likely by mediating integrin-β1 survival signaling to the actin cytoskeleton as OL undergo the large morphological changes required for their terminal differentiation.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>oligodendrocyte differentiation</kwd><kwd>tensin</kwd><kwd>oligodendroglial survival</kwd><kwd>immature oligodedrocyte marker</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000890</institution-id><institution>National Multiple Sclerosis Society</institution></institution-wrap></funding-source><award-id>NMSS RG-1501-02851</award-id><principal-award-recipient><name><surname>Parras</surname><given-names>Carlos</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007379</institution-id><institution>Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques</institution></institution-wrap></funding-source><award-id>ARSEP 2014 2015 2018 2019 2020</award-id><principal-award-recipient><name><surname>Marie</surname><given-names>Corentine</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000381</institution-id><institution>Multiple Sclerosis Society</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Parras</surname><given-names>Carlos</given-names></name><name><surname>Marie</surname><given-names>Corentine</given-names></name><name><surname>Merour</surname><given-names>Emeric</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002915</institution-id><institution>Fondation pour la Recherche Médicale</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Marie</surname><given-names>Corentine</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>Sorbonne Universite</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Merour</surname><given-names>Emeric</given-names></name><name><surname>Hmidan</surname><given-names>Hatem</given-names></name><name><surname>Marie</surname><given-names>Corentine</given-names></name><name><surname>Clavairoly</surname><given-names>Adrien</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A comprehensive analysis of Tensin3 function in oligodendrogenesis links the fields of transcriptional control in oligodendrocyte lineage cells with morphogenetic changes and integrin signaling mediated cell survival.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Oligodendrocyte (OL) lineage cells, mainly constituted by oligodendrocyte precursor cells (OPCs) and OLs, play key roles during brain development and neuronal support by allowing saltatory conduction of myelinated axons and metabolically supporting these axons with lactate or glucose shuttling through the myelin sheath (<xref ref-type="bibr" rid="bib26">Fünfschilling et al., 2012</xref>; <xref ref-type="bibr" rid="bib41">Lee et al., 2012</xref>; <xref ref-type="bibr" rid="bib55">Meyer et al., 2018</xref>). Accumulating evidence also indicates their fundamental contribution to different aspects of adaptive myelination, a type of brain plasticity (<xref ref-type="bibr" rid="bib56">Mount and Monje, 2017</xref>; <xref ref-type="bibr" rid="bib81">Yang et al., 2020</xref>), shown by the requirement of new oligodendrogenesis for proper learning and memory in motor, spatial, and fear-conditioning learning paradigms (<xref ref-type="bibr" rid="bib54">McKenzie et al., 2014</xref>; <xref ref-type="bibr" rid="bib79">Xiao et al., 2016</xref>; <xref ref-type="bibr" rid="bib69">Steadman et al., 2019</xref>; <xref ref-type="bibr" rid="bib63">Pan et al., 2020</xref>; <xref ref-type="bibr" rid="bib76">Wang et al., 2020</xref>; <xref ref-type="bibr" rid="bib80">Xin and Chan, 2020</xref>). Furthermore, oligodendroglia and myelin pathologies have been recently linked not only to the development of glioma (<xref ref-type="bibr" rid="bib46">Liu et al., 2011</xref>) but to developmental (<xref ref-type="bibr" rid="bib12">Castelijns et al., 2020</xref>; <xref ref-type="bibr" rid="bib66">Phan et al., 2020</xref>), neurodegenerative (<xref ref-type="bibr" rid="bib28">Grubman et al., 2019</xref>; <xref ref-type="bibr" rid="bib8">Bryois et al., 2020</xref>), and psychiatric (<xref ref-type="bibr" rid="bib62">Nott et al., 2019</xref>) diseases.</p><p>Unlike most precursor cells, OPCs constitute a stable population of the postnatal and adult central nervous system (CNS) (<xref ref-type="bibr" rid="bib25">Ffrench-Constant and Raff, 1986</xref>; <xref ref-type="bibr" rid="bib73">Suzuki and Goldman, 2003</xref>). Therefore, OPCs need to keep a tight balance between proliferation, survival, and differentiation. This balance is crucial to maintain the OPC pool while contributing to myelin plasticity in adult life and to remyelination in diseases such as multiple sclerosis (MS). Demyelinated MS plaques can be normally repaired in early stages of the disease, presumably by endogenous OPCs, but this repair process becomes increasingly inefficient with aging, when OPC differentiation seems to be partially impaired (<xref ref-type="bibr" rid="bib14">Chang et al., 2002</xref>; <xref ref-type="bibr" rid="bib20">Compston and Coles, 2002</xref>; <xref ref-type="bibr" rid="bib60">Neumann et al., 2019</xref>). Therefore, understanding the mechanisms involved in OPC differentiation is critical to foster successful (re)myelination in myelin pathologies.</p><p>A large diversity of extrinsic signals, including those mediated by integrin signaling (reviewed in <xref ref-type="bibr" rid="bib5">Bergles and Richardson, 2016</xref>), as well as many intrinsic factors, including transcription factors (TFs) and chromatin remodelers (reviewed in <xref ref-type="bibr" rid="bib23">Emery and Lu, 2015</xref>; <xref ref-type="bibr" rid="bib64">Parras et al., 2020</xref>), are involved in OPC proliferation, survival, and differentiation. However, the mechanisms for how these signals balance OPC behavior is largely unknown. OPC differentiation requires profound changes in chromatin and gene expression (<xref ref-type="bibr" rid="bib23">Emery and Lu, 2015</xref>; <xref ref-type="bibr" rid="bib38">Küspert and Wegner, 2016</xref>; <xref ref-type="bibr" rid="bib77">Wheeler and Fuss, 2016</xref>). TFs, such as Olig2, Sox10, Nkx2.2, or Ascl1, are key regulators of OL differentiation by directly controlling the transcription of genes implicated in this process (<xref ref-type="bibr" rid="bib67">Qi et al., 2001</xref>; <xref ref-type="bibr" rid="bib70">Stolt et al., 2002</xref>; <xref ref-type="bibr" rid="bib58">Nakatani et al., 2013</xref>; <xref ref-type="bibr" rid="bib82">Yu et al., 2013</xref>), but being already expressed at the OPC stage, it is still unclear how these TFs control the induction of differentiation. A growing body of evidence suggests that some of these TFs work together with chromatin remodeling factors during transcriptional initiation/elongation to drive robust transcription (<xref ref-type="bibr" rid="bib83">Zaret and Mango, 2016</xref>). Accordingly, Olig2 and Sox10 TFs have been shown to cooperate with chromatin remodelers such as Brg1 (<xref ref-type="bibr" rid="bib82">Yu et al., 2013</xref>), Chd7 (<xref ref-type="bibr" rid="bib29">He et al., 2016</xref>; <xref ref-type="bibr" rid="bib50">Marie et al., 2018</xref>), Chd8 (<xref ref-type="bibr" rid="bib50">Marie et al., 2018</xref>; <xref ref-type="bibr" rid="bib86">Zhao et al., 2018</xref>), and EP400 (<xref ref-type="bibr" rid="bib22">Elsesser et al., 2019</xref>), to promote the expression of OL differentiation genes. To improve our understanding of the mechanisms of OL differentiation, we searched for novel common targets of these key regulators by generating and analyzing the common binding profiles of Olig2, Chd7, and Chd8 in gene regulatory elements of differentiating oligodendroglia. We identified <italic>Tns3</italic>, coding for the focal adhesion protein Tensin3, as one such target and showed that it is expressed in immature OLs (iOLs) during myelination and remyelination, thus constituting a marker for this transient oligodendroglial stage. Using different genetic strategies to induce <italic>Tns3</italic> loss-of-function mutations in vivo, we describe the function of a Tensin family member in the CNS, demonstrating that Tns3 is required for OL differentiation in the postnatal mouse brain, at least in part by mediating integrin-β1 signaling, essential for survival of differentiating oligodendroglia (<xref ref-type="bibr" rid="bib18">Colognato et al., 2002</xref>; <xref ref-type="bibr" rid="bib4">Benninger et al., 2006</xref>).</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title><italic>Tns3</italic> is a direct target gene of key regulators of oligodendrocyte differentiation</title><p>To find new factors involved in OL differentiation, we screened for target genes of Olig2, Chd7, and Chd8, key regulators of oligodendrogenesis (<xref ref-type="bibr" rid="bib47">Lu et al., 2000</xref>; <xref ref-type="bibr" rid="bib48">Lu et al., 2002</xref>; <xref ref-type="bibr" rid="bib82">Yu et al., 2013</xref>; <xref ref-type="bibr" rid="bib29">He et al., 2016</xref>; <xref ref-type="bibr" rid="bib50">Marie et al., 2018</xref>; <xref ref-type="bibr" rid="bib86">Zhao et al., 2018</xref>; <xref ref-type="bibr" rid="bib64">Parras et al., 2020</xref>). We generated and compared the genome-wide binding profiles for these factors in acutely purified oligodendroglial cells from postnatal mouse brain cortices by magnetic cell sorting (MACS) of O4<sup>+</sup> cells (<xref ref-type="bibr" rid="bib50">Marie et al., 2018</xref>). MACS-purified cells, composed of 80% PDGFRα<sup>+</sup> OPCs and 20% of Nkx2.2<sup>+</sup>/CC1<sup>+</sup> iOLs, were subjected to chromatin immunoprecipitation followed by sequencing (ChIP-seq) for Olig2 and histone modifications marking the transcription activity of gene regulatory elements (H3K4me3, H3K4me1, H3K27me3, and H3K27ac; <xref ref-type="fig" rid="fig1">Figure 1a</xref>). The profile of activity histone marks at Olig2-binding sites indicated that Olig2 binds promoters (60%) and enhancers (40%) with either active or more poised/repressive states (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1a–f</xref>), supporting the suggested pioneer function of Olig2 in oligodendrogenesis (<xref ref-type="bibr" rid="bib82">Yu et al., 2013</xref>). Among the 16,578 chromatin sites bound by Olig2 corresponding to 8672 genes (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1d</xref>), there were key regulators of OL differentiation, including <italic>Ascl1, Sox10, Myrf, Chd8,</italic> and <italic>Smarca4/Brg1</italic> (<xref ref-type="fig" rid="fig1">Figure 1b</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Combining Olig2 with Chd7 and Chd8 binding profiles, which we previously generated using the same protocol (<xref ref-type="bibr" rid="bib50">Marie et al., 2018</xref>), we found 1774 chromatin sites commonly bound by the three regulators, with half of them (47% and 832 peaks) corresponding to active promoters (H3K4me3/H3K27ac marks) of 654 protein-coding genes (<xref ref-type="fig" rid="fig1">Figure 1c</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Among these genes, <italic>Tns3</italic> coding for Tensin3, a focal adhesion protein deregulated in certain cancers (<xref ref-type="bibr" rid="bib52">Martuszewska et al., 2009</xref>), showed the highest expression levels in iOLs relative to other brain cell types (<xref ref-type="bibr" rid="bib85">Zhang et al., 2014</xref>; <xref ref-type="fig" rid="fig1">Figure 1d</xref>). Indeed, Olig2, Chd7, and Chd8 commonly bound three putative promoters of <italic>Tns3</italic> having active transcription marks in purified oligodendroglia (H3K27ac/H3K24me3; <xref ref-type="fig" rid="fig1">Figure 1e</xref>). To directly assess whether <italic>Tns3</italic> expression requires the activity of these key regulators, we interrogated the transcriptomes of these oligodendroglial cells purified from <italic>Chd7iKO</italic> (<italic>Pdgfra-CreER<sup>T</sup>; Chd7<sup>flox/flox</sup></italic>), <italic>Chd8cKO (Olig1<sup>Cre</sup>; Chd8 <sup>flox/flox</sup></italic>), and their respective control cortices (<xref ref-type="bibr" rid="bib50">Marie et al., 2018</xref>; <xref ref-type="bibr" rid="bib86">Zhao et al., 2018</xref>). <italic>Tns3</italic> transcripts were largely downregulated upon acute deletion of these factors in postnatal OPCs/iOLs (<xref ref-type="fig" rid="fig1">Figure 1f and g</xref>), indicating that <italic>Tns3</italic> expression in OPCs/iOLs is directly controlled by Chd7 and Chd8 chromatin remodelers, key regulators of OL differentiation.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title><italic>Tns3</italic> is a target gene of Olig2 and Chd7/8 regulators of oligodendrocyte differentiation.</title><p>(<bold>a</bold>) Scheme representing MACSorting of O4<sup>+</sup> cells from wild-type cortices followed by ChIP-seq for Olig2 and histone marks (H3K4me3, H3K27Ac, H3K4me1, and H3K27me3). (<bold>b</bold>) Tracks from IGV browser of <italic>Ascl1, Sox10, Pdgfra, Myrf,</italic> and <italic>Mbp</italic> gene regions depicting ChIP-seq data in O4<sup>+</sup> cells (OPCs/OLs) for transcription factor Olig2, chromatin remodelers Chd7 and Chd8, and epigenetic marks (H3K4me3, H3K27ac, H3K4me1, and H3K27me3). Mock (control IgG) shows no peaks in the regions of interest. Lines present below peaks indicate statistical significance (by peak calling). (<bold>c</bold>) Strategy used to identify <italic>Tns3</italic> as a gene target of Olig2, Chd7, and Chd8, potentially involved in oligodendrogenesis. Left: Venn diagrams depicting the overlap of binding peaks between Chd7 (blue), Chd8 (cyan), and Olig2 (purple) in O4<sup>+</sup> cells. Right: Venn diagram showing that 836 (47%) of the 1774 common regions have marks of active promoters, corresponding to 794 genes, including <italic>Tns3</italic>. (<bold>d</bold>) Heatmap representing the expression of the 794 genes in immature oligodendrocytes (iOLs) compared to oligodendrocyte precursor cells (OPCs), myelinating oligodendrocytes (mOLs), astrocytes, and neurons. <italic>Tns3</italic> is the third most specific (data from <xref ref-type="bibr" rid="bib85">Zhang et al., 2014</xref>). (<bold>e</bold>) Tracks from IGV browser of <italic>Tns3</italic> gene region depicturing ChIP-seq data in O4<sup>+</sup> cells (OPCs/OLs) for transcription factor Olig2 and epigenetic marks (H3K4me3, H3K27ac, H3K4me1, and H3K27me3), zooming in Tns3 alternative promoters. Mock (control IgG) shows no peaks in the regions of interest. Horizontal lines present below peaks indicate statistical significance (peak calling). (<bold>f, g</bold>) Barplots showing <italic>Tns3</italic> transcript count per million (CPM) in O4<sup>+</sup> cells upon tamoxifen-induced <italic>Chd7</italic> deletion (<italic>Chd7iKO</italic>), (<bold>f</bold>) or <italic>Chd8</italic> deletion (<italic>Chd8cKO</italic>), (<bold>g</bold>) compared to control (Ctrl). Statistics done using edgeR suite.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80273-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title><italic>Tns3</italic> is a target gene of Olig2 and Chd7/8 regulators of oligodendrocyte differentiation.</title><p>(<bold>a</bold>) Scheme representing MACSorting of O4<sup>+</sup> cells from wild-type cortices followed by ChIP-seq for histone marks H3K4me3, H3K27Ac, H3K4me1, and H3K27me3. (<bold>b</bold>) Schematic representing gene regulatory elements in O4<sup>+</sup> cells as active, poised, and repressed, according to their histone marks. (<bold>c</bold>) Left: diagram representing the classification of gene expression (data from <xref ref-type="bibr" rid="bib50">Marie et al., 2018</xref>). Right: pie chart representing percentage of medium-to-high, low or not expressed genes having an active, poised, and repressed promoter in O4<sup>+</sup> cells. Note the high percentage of medium-to-high expressed genes having active marks in their promoter and the high percentage of not expressed genes having repression marks in their promoter. (<bold>d</bold>) Venn diagram representing the method used to determine Olig2 binding peaks. As the quality of the peaks in replicate 2 was better than in replicate 1, we considered peaks common in both replicate and the peaks of replicate 2 that were present in regulatory elements (regions with histone marks). 16,578 peaks were found corresponding to 8672 genes bound by Olig2. (<bold>e</bold>) Gene Ontology category found enriched in Olig2-bound genes. (<bold>f</bold>) Pie chart representing the number and repartition of Olig2-binding sites in regulatory regions with different activity histone marks. Note that Olig2 binds in both promoters (60%) and enhancers (40%), and that it is found in either active, poised, or repressed regions. (<bold>g</bold>) Venn diagram representing the amount of Olig2-binding sites that are also bound by Chd7 and/or Chd8 (7674; Olig2 co-bound) or not (8894; Olig2 alone). (<bold>h, i</bold>) Pie chart representing the number and repartition of Olig2 co-bound (<bold>h</bold>) or alone (<bold>i</bold>) sites in regulatory regions with different activity histone marks. Note that 42% Olig2 co-bound sites are in active promoters, whereas 48% of Olig2 alone sites are in repressed promoter or enhancers.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80273-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Strong expression of <italic>Tns3</italic> transcripts in mouse and human immature oligodendrocytes.</title><p>(<bold>a</bold>) Barplot of Tns3 mRNA transcript levels (FKPM) in postnatal brain cell types (<xref ref-type="bibr" rid="bib85">Zhang et al., 2014</xref>; <ext-link ext-link-type="uri" xlink:href="https://www.brainrnaseq.org/">brainrnaseq.org</ext-link>). (<bold>b</bold>) In situ hybridization in sagittal section of the adult (P56) mouse brain at the level of the lateral ventricles showing <italic>Tns3</italic> transcript expression in sparse white matter cells (Allen Brain Atlas, <ext-link ext-link-type="uri" xlink:href="https://portal.brain-map.org/">portal.brain-map.org</ext-link>). (<bold>c</bold>) Uniform manifold approximation and projection (UMAP) representation of neural progenitors and oligodendroglial cells extracted and integrated using Seurat from scRNA-seq datasets (<xref ref-type="bibr" rid="bib51">Marques et al., 2016</xref>), representing different clusters corresponding to different oligodendroglial stages of neural stem cells (NSCs) to myelinating oligodendrocytes (mOLs). (<bold>d</bold>) Feature plot representing relative expression levels of <italic>Tns3</italic> transcript. (<bold>e</bold>) Dot plot representing the transcript expression of key markers for each cell stage/subtype and key oligodendroglial factors in the different clusters showing the predominant expression of <italic>Tns3</italic> in iOL1s and iOL2s clusters, similar to <italic>Enpp6</italic> and <italic>Itpr2</italic>. NPC, neural progenitor cells; cycOPC, cycling OPC; MFOL, myelin-forming OL; MOL1/2, myelinating OL 1/2. (<bold>f–h</bold>) <italic>TNS3</italic> expression in human oligodendroglial cells differentiated from iPSCs by scRNA-seq (<xref ref-type="bibr" rid="bib13">Chamling et al., 2021</xref>), showing <italic>TNS3</italic> high levels of expression in immature oligodendrocytes. (<bold>f</bold>) Uniform manifold approximation and projection (UMAP) representation showing six clusters (NSC, cycOPC, OPCs, and two iOL stages, iOL1 and iOL2, similar to mouse oligodendroglia). (<bold>g</bold>) Feature plot showing <italic>TNS3</italic> expression levels. (<bold>h</bold>) Dot plots showing <italic>TNS3</italic> expression pattern together with key markers of each cluster and regulators of oligodendrogenesis.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80273-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Strong expression of <italic>Tns3</italic> transcripts in immature oligodendrocytes (iOLs) of human fetal cerebellum.</title><p>(<bold>a</bold>) Uniform manifold approximation and projection (UMAP) representation of different cell-type cluster found in human fetal cerebellum (GW 9–22), including oligodendrocyte precursor cells (OPCs) and iOLs clusters (blue circle). (<bold>b</bold>) Feature plot representing relative expression levels of <italic>Tns3</italic> transcript, presenting high levels in iOL cluster cells (<bold>c</bold>) Dot plot representing the transcript expression of key markers for each cell stage/subtype and key oligodendroglial factors in the different clusters showing the predominant expression of <italic>TNS3</italic> in iOLs clusters (OPC and iOL clusters highlighted by blue rectangle). (<bold>d</bold>) UMAP representation of new clustering of oligodendroglial cells (11-OPC and 12-iOL clusters) showing OPCs, cycling (cyc) OPCs, and iOLs. (<bold>e</bold>) Feature plot representing relative expression levels of <italic>TNS3</italic> transcript showing highest levels in iOL cells. (<bold>f</bold>) Dot plot showing <italic>TNS3</italic> expression pattern together with key markers of each cluster and regulators of oligodendrogenesis, showing similar expression pattern of <italic>TNS3</italic> and other suggested iOL markers (including <italic>ITPR2, ENPP6,</italic> and <italic>BCAS1</italic>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80273-fig1-figsupp3-v2.tif"/></fig></fig-group></sec><sec id="s2-2"><title><italic>Tns3</italic> transcripts are highly expressed in mouse and human immature oligodendrocytes</title><p>We then investigated <italic>Tns3</italic> expression pattern in the brain. High expression levels of <italic>Tns3</italic> transcripts in iOLs, compared to its low expression in other cells of the postnatal mouse brain detected by bulk transcriptomics (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2a</xref>; <xref ref-type="bibr" rid="bib85">Zhang et al., 2014</xref>), were paralleled by the sparse labeling with <italic>Tns3</italic> probes enriched in the white matter of the postnatal and adult brain detected by in situ hybridization (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2b</xref>; Allen Brain Atlas, <ext-link ext-link-type="uri" xlink:href="https://portal.brain-map.org/">https://portal.brain-map.org/</ext-link>). By harnessing single-cell transcriptomics (scRNA-seq), we sought to create an integrative gene profiling for OL lineage cells by bioinformatics integration and analyses of OL lineage cells at embryonic, postnatal, and adult stages (<xref ref-type="bibr" rid="bib51">Marques et al., 2016</xref>). We thus integrated these datasets using Seurat (<xref ref-type="bibr" rid="bib71">Stuart et al., 2019</xref>) and selected 5516 progenitor and oligodendroglial cells. Unsupervised clustering and visualization of cells in two dimensions with uniform manifold approximation and projection (UMAP) identified nine different clusters following a differentiation trajectory. Based on known cell-subtype-specific markers (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2e</xref> and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>), we could identify these clusters as (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2c and e</xref>): (1) two types of neural stem/progenitor cells, which we named NSCs and NPCs according to their expression of stem cell (<italic>Vim, Hes1, Id1</italic>) and neural progenitor (<italic>Sox11, Sox4, Dcx</italic>) markers; (2) OPCs expressing their known markers (<italic>Pdgfra, Cspg4, Ascl1</italic>) and cycling OPCs also enriched in cell cycle markers (<italic>Mki67, Pcna, Top2</italic>); (3) two stages of iOLs, both expressing the recently proposed markers <italic>Itpr2</italic> and <italic>Enpp6</italic> (<xref ref-type="bibr" rid="bib51">Marques et al., 2016</xref>; <xref ref-type="bibr" rid="bib79">Xiao et al., 2016</xref>), and which are split by the expression of <italic>Nkx2-2</italic> (iOL1 being <italic>Nkx2-2</italic><sup>+</sup> and iOL2 being <italic>Nkx2-2</italic><sup>-</sup>), in agreement with our previous characterization by immunofluorescence (<xref ref-type="bibr" rid="bib58">Nakatani et al., 2013</xref>; <xref ref-type="bibr" rid="bib50">Marie et al., 2018</xref>); (4) myelin-forming oligodendrocytes (MFOLs), enriched in markers such as <italic>Slc9a3r2</italic> and <italic>Igsf8</italic>; and (5) two clusters of myelinating OLs, which we named MOL1 and MOL2, expressing transcripts of myelin proteins (<italic>Cnp, Mag, Mbp</italic>, <italic>Plp1</italic>, <italic>Mog</italic>) and some specific markers of each cluster, including <italic>Mgst3, Pmp22</italic> for MOL1 (corresponding to MOL1/2/3/4 clusters of <xref ref-type="bibr" rid="bib51">Marques et al., 2016</xref>), and <italic>Neat1</italic>, <italic>Grm3</italic>, <italic>Il33</italic> for MOL2 (corresponding to MOL5/6 clusters of <xref ref-type="bibr" rid="bib51">Marques et al., 2016</xref>). Interestingly, <italic>Tns3</italic> transcripts were strongly expressed in both iOL1 and iOL2 clusters (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2d and e</xref>), similar to the recently proposed iOL markers <italic>Itpr2</italic> and <italic>Enpp6</italic> (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2e</xref>), and downregulated in mature/terminally differentiated OLs, indicating that high levels of <italic>Tns3</italic> expression are specific to iOLs. We finally assessed whether <italic>Tns3</italic> expression pattern was conserved in human oligodendroglia pursuing a similar bioinformatics analysis using single-cell transcriptomes from human oligodendroglia differentiated from embryonic stem cells (<xref ref-type="bibr" rid="bib13">Chamling et al., 2021</xref>). Upon integration with Seurat and identification of cluster cell types using specific markers, we selected 7690 progenitor and oligodendroglial cells that corresponded to six main cluster cell types following a differentiation trajectory from neural cells (NSCs) up to iOLs (iOL1 and iOL2), as depicted by UMAP representation (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2f and h</xref>). Cells expressing high levels of <italic>TNS3</italic> corresponded to iOLs (iOL1 and iOL2 clusters, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2g and h</xref>). We obtained similar results analyzing a human fetal midterm cerebellum (GW9-GW22) dataset (<xref ref-type="bibr" rid="bib1">Aldinger et al., 2021</xref>), with high levels of <italic>TNS3</italic> in iOLs similar to other suggested iOL markers such as <italic>ITPR2</italic>, <italic>ENPP6,</italic> and <italic>BCAS1,</italic> indicating a conserved expression pattern of Tns3/TNS3 between mouse and human oligodendrogenesis (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>).</p></sec><sec id="s2-3"><title>Tns3 protein is enriched in the cytoplasm and processes of immature oligodendrocytes</title><p>Given the high expression level of <italic>Tns3</italic> transcripts in iOLs, we characterized the Tns3 protein expression pattern in the postnatal brain using commercial and homemade Tns3-recognizing antibodies. Optimization of immunofluorescence protocols demonstrated signal in CC1<sup>+</sup> OLs in the postnatal brain with four different antibodies (P24, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). To our surprise, while all antibodies showed signal localized in the cytoplasm and main processes of CC1+ OLs (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1a–d</xref>), one Tns3-recognizing antibody (Millipore) also presented a strong nuclear signal (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1d</xref>) never reported for Tns3 localization in other tissues (such as lung, liver, and intestine) (<xref ref-type="bibr" rid="bib35">Katz et al., 2007</xref>; <xref ref-type="bibr" rid="bib61">Nishino et al., 2012</xref>; <xref ref-type="bibr" rid="bib10">Cao et al., 2015</xref>). To better characterize Tns3 protein expression pattern and its subcellular localization, we generated a knock-in mice tagging the Tns3 C-terminal side with a V5-tag (<italic>Tns3<sup>Tns3</sup></italic><sup>-V5</sup> mice) by microinjecting mouse zygotes with a single-strand oligodeoxynucleotide (ssODN) containing V5 sequence together with Cas9 protein and a gRNA targeting the stop codon region of <italic>Tns3</italic> (‘Materials and methods’; <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2a–c</xref>). We first verified by immunofluorescence that Tns3-V5 protein in <italic>Tns3<sup>Tns3</sup></italic><sup>-V5</sup> mice presented the expression pattern reported for Tns3 in the lung and the kidney (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2d and e</xref>). We then characterized Tns3 protein expression in oligodendroglia using V5 antibodies, finding that Tns3 protein can be detected at high levels in the cytoplasm and main processes of CC1<sup>+</sup> iOLs but not in their nuclei (<xref ref-type="fig" rid="fig2">Figure 2a</xref>). Using an antibody recognizing Itpr2, a suggested iOL marker (<xref ref-type="bibr" rid="bib51">Marques et al., 2016</xref>), we saw that Tns3 largely overlapped with Itpr2 (<xref ref-type="fig" rid="fig2">Figure 2b</xref>). Using Nkx2.2 and Olig1<sup>cytoplamic</sup> expression distinguishing iOL1 and iOL2, respectively, we found high levels of Tns3 in iOL1s (Nkx2.2<sup>+</sup>/Olig1<sup>-</sup> cells) and a fraction of iOL2s (Nkx2.2<sup>-</sup>/Olig1<sup>cytoplamic</sup> cells; <xref ref-type="fig" rid="fig2">Figure 2c, i and j</xref>), suggesting that Tns3 protein expression peaks in early iOLs. Comparison with Opalin protein localized in the cell body, processes, and myelin segments of OLs showed that Tns3 levels decreased with increasing levels of Opalin, with Tns3-V5 levels undetectable in myelinating OLs (i.e., Opalin<sup>+</sup>/CC1<sup>+</sup> cells presenting myelinated segments; <xref ref-type="fig" rid="fig2">Figure 2d</xref>, arrowheads). We then performed Western blot analysis with anti-V5 antibodies in purified O4<sup>+</sup> cells from P7, P14, and P21 <italic>Tns3<sup>Tns3</sup></italic><sup>-V5</sup> mouse brains to assess their specificity to recognize Tns3-V5, knowing that two Tns3 isoforms can be detected at the transcript level in the human brain (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2f</xref>, GTEX project, <ext-link ext-link-type="uri" xlink:href="http://www.gtexportal.org/home/gene/TNS3">gtexportal.org/home/gene/TNS3</ext-link>). Indeed, we could detect both the full-length (1450 aa, 155 kDa) and the Tns3 short (C-term, 61 kDa) isoforms in O4<sup>+</sup> cells from brains at P7 and P14 stages having many iOLs, but not at P21 having mainly mOLs (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2g and h</xref>), thus validating the specificity of the anti-V5 antibodies in recognizing Tns3 protein. We eventually found a Tns3 antibody also recognizing the C-terminal of Tns3 protein (Sigma Ct) that upon optimized immunofluorescence labeling confirmed the Tns3 expression pattern seen with the V5 antibodies. In combination with Nkx2.2 and Olig1 immunofluorescence, it showed that Tns3 is strongly detected in the cytoplasm and main cellular processes of all iOL1s, defined as Nkx2.2<sup>high</sup>/Olig1<sup>-</sup> cells having a round nucleus and small cytoplasm (<xref ref-type="fig" rid="fig2">Figure 2e, i and j</xref>, white arrows), and it divided iOL2s, defined as Nkx2.2<sup>-</sup>/CC1<sup>high</sup> cells, into three stages: (1) Tns3<sup>high</sup>/Nkx2.2<sup>-</sup>/Olig1<sup>-</sup> (<xref ref-type="fig" rid="fig2">Figure 2e, i and j</xref>, arrowheads), (2) Tns3<sup>high</sup>/Nkx2.2<sup>-</sup>/Olig1<sup>high-cytoplamic</sup> (<xref ref-type="fig" rid="fig2">Figure 2e, i and j</xref>, gray arrows), and (3) Tns3<sup>-</sup>/Nkx2.2<sup>-</sup>/ Olig1<sup>high-cytoplamic</sup> (<xref ref-type="fig" rid="fig2">Figure 2e, i and j</xref>). A similar Tns3 expression pattern and localization was found in vitro using neonatal neural progenitors’ differentiating cultures, where Tns3 was detected together with CNP myelin protein in the cytoplasm and cell processes of Nkx2.2<sup>high</sup>/CNP<sup>+</sup> differentiating OLs (<xref ref-type="fig" rid="fig2">Figure 2f and g</xref>). Altogether, these results indicate that high but transient levels of Tns3 protein characterize early iOLs (iOL1s and early iOL2s), being localized at their cytoplasm and cell processes (<xref ref-type="fig" rid="fig2">Figure 2h and k</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Tns3 protein is detected at high levels in the cytoplasm and main cell processes of immature oligodendrocytes (iOLs) in the postnatal brain.</title><p>Immunofluorescence in sagittal sections of postnatal brain at the level of the corpus callosum at P14 (<bold>a–c</bold>) and P21 (<bold>d-e</bold>) using V5 and Tns3 antibodies. (<bold>a</bold>) Tns3-V5 is detected at high levels in CC1<sup>+</sup> OLs (arrows) but not in PDGFRα<sup>+</sup> oligodendrocyte precursor cells (OPCs). (<bold>b</bold>) Tns3-V5 expression overlaps well with Itpr2 (arrows), with some of them being Olig1<sup>high-cytoplamic</sup> cells. (<bold>c</bold>) Tns3-V5 overlaps with high levels of Nkx2.2 expression (arrows) and also with Nkx2.2<sup>-</sup>/Olig1<sup>high-cytoplamic</sup> cells (arrowheads). (<bold>d</bold>) Tns3-V5 expression overlaps with Opalin in iOLs (arrows, CC1<sup>+</sup> cells with large cytoplasm) but is downregulated in Opalin<sup>+</sup> myelinating oligodendrocytes (mOLs) (arrowheads, CC1<sup>+</sup> cells with small cytoplasm and myelin segments). (<bold>e</bold>) Tns3 (Sigma-Ct antibody) is detected at high levels in Nkx2.2<sup>+</sup>/Olig1<sup>-</sup> early iOL1s (white arrows), in late Nkx2.2<sup>-</sup>/Olig1<sup>-</sup> iOL1s (white arrowheads), and in Nkx2.2<sup>-</sup>/Olig1<sup>high-cytoplamic</sup> iOL2s (gray arrows). (<bold>f</bold>) Tns3-V5 expression neural stem cell (NSC) cultures after 5 days in differentiation. Note the Tns3 expression in Nkx2.2<sup>+</sup>/CNP<sup>+</sup> OLs (arrows). (<bold>g</bold>) Subcellular localization of Tns3 expression in CNP<sup>+</sup> OLs present in the cytoplasm and in dots distributed along the cell processes, overlapping with CNP signal (arrows). (<bold>h</bold>) Schematic representation of Tns3 expression together with key markers of different oligodendroglial stages summarizing data shown in (<bold>a–e</bold>). (<bold>i</bold>) Histograms representing the percentage of Nkx2.2<sup>-</sup>/Olig1<sup>high-nuclear</sup>, Nkx2.2<sup>high</sup>/Olig1<sup>-</sup>, Nkx2.2<sup>low</sup>/Olig1<sup>low-cytoplamic</sup> and Nkx2.2<sup>-</sup>/Olig1<sup>high-cytoplamic</sup> cells expressing Tns3-V5 and Tns3 at P14. (<bold>j</bold>) Histograms representing the percentage of Tns3-V5<sup>+</sup> and Tns3<sup>+</sup> cells at P14 that are Nkx2.2<sup>-</sup>/Olig1<sup>high-nuclear</sup>, Nkx2.2<sup>high</sup>/Olig1<sup>-</sup>, Nkx2.2<sup>low</sup>/Olig1<sup>low-cytoplamic</sup> and Nkx2.2<sup>-</sup>/Olig1<sup>high-cytoplamic</sup>. (<bold>k</bold>) Schematic representation of Tns3 expression and subcellular localization in oligodendroglia. Scale bars: (<bold>a–f</bold>) 20 μm; (<bold>g</bold>) 10 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80273-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Immunodetection of Tns3 protein in immature oligodendrocytes (OLs) of the postnatal brain.</title><p>(<bold>a–d</bold>) Tns3 expression in CC1<sup>+</sup> OLs (arrows) at the level of the corpus callosum (CC) of P24 mice, using a homemade antibody from Sassan Hafizi lab (University of Portsmouth) (<bold>a</bold>), and commercial antibodies from Santa Cruz (<bold>b</bold>), Thermo Fisher (<bold>c</bold>), and Millipore (<bold>d</bold>). Note that Millipore antibody is the only one to show clear nuclear localization in OLs. Thermo Fisher and Millipore antibodies also recognize a nuclear signal in cortical neurons (<bold>c, d</bold>, stars), not found with other Tns3 antibodies. Scale bar, 20 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80273-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Generation of <italic>Tns3<sup>Tns3-V5</sup></italic> knock-in mice.</title><p>(<bold>a</bold>) Scheme of V5 tag knock-in strategy in mice. (<bold>b</bold>) Schematic of Tns3 protein with a V5 tag at the C-terminal. (<bold>c</bold>) Nucleotide sequence of a wild-type mice <italic>Tns3</italic> 3′ region (upper), of the targeting single-strand oligodeoxynucleotide (ssODN) vector (middle), and of the 3′ region of the first Tns3<sup>Tns3-V5</sup> knock-in mice generated (lower). (<bold>d, e</bold>) Immunostaining using V5 antibody in kidney (<bold>d</bold>) and lung (<bold>e</bold>) of P14 <italic>Tns3<sup>Tns3-V5</sup></italic> mice. Note the expression of Tns3 in kidney glomeruli and lung alveolar cells (<bold>f</bold>) Schematic of the exons present in the two main <italic>TNS3</italic> transcript isoforms expressed in the human brain (<ext-link ext-link-type="uri" xlink:href="http://www.gtexportal.org/home/gene/TNS3">gtexportal.org/home/gene/TNS3</ext-link>). A dark color is associated with higher expression. (<bold>g</bold>) Western blots of V5 antibody in O4<sup>+</sup> MACSorted cells from P7 oligodendrocyte precursor cells (OPCs)/immature oligodendrocytes (iOLs) (left), P14 iOLs (middle), and P21 OLs (right) of <italic>Tns3<sup>Tns3-V5</sup></italic> mouse brains. Bottom: actin loading control. Note the presence of the full-length isoform only in OPC/iOLs. (<bold>h</bold>) Schematic of Tns3 protein brain isoforms and their interactions with actin and integrins. Scale bar, 20 μm.</p><p><supplementary-material id="fig2s2sdata1"><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>Anti-V5 Western blot followed by anti-actinWestern blot at P7, P14 and P21.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80273-fig2-figsupp2-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80273-fig2-figsupp2-v2.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Tns1 and Tns2 proteins are detected at low levels in immature oligodendrocytes (OLs).</title><p>Immunofluorescence in sagittal section of P24 mouse brain. Tns1 (<bold>a</bold>) and Tns2 (<bold>b</bold>) immunodetection in CC1<sup>+</sup> OLs of the corpus callosum. Tns1 is detected in the cytoplasm and excluded from OL nucleus (<bold>a<sub>1</sub></bold>), as is Tns2 (<bold>b<sub>1</sub></bold>). (<bold>c</bold>) <italic>Tns1</italic>, <italic>Tns2,</italic> and <italic>Tns3</italic> mRNA expression in postnatal brain (<ext-link ext-link-type="uri" xlink:href="https://www.brainrnaseq.org/">brainrnaseq.org</ext-link>). Note that <italic>Tns3</italic> is the main Tensin expressed in oligodendroglia. Scale bar, 20 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80273-fig2-figsupp3-v2.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title>Tns3 is expressed in newly formed oligodendrocytes (OLs) during adult brain remyelination.</title><p>(<bold>a, b</bold>) Tns3-expressing cells in the corpus callosum (CC) of adult (P90) mice, 7 days after chemically induced demyelination, showing strong Tns3 expression in CC1<sup>+</sup>/Olig1<sup>-</sup> iOL1s (arrowheads) and CC1<sup>+</sup>/Olig1<sup>cytoplasmic</sup> iOL2s (arrows) around the lesion using either anti-V5 antibody in <italic>Tns3<sup>Tns3</sup></italic><sup>-V5</sup> mice (<bold>a–a<sub>1</sub></bold>) or anti-Tns3 antibody in wild-type mice (<bold>b–b<sub>1</sub></bold>). Note the absence of CC1<sup>+</sup>/Olig1<sup>+</sup> OLs in the lesion. (<bold>c–c<sub>1</sub></bold>) Tns3 expression in CC1<sup>high</sup> iOLs (arrows) around the lesion and in some F4/80<sup>+</sup> microglia (arrowheads) in the lesion area. (<bold>a<sub>1</sub>), (b<sub>1</sub></bold>), and (<bold>c<sub>1</sub></bold>) are higher magnification of corresponding insets (squares). (<bold>d</bold>) Quantification of the Tns3<sup>+</sup> OLs density each 50 μm distance away from the lesion. Scale bar, 20 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80273-fig2-figsupp4-v2.tif"/></fig></fig-group><p>Finally, we investigated whether other Tensin family members were expressed in oligodendroglia, finding that Tns1 and Tns2 but not Tns4 were detectable at low levels in iOLs by immunofluorescence (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3a and b</xref>), paralleling their low transcription levels compared to <italic>Tns3</italic> (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3c</xref>; <ext-link ext-link-type="uri" xlink:href="https://www.brainrnaseq.org/">brainrnaseq.org</ext-link>). Therefore, Tns3 appears to be the main Tensin expressed during OL differentiation, suggesting that Tns3 function in iOLs is likely to be evolutionarily selected, and thus of biological importance in oligodendrogenesis.</p></sec><sec id="s2-4"><title>Tns3 expression is found in immature oligodendrocytes during remyelination</title><p>Given the strong Tns3 expression in iOLs during postnatal myelination, we hypothesized that Tns3 expression could be enriched during remyelination in newly formed OLs contributing to remyelination. To test this hypothesis, we performed lysolecithin (LPC) focal demyelinating lesions in the corpus callosum of adult (P90) <italic>Tns3<sup>Tns3</sup></italic><sup>-V5</sup> and wild-type mice, and assessed for Tns3 expression at the peak of OL differentiation (8 days post-lesion) in this remyelinating model (<xref ref-type="bibr" rid="bib57">Nait-Oumesmar et al., 1999</xref>). We found that while non-lesioned adult brain regions contained only sparse Tns3<sup>+</sup> iOLs (CC1<sup>high</sup>/Olig1<sup>cyto-high</sup> cells), remarkably many Tns3<sup>+</sup> iOLs were detected in the remyelinating area using both V5 (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4a and c</xref>, arrows) and Tns3 antibodies (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4b</xref>, arrows). Quantification of Tns3<sup>+</sup> cells showed a clear increase in Tns3<sup>+</sup> iOLs around the lesion borders compared to the corpus callosum far from the lesion area (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4d</xref>), suggesting that Tns3 expression may be a useful marker of ongoing remyelination and lesion repair. Of note, we could also detect Tns3 expression in some microglia/macrophages in the lesion area using a combination of F4/80 antibodies (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4c</xref>, arrowheads). Altogether, all these data indicate that Tns3 expression peaks at the onset of OL differentiation, labeling iOLs during both myelination and remyelination.</p></sec><sec id="s2-5"><title>In vivo CRISPR-mediated <italic>Tns3</italic> loss of function in neonatal neural stem cells impairs oligodendrocyte differentiation</title><p>To explore the role of Tns3 in OL differentiation, we first utilized a <italic>Tns3</italic> gene trap mouse line (<italic>Tns3<sup>βgeo</sup></italic>; <xref ref-type="bibr" rid="bib17">Chiang et al., 2005</xref>) and two CRISPR-mediated indel mutation mice presumptively leading to Tns3 constitutive knockout. Analyses of these three mouse lines (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>; see ‘Materials and methods’ for details) showed both developmental lethality (in line with loss-of-function variants of TNS3 causing ~80% developmental mortality in the human population; <ext-link ext-link-type="uri" xlink:href="https://gnomad.broadinstitute.org">https://gnomad.broadinstitute.org</ext-link>; <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>; ‘Materials and methods’) and possible genetic compensation in Tns3 expression, making them inappropriate tools to study Tns3 function in oligodendrogenesis.</p><p>Given the tendency of cells to escape the <italic>Tns3</italic> loss of function upon constitutive knockout mutations, we decided to assess <italic>Tns3</italic> requirement during postnatal oligodendrogenesis by inducing in vivo acute <italic>Tns3</italic> deletion in few neural stem cells (NSCs) of the neonatal brain and tracing their cell progeny with a GFP reporter. For this, we combined the postnatal electroporation technique with CRISPR/Cas9 technology. First, we used our previously validated gRNAs targeting <italic>Tns3</italic> at the first coding ATG (exon 6; <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>; ‘Materials and methods’) inserting them in an integrative CRISPR/Cas9 plasmid also expressing the GFP reporter (<xref ref-type="fig" rid="fig3">Figure 3a</xref>), to transfect neonatal NSCs of the dorsal subventricular zone (SVZ), which generate a large number of oligodendroglial cells during the first postnatal weeks (<xref ref-type="bibr" rid="bib36">Kessaris et al., 2006</xref>; <xref ref-type="bibr" rid="bib58">Nakatani et al., 2013</xref>), and focused our study on glial cells by quantifying the GFP<sup>+</sup> progeny of targeted NSCs, outside the SVZ and located in the dorsal telencephalon 3 weeks later (P22, <xref ref-type="fig" rid="fig3">Figure 3b</xref>). The fate of GFP<sup>+</sup> cells was determined by immunodetection of GFP and glial subtype markers (CC1<sup>high</sup> for OLs, PDGFRα for OPCs, and CC1<sup>low</sup> and their unique branched morphology for astrocytes). Remarkably, brains electroporated with the CRISPR plasmids targeting <italic>Tns3</italic> had a twofold reduction in GFP<sup>+</sup> OLs compared to brains electroporated with control plasmids, while GFP<sup>+</sup> OPCs were found in similar proportions (<xref ref-type="fig" rid="fig3">Figure 3c, c’ and d</xref>). The proportion of GFP<sup>+</sup> astrocytes was increased by 1.5-fold, likely as a result of the large reduction in OLs, as the number of GFP<sup>+</sup> astrocytes was not changed (61.3 ± 10.9 in experimental versus 57.2 ± 11.8 in controls; <xref ref-type="fig" rid="fig3">Figure 3c, c’ and d</xref>). To assess whether the reduction in OLs from <italic>Tns3</italic>-deleted NSCs was the consequence of a reduction in OPCs generated, we assessed for possible changes in numbers, proliferation, and survival of OPC at P11, when most cortical OPCs have not yet started differentiation. We found no differences in the proportion of GFP cells being OPCs (<xref ref-type="fig" rid="fig3">Figure 3e</xref>), nor the proliferative status of GFP<sup>+</sup> OPCs (MCM2<sup>+</sup>/PDGFRα<sup>+</sup> cells; <xref ref-type="fig" rid="fig3">Figure 3f</xref>) between experimental and control brains, while the reduction of OLs was already marked (<xref ref-type="fig" rid="fig3">Figure 3e</xref>), indicating that loss of <italic>Tns3</italic> only affected the process of OPC differentiation into OLs.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>CRISPR-mediated <italic>Tns3</italic> mutation in neural stem cells (NSCs) reduces oligodendrocyte (OL) differentiation in the postnatal brain.</title><p>(<bold>a</bold>) Schematic of the CRISPR/Cas9 expression vector allowing Tol2-DNA integration driving Cas9 and GFP expression (from polycistronic 2A-mediated cleaved) from CAG promoter and sgRNA expression from U6 promoter. (<bold>b</bold>) Schematic of the dorsal subventricular zone (SVZ) NSC electroporation of CRISPR-plasmid at postnatal day 1 (P1) and traced neural cell-subtype progeny. (<bold>c, c’</bold>) Immunofluorescence of representative P22 sagittal sections of the dorsal telencephalon showing GFP<sup>+</sup> cells being either PDGFRα<sup>+</sup> oligodendrocyte precursor cells (OPCs) (arrowheads), CC1<sup>high</sup> OLs (arrows), or CC1<sup>low</sup> astrocytes (asterisks) progeny of P1 NSCs electroporated either with <italic>Ctrl</italic> plasmid (<bold>c</bold>) or <italic>Tns3-gRNA#1</italic> plasmid (<bold>c’</bold>). (<bold>d</bold>) Histograms showing the percentage of GFP<sup>+</sup> glial cell types found in <italic>Ctrl</italic>, <italic>gRNA#1</italic> or <italic>gRNA#2</italic> electroporated brains being PDGFRα<sup>+</sup>-OPCs, CC1<sup>high</sup>-OLs and CC1<sup>low</sup>-astrocytes. Note the twofold reduction of CC1<sup>+</sup> OLs in <italic>Tns3-gRNA</italic>-transfected brains, as illustrated in (<bold>c’</bold>) compared to (<bold>c</bold>). (<bold>e</bold>) Histograms representing the percentage of GFP<sup>+</sup> differentiated cells at P11. Note the lack of changes in OPCs, and the incipient reduction in OLs. (<bold>f</bold>) Histograms quantifying the proportion of proliferative (MCM2<sup>+</sup> cells) GFP<sup>+</sup> OPCs in electroporated P11 mice brain. (<bold>g</bold>) Schematic of Tns3 expression in mice (upper) and of the effects of <italic>Tns3</italic> CRISPR-mediated deletion (lower). (<bold>h, h’</bold>) Representative P22 sagittal sections of the dorsal telencephalon showing GFP<sup>+</sup> cells being either PDGFRα<sup>+</sup> OPCs (arrowheads), CC1<sup>high</sup> OLs (arrows), or CC1<sup>low</sup> astrocytes (asterisks) progeny of P1 NSCs electroporated either with <italic>Ctrl</italic> plasmid (<bold>h</bold>) or <italic>Tns3-5′–3′</italic> targeting plasmid (labeled as <italic>5′–3′ gRNAs</italic>) (<bold>h’</bold>). (<bold>i</bold>) Histograms showing the percentage of GFP<sup>+</sup> glial cell types found in <italic>Ctrl</italic> or 3′–5′ <italic>gRNA</italic> electroporated brains being PDGFRα<sup>+</sup>-OPCs, CC1<sup>high</sup> OLs, and CC1<sup>low</sup> astrocytes in the corpus callosum (CC) and cortex (Ctx). Note the twofold reduction of CC1<sup>+</sup> OLs in <italic>Tns3-5′–3′ gRNA</italic>-transfected brains. Scale bar, 20 μm.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Subcloning strategy of to generate the Tol2-pCAG-Cas9-2A-GFP plasmid.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-80273-fig3-data1-v2.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80273-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Oligodendrogenesis is normal in <italic>Tns3</italic> constitutive mutant mice, which still express <italic>Tns3</italic> full-length transcripts in the brain.</title><p>(<bold>a</bold>) Schematic of <italic>Tns3<sup>βgeo</sup></italic> allele, showing localization of primers used for PCR amplification. (<bold>b, c</bold>) β-Galactosidase immunofluorescence in P21 sagittal brain sections, corresponding to CC1<sup>+</sup> oligodendrocytes (OLs) (arrows, <bold>b</bold>) or Olig2<sup>high</sup>/PDGFRα− OLs (arrows, <bold>c</bold>) immature OLs. (<bold>d, d’</bold>) Immunofluorescence for PDGFRα<sup>+</sup> oligodendrocyte precursor cells (OPCs) and CC1<sup>+</sup> OLs showing similar cell numbers in the corpus callosum (CC) of <italic>Tns3<sup>βgeo/+</sup></italic> (<bold>d</bold>) and <italic>Tns3<sup>βgeo/βgeo</sup></italic> (<bold>d’</bold>) brains. (<bold>e</bold>) Histograms representing density of PDGFRα<sup>+</sup> OPCs and CC1<sup>+</sup> OLs in the CC and the fimbria. (<bold>f, f’</bold>) Immunofluorescence for Olig2, CC1, and Olig1 allowing to identify three OL stages: CC1<sup>high</sup>/Olig1<sup>-</sup> cells (iOL1), CC1<sup>high</sup>/Olig1<sup>high-cytoplasmic</sup> cells (iOL2), and CC1<sup>low</sup>/Olig1<sup>cytoplasmic</sup> (mOL), showing similar numbers of each OL stage in the CC of Tns<italic>3<sup>βgeo/+</sup></italic> (<bold>f</bold>) and <italic>Tns3<sup>βgeo/βgeo</sup></italic> (<bold>f’</bold>) brains. (<bold>g</bold>) Histograms representing the quantification of the density of iOL1s, iOL2s, and mOLs, in the CC and the fimbria. (<bold>h</bold>) PCR from genomic DNA showing the presence of the native intron 4 only in wild-type (+/+) mice, of the intron 4-βgeo only in <italic>Tns3<sup>βgeo/βgeo</sup></italic> mice, and of intron 5/intron 6 in both mice. (<bold>i</bold>) Caliper visualization of PCR from cDNA showing the presence of exon 17 and exon 31 both in <italic>Tns3<sup>βgeo/βgeo</sup></italic> and wild-type mice despite the amplification with primers for exons 2–14 only in wild-type mice, and with primers for Exon2-βgeo only in <italic>Tns3<sup>βgeo/βgeo</sup></italic> mice. (<bold>j</bold>) Genotyping by TIDE analysis of <italic>Tns3<sup>4del</sup></italic> and <italic>Tns3<sup>14del</sup></italic> heterozygous mice showing wild-type Tns3 allele and the 4 nucleotides deletion in <italic>Tns3<sup>4del</sup></italic> allele and the 14 nucleotides deletion in <italic>Tns3<sup>14del</sup></italic> allele. (<bold>k</bold>) Pie charts representing the genotypes of E14.5 embryos obtained from <italic>Tns3<sup>4del</sup></italic> heterozygous inter-crosses. Note the sublethal phenotype indicated by the reduced number of <italic>Tns3<sup>4de/4del</sup></italic> embryos compared to Mendelian ratios. (<bold>l</bold>) <italic>Tns3<sup>4del</sup></italic> mice presenting growth defects in homozygous pups (arrow) at P14 compared to their heterozygous littermates. (<bold>m, n</bold>) Immunofluorescence showing that Tns3 is still detected in CC1<sup>+</sup> OLs of <italic>Tns3<sup>4de/4del</sup></italic> P21 mice, with four different Tns3 recognizing antibodies: (<bold>m</bold>) Sassan Hafizi lab and Santa Cruz, (<bold>n</bold>) Millipore, and Sigma. (<bold>o</bold>) Histogram representing qPCR on cDNA from P21 brains showing no differences in the amplification of <italic>Tns3</italic> exons 13–15, exon 17, and exon 31 between <italic>Tns3<sup>4del/4del</sup></italic>, <italic>Tns3<sup>4del/+</sup></italic> or WT mice, indicating the presence of a long <italic>Tns3</italic> transcript containing these exons in <italic>Tns3<sup>4del/4del</sup></italic> brains. Scale bar, 20 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80273-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Intolerance for <italic>TNS3</italic> loss-of-function variants in the human population.</title><p>(<bold>a–f</bold>) GnomAD data for <italic>TNS3</italic> and key regulators of oligodendrogenesis (<italic>SOX10, CHD7, CHD8, NKX2-1</italic>, and <italic>OLIG1</italic>) showing frequency and scores of different genetic variants in the human population: synonymous, missense, and predicted loss-of-function (pLOF) (nonsense, splice acceptor, and splice donor variants). The numbers highlighted colored squares correspond to the LOEF (loss-of-function observed/expected upper bound fraction), that it is a conservative estimate of the observed/expected ratio. Low LOEUF scores indicate strong selection against pLoF variation in a given gene, while high LOEUF scores suggest a relatively higher tolerance to inactivation. Note that <italic>TNS3</italic>, like <italic>SOX10</italic>, <italic>CHD7</italic>, and <italic>CHD8,</italic> has very low LOEUF scores indicating high intolerance for its inactivation, contrary to <italic>NKX2-1</italic> and <italic>OLIG1,</italic> which show more tolerance to their inactivation.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80273-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Generation and validation of <italic>Tns3</italic>-targeting CRISPR/Cas9 tools.</title><p>(<bold>a</bold>) Schematic of the <italic>Tol2-PX459</italic> CRISPR/Cas9 expression vector allowing Tol2-DNA integration driving Cas9 and puromycin resistance expression (from polycistronic 2A-mediated cleaved) by CMV promoter and sgRNA expression from U6 promoter. (<bold>b</bold>) Scheme of C17.1 neuroblastoma cell line lipofection followed by puromycin selection of transfected cells used to amplify by PCR the <italic>Tns3</italic>-targeted region and assess for indel mutations. (<bold>c</bold>) Caliper visualization of PCR products obtained after T7-mediated cleavage of DNA heteroduplex due to the indel mutations, showing smaller products (arrows) generated by Cas9 cutting with gRNA#1 or gRNA#2. (<bold>d</bold>). Visualization of Tns3-targeted region amplified by PCR run in a PAGE gel. Note the extra bands in gRNA#1 or gRNA#2-transfected cells corresponding to Cas9 cut products, contrary to <italic>Tol2-PX459</italic> empty plasmid (control). (<bold>e, f</bold>) TIDE analysis representing the percentage of sequences presenting a given indel mutation in cells transfected with gRNA#1 (<bold>e</bold>) or gRNA#2 (<bold>f</bold>).</p><p><supplementary-material id="fig3s3sdata1"><label>Figure 3—figure supplement 3—source data 1.</label><caption><title>Polyacrylamine gel (PAGE) showing efficient cutting of Tns3 gRNAs #1 and #2 as extrabands formed by hybrid DNA pairing of indels and wild-type PCR products of Tns3 targeted region.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-80273-fig3-figsupp3-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig3s3sdata2"><label>Figure 3—figure supplement 3—source data 2.</label><caption><title>gRNA selection strategy, targeting either the ATG region of Tns3 locus (5') gRNA#1 and gRNA#2, and the stop codon (3') region of Tns3, gRNA#3.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-80273-fig3-figsupp3-data2-v2.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80273-fig3-figsupp3-v2.tif"/></fig></fig-group><p>Given the expression of two Tns3 isoforms in the brain (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2f and g</xref>), we asked whether a deletion of both isoforms would have a greater impact in OL differentiation. We thus used two gRNAs efficiently cutting the beginning and the end of <italic>Tns3</italic> coding sequence (5′–3′gRNAs, ‘Materials and methods’) to delete the whole <italic>Tns3</italic> locus. We found a similar reduction of OLs in the loss of the two <italic>Tns3</italic> isoforms than in mutations affecting only full-length Tns3 (<xref ref-type="fig" rid="fig3">Figure 3h, h’ and i</xref>), suggesting that the small Tns3 isoform does not play an additional role with full-length Tns3 in OL formation. Altogether, these results indicate that <italic>Tns3</italic> loss-of-function mutations in neonatal SVZ-NSCs impair OPC differentiation without apparent changes in OPC generation and proliferation, thus suggesting that Tns3 is largely required for OPC differentiation into OLs in the postnatal brain (<xref ref-type="fig" rid="fig3">Figure 3g</xref>).</p></sec><sec id="s2-6"><title>OPC-specific <italic>Tns3</italic> deletion impairs oligodendrocyte differentiation in the postnatal brain</title><p>Given the heterogeneity of CRISPR/Cas9-mediated indels and the difficulties to assess in vivo the penetrance of their <italic>Tns3</italic> loss of function, to address in more detail the consequences of <italic>Tns3</italic> loss of function, we designed a <italic>Tns3</italic> conditional knockout allele by flanking with LoxP sites the exon 9 (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). In order to specifically delete <italic>Tns3</italic> in postnatal OPCs, we administered tamoxifen at P7 to <italic>Pdgfra-CreER<sup>T</sup>; Tns3<sup>fl/fl</sup>; Rosa26<sup>stop</sup></italic><sup>-<italic>YFP</italic></sup> (hereafter called <italic>Tns3-iKO</italic> mice) and control pups (<italic>Pdgfra-CreER<sup>T</sup>; Tns3<sup>+/+</sup>; Rosa26<sup>stop</sup></italic><sup>-<italic>YFP</italic></sup> littermates) and analyzed its effects on oligodendrogenesis at P14 and P21 (<xref ref-type="fig" rid="fig4">Figure 4a</xref>) both in white matter (corpus callosum and fimbria) and gray matter regions (cortex and striatum). We first assessed for the efficiency of <italic>Tns3</italic> deletion in Nkx2.2<sup>+</sup>/GFP<sup>+</sup> iOLs from different regions by immunofluorescence using a Tns3 antibody (Sigma Ct), finding that the strong Tns3 signal present in Nkx2.2<sup>+</sup>/GFP<sup>+</sup> iOLs of control brains was almost completely eliminated in <italic>Tns3-iKO</italic> iOLs without affecting Tns3 expression in vessels (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2b,b',c</xref>, arrows and arrowheads versus asterisks). We then assessed for changes in oligodendrogenesis. Remarkably, the number of OLs (CC1<sup>+</sup>/GFP<sup>+</sup> cells) was reduced by half in all quantified regions (reduction of 38.95% in the CC, 48.60% in cortex, 50.88% in the fimbria, 38% in the striatum; <xref ref-type="fig" rid="fig4">Figure 4b–d</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2e–f'</xref>, <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3b and b'</xref>) in <italic>Tns3-iKO</italic> compared to control, while OPC (PDGFRα<sup>+</sup>/GFP<sup>+</sup> cells) density was unchanged (<xref ref-type="fig" rid="fig4">Figure 4b–d</xref>). Using markers distinguishing different stages of OL differentiation (iOL1 and iOL2/mOL), we found that the density of iOL1s (Nkx2.2<sup>high</sup> cells), which express the highest levels of Tns3 protein in control brains, was unchanged (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2b,b',d</xref>), while the density of early iOL2s (CC1<sup>+</sup>/Olig1<sup>-</sup> cells) and later OL stages (iOL2/mOLs CC1<sup>+</sup>/Olig1<sup>+</sup> cells) was reduced by 30 and 50%, respectively, in <italic>Tns3-iKO</italic> compared to controls (<xref ref-type="fig" rid="fig4">Figure 4e–f</xref>), suggesting that Tns3 is required for normal OL differentiation. Finally, we assessed possible changes in OPC proliferation by immunodetection of Mcm2, finding no significant changes in the proliferation of <italic>Tns3-iKO</italic> OPCs compared to control OPCs (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3c,c',d</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Oligodendrocyte precursor cell (OPC)-specific <italic>Tns3</italic> deletion reduces the number of differentiating oligodendrocytes (OLs) in the postnatal brain.</title><p>(<bold>a</bold>) Scheme of tamoxifen administration to <italic>Tns3-iKO</italic> and control (<italic>Cre<sup>+</sup>; Tns3<sup>+/+</sup></italic>) mice, Cre-mediated genetic changes, and timing of experimental analysis. (<bold>b, b’, c, c’</bold>) Immunofluorescence in P21 sagittal brain sections for CC1, GFP, and PDGFRα illustrating similar density of OPCs (PDGFRα<sup>+</sup>) and twofold reduction in OL (CC1<sup>+</sup>) density in <italic>Tns3-iKO</italic> (<bold>b’, c’</bold>) compared to control (<bold>b, c</bold>) in the fimbria (<bold>b</bold>) and the cortex (Ctx) (<bold>c</bold>). (<bold>d</bold>) Histograms showing OPC and OL density in P21 <italic>Tns3-iKO</italic> and control (<italic>Ctrl</italic>) mice, in the corpus callosum (CC), fimbria, Ctx, and striatum. Note the systematic OL decrease of 40–50% in each region. (<bold>e–e<sub>1</sub>’</bold>) Immunofluorescence in P21 sagittal brain sections for Olig1, GFP, and CC1 to distinguish three stages of oligodendrogenesis: OPCs (Olig1<sup>+</sup>/CC1<sup>-</sup>), iOL1s (CC1<sup>+</sup>/Olig1<sup>-</sup>), and iOL2s/mOLs (CC1<sup>+</sup>/Olig1<sup>+</sup>) in <italic>Ctrl</italic> (<bold>e</bold>) or <italic>Tns3-iKO</italic> mice (<bold>e’</bold>). (<bold>e<sub>1</sub></bold>) and (<bold>e<sub>1</sub>’</bold>) are higher magnification of the squared area in (<bold>e</bold>) and (<bold>e</bold>’). (<bold>f</bold>) Histograms showing the OPCs, the iOL1s, and the iOL2s/mOLs density in P21 <italic>Tns3-iKO</italic> and control mice, in the CC, fimbria, Ctx, and striatum. Note the decrease of iOL1s and iOL2s over 40% in each area quantified (except for iOL1 density in the CC). (<bold>g</bold>) Schematic representing defects in oligodendrogenesis found in <italic>Tns3-iKO</italic> compared to control. Scale bar, 20 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80273-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Generation of <italic>Tns3</italic> floxed allele.</title><p>(<bold>a</bold>) Schematic of <italic>Tns3</italic> locus, <italic>Tns3<sup>Flox</sup></italic> allele, and targeting vector with LoxP sites flanking exon 9 used to induce homologous recombination in mouse ESCs. (<bold>b</bold>) Full-length Tns3 amino acid sequence indicating its protein domains. Squared in red highlights the 109 amino acid sequence of the Tns3 peptide produced upon Cre-mediated recombination in <italic>Tns3<sup>Flox</sup></italic>-expressing cells. (<bold>c</bold>) Peptide sequence of protein product predicted for <italic>Tns3-iKO</italic>-expressing cells. (<bold>d</bold>) <italic>Tns3<sup>Flox</sup></italic> targeting vector sequence used for homologous recombination in mouse ESCs and generation of <italic>Tns3<sup>Flox</sup></italic> mice, with LoxP sites highlighted in blue and exon 9 highlighted in red.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80273-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Efficient oligodendrocyte precursor cell (OPC)-specific <italic>Tns3</italic> deletion in the postnatal brain and reduced oligodendrocyte generation from OPCs.</title><p>(<bold>a</bold>) Scheme of tamoxifen administration to <italic>Tns3-iKO</italic> (<italic>Cre<sup>+</sup>; Tns3<sup>fl/fl</sup></italic>) and control (<italic>Cre<sup>+</sup>; Tns3<sup>+/+</sup></italic>) mice, Cre-mediated genetic changes, and timing of experimental analysis. (<bold>b, b’</bold>) Immunofluorescence for Tns3, GFP, and Nkx2.2 in P21 mice sagittal brain sections at the level of the corpus callosum (CC), illustrating the loss of Tns3 signal in Nkx2.2<sup>high</sup> iOL1s (arrows) but not in vessels (asterisk) of <italic>Tns3-iKO</italic> (<bold>b’</bold>) compared to control (<bold>b</bold>). Note that Nkx2.2<sup>high</sup> iOL1s do not change in density in <italic>Tns3-iKO</italic> compared to control. (<bold>c</bold>) Histograms showing the Tns3+ cells density in the CC, fimbria, cortex, and striatum, in <italic>Tns3-iKO</italic> and control. (<bold>d</bold>) Histograms showing the Nkx2.2<sup>high</sup> iOL1s density in the CC, fimbria, cortex, and striatum, in <italic>Tns3-iKO</italic> and control. (<bold>e–f’</bold>) Immunostaining corresponding to <xref ref-type="fig" rid="fig4">Figure 4b–c’</xref> showing individual channels for CC1, PDGFRα, and DAPI in the fimbria (<bold>e, e’</bold>) and cortex (<bold>f, f’</bold>) of control mice (<bold>e, f</bold>) and <italic>Tns3-iKO</italic> mice (<bold>e’, e’</bold>). Scale bar, 20 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80273-fig4-figsupp2-v2.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Oligodendrocyte precursor cell (OPC)-specific <italic>Tns3</italic> deletion reduces oligodendrocyte (OL) generation without changing OPC proliferation in the postnatal brain.</title><p>(<bold>a</bold>) Scheme of tamoxifen administration to <italic>Tns3-iKO</italic> (<italic>Cre<sup>+</sup>; Tns3<sup>fl/fl</sup></italic>) and control (<italic>Cre<sup>+</sup>; Tns3<sup>+/+</sup></italic>) mice, Cre-mediated genetic changes, and timing of experimental analysis. (<bold>b, b’</bold>) Immunostaining illustrating at low magnification the reduction in number of CC1<sup>+</sup> OLs but not PDGFRα<sup>+</sup> OPCs in the cortex (Ctx) and corpus callosum (CC) of <italic>Tns3-iKO</italic> mice (<bold>b’</bold>) compared to control mice (<bold>b</bold>), showing each individual channel and DAPI. (<bold>c, c’</bold>) Immunofluorescence for MCM2 proliferative marker, GFP, and PDGFRα illustrating similar proportion of proliferative OPCs in control (<bold>c</bold>) and <italic>Tns3-iKO</italic> mice (<bold>c’</bold>). (<bold>d</bold>) Histograms quantifying the proliferative fraction of GFP<sup>+</sup> OPCs in the fimbria (upper) and CC (lower). Note the slight reduction (nonsignificant) in proliferation in <italic>Tns3-iKO</italic> OPCs compared to control OPCs. Scale bar, 20 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80273-fig4-figsupp3-v2.tif"/></fig></fig-group><p>Altogether, these results indicate that acute deletion of <italic>Tns3</italic> in OPCs reduces by twofold generation of OLs in the postnatal brain, without major changes in OPC numbers and proliferation (<xref ref-type="fig" rid="fig4">Figure 4g</xref>).</p></sec><sec id="s2-7"><title><italic>Tns3-iKO</italic> oligodendroglia undergo apoptosis</title><p>Tensins are known to mediate integrin stabilization and activation in other cell types (<xref ref-type="bibr" rid="bib45">Liao and Lo, 2021</xref>), with Tns3 been shown to bind integrin-β1 through its phosphotyrosine-binding domain and FAK through its SH2 domain in fibroblasts (<xref ref-type="bibr" rid="bib21">Cui et al., 2004</xref>; <xref ref-type="bibr" rid="bib44">Liao et al., 2007</xref>; <xref ref-type="bibr" rid="bib27">Georgiadou et al., 2017</xref>). In oligodendroglia, integrin α6β1 association with Fyn kinase is required to amplify PDGF survival signaling and promote myelin membrane formation by switching neuregulin signaling from a PI3K to a MAPK pathway (<xref ref-type="bibr" rid="bib19">Colognato et al., 2004</xref>). Moreover, by conditional ablation of integrin-β1 in vivo, it was demonstrated that integrin-β1 signaling is involved in survival of differentiating oligodendroglia, but not required for axon ensheathment and myelination per se (<xref ref-type="bibr" rid="bib4">Benninger et al., 2006</xref>). We, therefore, investigated the expression of genes involved in integrin signaling in the transcriptome of oligodendroglial cells. Indeed, <italic>Tns3</italic> expression pattern in iOLs was closely matching that of <italic>Itgb1</italic> (integrin-b1), <italic>Fyn</italic>, <italic>Bcar1</italic>/<italic>p130Cas</italic>, and <italic>Ptk2</italic>/<italic>Fak</italic> both in mouse and human oligodendroglia (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1a and b</xref>). Furthermore, using neural progenitor differentiation cultures, we observed co-expression of integrin-β1 and Tns3 in CNP<sup>+</sup> OLs by immunofluorescence (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1c</xref>), suggesting that Tns3 could relay integrin-β1-mediated survival signal in differentiating oligodendroglia. Therefore, we assessed for signs of cell death in <italic>Tns3-iKO</italic> oligodendroglia by performing the TUNEL technique together with GFP and CC1 immunodetection. Interestingly, we found a fivefold increase in TUNEL<sup>+</sup> cells in the dorsal telencephalon of <italic>Tns3-iKO</italic> brain, compared to control, without significant changes in non-oligodendroglial cells present in the SVZ (<xref ref-type="fig" rid="fig5">Figure 5a–c</xref>). To gain more insight into the cellular alterations and cell death of <italic>Tns3-</italic>deleted oligodendroglia, we investigated their cellular morphology and behavior by video microscopy during their differentiation in culture. To this end, we MACS-purified OPCs from <italic>Tns3-iKO</italic> and control (<italic>Tns3<sup>flox/flox</sup>; Rosa26<sup>stop</sup></italic><sup>-YFP</sup> littermates) mice at P7, 2 days after administration of tamoxifen, plated them in proliferating medium for 3 days, and recorded their behavior during 3 days in the presence of differentiation medium (<xref ref-type="fig" rid="fig5">Figure 5d</xref>). Using the expression of the YFP as a readout of Cre-mediated recombination, we compared the behavior of YFP<sup>+</sup> cells (<italic>Tns3-iKO</italic>) with neighboring YFP<sup>-</sup> cells (internal control) in the same cultures. In parallel, we used MACSorted cells from control mice as external control. Quantification of the proportion of YFP<sup>+</sup> cells over time showed a 20% reduction of YFP<sup>+</sup> cells (from 80% to 60%) during the 3 days in proliferation medium followed by a reduction to 50% by day 3 in differentiation medium (<xref ref-type="fig" rid="fig5">Figure 5e</xref>), suggesting possible cell death of <italic>Tns3</italic>-mutant cells. Live-imaging monitoring of cell behavior showed that once YFP<sup>+</sup> cells had developed multiple branched morphology, characteristic of differentiating OLs, they showed a fourfold increase in their probability to die compared to YFP<sup>−</sup> cells of the same culture (<xref ref-type="fig" rid="fig5">Figure 5f–h</xref>, yellow and white arrows, respectively) or to cells from control cultures, with more pronounced cell death by the third day of culture (<xref ref-type="fig" rid="fig5">Figure 5f and g</xref>). Together, these results indicate that <italic>Tns3-iKO</italic> oligodendroglia present increased cell death both in vivo and in primary cultures at the stage when Tns3 is upregulated and cells start to develop their branched morphology, suggesting that Tns3 likely mediates β1-integrin signaling required for their survival.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Increased cell death of <italic>Tns3-iKO</italic> oligodendroglia.</title><p>(<bold>a</bold>) Scheme of tamoxifen administration to <italic>Tns3-iKO</italic> (<italic>Cre<sup>+</sup>; Tns3<sup>fl/fl</sup></italic>) and control (<italic>Cre<sup>+</sup>; Tns3<sup>+/+</sup></italic>) mice, Cre-mediated genetic changes, and timing of experimental analysis. (<bold>a–b’</bold>) Immunodetection of death cells by TUNEL together with recombined cells (GFP) and oligodendrocytes (OLs) (CC1<sup>+</sup> cells) showing increased number of TUNEL<sup>+</sup> cells in the cortex and corpus callosum of <italic>Tns3-iKO</italic> mice (<bold>b’</bold>) compared to control mice (<bold>b</bold>), including some GFP<sup>+</sup>/CC1<sup>−</sup> oligodendrocyte precursor cells (OPCs) (insets <bold>b’<sub>1</sub></bold> and <bold>b’<sub>2</sub></bold>). (<bold>c</bold>) Histograms quantifying the number of TUNEL<sup>+</sup> cells in the subventricular zone (SVZ), cortex, and both together (dorsal) per section. (<bold>d</bold>) Scheme of the video microscopy protocol in MACSorted OPCs purified from <italic>Tns3-iKO</italic> and control P7 mice. Cells were imaged every 10 min during 72 hr in differentiation medium. (<bold>e</bold>) Histograms showing the reduction of the GFP<sup>+</sup> cells proportion from the plating (–72 hr) to the end of the experiment (72 hr after differentiation onset). (<bold>f</bold>) Time curve quantifying the loss of GFP<sup>+</sup> OLs compared to GFP<sup>-</sup> OLs during the 72 hr of differentiation. (<bold>g</bold>) Histograms representing the quantification of cells lost per hour during the 72 hr differentiation period, showing a fivefold increase in loss of GFP<sup>+</sup> <italic>Tns3-iKO</italic> cells compared to GFP<sup>-</sup> cells (nonrecombined cells from <italic>Tns3-iKO</italic> mice, internal negative control) or cells coming from <italic>Cre<sup>−</sup></italic> littermates (<italic>Cre<sup>−</sup></italic>, external negative control). (<bold>h</bold>) Time-lapse frames showing cells every 12 hr illustrating both GFP<sup>+</sup> (green arrowheads, recombined <italic>Tns3-iKO</italic> cells) and GFP<sup>-</sup> (white arrowheads, nonrecombined <italic>Tns3-iKO</italic> cells) that die over the time of video microscopy. Note the larger number of GFP<sup>+</sup> OLs (cells with multibranched OL morphology) dying compared to GFP<sup>-</sup> OLs. Scale bar, 20 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80273-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title><italic>Tns3</italic> is co-expressed with integrin signaling genes in immature oligodendrocytes (iOLs).</title><p>(<bold>a, b</bold>) Dot plots showing <italic>Tns3/TNS3</italic> expression pattern in mouse (<bold>a</bold>) and human (<bold>b</bold>) single cells at different stages of oligodendrogenesis together with key markers of each cluster and genes involved in integrin signaling pathway. Note the high levels of Tns3/TNS3 in iOLs (iOL1 and iOL2) together with known genes of integrin pathway previously implicated in oligodendrogenesis (<italic>Itgb1, Fyn, FAK/Bcar1, p130Cas/Ptk2</italic>) both in mouse and human cells. (<bold>c</bold>) Immunofluorescence in neurosphere-derived neural progenitor cultures generated from <italic>Tns3<sup>Tns3-V5</sup></italic> neonatal brain after 3 days of differentiation showing co-expression of Tns3-V5 (V5 antibody) and Integrin-β1 in CNP<sup>+</sup> differentiating OLs (arrows). Scale bar, 20 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80273-fig5-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-8"><title>Apoptosis of <italic>Tns3-iKO</italic> oligodendroglia is mediated by p53 upregulation</title><p>To study the molecular mechanisms of Tns3 function in oligodendroglia, we first looked at p53 expression, the master transcriptional regulator of the cellular genotoxic stress response (<xref ref-type="bibr" rid="bib34">Kastenhuber and Lowe, 2017</xref>; <xref ref-type="bibr" rid="bib2">Aubrey et al., 2018</xref>). Interestingly, we found a tenfold increase in p53<sup>+</sup> OPCs (GFP<sup>+</sup>/CC1<sup>-</sup> cells) and fourfold increase in p53<sup>+</sup> iOLs (GFP<sup>+</sup>/CC1<sup>+</sup> cells) in <italic>Tns3-iKO</italic> compared to control (<xref ref-type="fig" rid="fig6">Figure 6a–c</xref>), suggesting that the loss of Tns3 leads to an upregulation of p53, which, together with the loss of integrin-β1 survival signal, mediates the cell death of <italic>Tns3-iKO</italic> differentiating oligodendroglia (<xref ref-type="fig" rid="fig6">Figure 6d</xref>).</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>p53-mediated cell death of <italic>Tns3-iKO</italic> oligodendroglia.</title><p>(<bold>a</bold>) Scheme of tamoxifen administration to <italic>Tns3-iKO</italic> (<italic>Cre<sup>+</sup>; Tns3<sup>fl/fl</sup></italic>) and control (<italic>Cre<sup>+</sup>; Tns3<sup>+/+</sup></italic>) mice, Cre-mediated genetic changes, and timing of experimental analysis. (<bold>b, b’</bold>) Immunodetection of p53 together with GFP to label recombined cells and CC1 to label oligodendrocytes (OLs) showing a strong increased number of p53<sup>+</sup>/GFP<sup>+</sup>/CC1<sup>−</sup> oligodendrocyte precursor cells (OPCs) and p53<sup>+</sup>/GFP<sup>+</sup>/CC1<sup>+</sup> OLs in the cortex (Ctx) and corpus callosum (CC) of <italic>Tns3-iKO</italic> mice (<bold>b</bold>) compared to control mice (<bold>b’</bold>). Dotted squares highlight some cases of p53<sup>+</sup> cells, shown at higher magnification below. (<bold>c</bold>) Histograms quantifying the number of p53<sup>+</sup> cells per area (mm<sup>2</sup>) in the dorsal telencephalon. Scale bar, 20 μm. (<bold>d</bold>) Schematics representing <italic>Tns3</italic>-deleted phenotypes in oligodendroglia. Scale bar, 20 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80273-fig6-v2.tif"/></fig></sec><sec id="s2-9"><title><italic>Tns3-iKO</italic> oligodendroglia shows transcriptional dysregulation of genes involved in OPC differentiation, apoptosis, integrin signaling, and cell cycle regulation</title><p>To further unravel the defects of <italic>Tns3</italic>-deleted oligodendroglia, we purified oligodendroglia (O4<sup>+</sup> cells) from P12 <italic>Tns3-iKO</italic> and control cortices by MACS (<xref ref-type="fig" rid="fig7">Figure 7a</xref>). Upon validation of Tns3 deletion at the transcript and protein levels (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1a–c</xref>) and that similar proportion of oligodendroglia were present in each genotype (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1d–f</xref>), we compared their transcriptomes obtained by bulk RNA sequencing (<xref ref-type="fig" rid="fig7">Figure 7a</xref>). Principal component analysis of Tns3-iKO and control samples shows clear separation between the groups (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1g</xref>). Statistical analyses using edgeR (<xref ref-type="bibr" rid="bib15">Chen et al., 2016</xref>) showed 2082 differentially expressed genes (DEGs, p-value&lt;0.05) between <italic>Tns3-iKO</italic> and control, with 834 downregulated and 1248 upregulated genes (<xref ref-type="fig" rid="fig7">Figure 7b</xref>). Gene Ontology (GO) analysis of biological processes indicated that main downregulated processes were involved in terms related OL differentiation (including gliogenesis, glial cell differentiation, OL differentiation, lipid metabolism, and positive regulation of cell projection organization; <xref ref-type="fig" rid="fig7">Figure 7c and e</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>), while the upregulated biological processes related to terms such as cellular stress and p53 pathway (including double-strand break repair, cellular response to oxidative stress, and signal transduction of p53 class mediator), opposite processes involved in cell cycle regulation (including DNA integrity check point, G2/M transition of mitotic cell cycle, and positive- and negative regulation of cell cycle process) (<xref ref-type="fig" rid="fig7">Figure 7d, f and g</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Interestingly, GO processes related to integrin signaling and cell adhesion were upregulated (including positive regulation of cell adhesion, regulation of cell adhesion mediated by integrin, integrin-mediated signaling pathway, and positive regulation of cell adhesion; <xref ref-type="fig" rid="fig7">Figure 7d</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>), with several integrin transcripts upregulated (<italic>Itgam, Itga8, Itgb2, Itga4, Itgb3, Itgb5, Itga6, Itgb8,</italic> which are normally not expressed in OPCs/iOLs; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>), while <italic>Fyn,</italic> Src family kinase that associates with α6β1 and is required to amplify PDGF survival signaling (<xref ref-type="bibr" rid="bib19">Colognato et al., 2004</xref>) was downregulated (1.4-fold, p-value=0.03; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>), suggesting that Tns3 deletion impairs normal integrin signaling, and as a consequence <italic>Tns3</italic>-deleted cells try to compensate this impairment upregulating of other integrin family members. These results, confirming and expanding those obtained by immunofluorescence analyses, led us to propose a model suggesting that <italic>Tns3</italic>-deleted oligodendroglia present signs of cellular stress accompanied by double-strand break signaling upregulation (including ATM and CHK2 regulators), p53 stabilization and upregulation of p53 target genes involved in apoptosis (including PUMA, APAF1, and Caspase 7; <xref ref-type="fig" rid="fig7">Figure 7h</xref>), and conflicting signals related to cell cycle (upregulation of p21, promoting cell cycle arrest, and upregulation of CDK/cyclin complexes promoting cell cycle progression; <xref ref-type="fig" rid="fig7">Figure 7h</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Mechanisms involved in <italic>Tns3-iKO</italic> oligodendroglial defects.</title><p>(<bold>a</bold>) Diagram representing tamoxifen (Tam) injection in P5 and P8 <italic>Ctrl</italic> and <italic>Tns3-iKO</italic> pups followed by MACSorting of O4<sup>+</sup> cells that were used to do RNA-seq. (<bold>b</bold>) Pie chart showing the amount of differentially expressed genes (DEGs; p-value&lt;0.05) in <italic>Tns3-iKO</italic> O4<sup>+</sup> cells compared to <italic>Ctrl</italic>. (<bold>c, d</bold>) Gene Ontology (GO) analysis of biological processes downregulated (<bold>c</bold>) and upregulated (<bold>d</bold>) in <italic>Tns3-iKO</italic> O4<sup>+</sup> cells compared to <italic>Ctrl</italic>. Numbers on left represent the number of deregulated genes in each GO process. (<bold>e–g</bold>) Graphs representing the logarithmic fold change (LogFC) for an example of genes involved in oligodendrocyte differentiation (<bold>e</bold>), cell cycle (<bold>f</bold>), and p53 pathway (<bold>g</bold>). (<bold>h</bold>) Summary schematics of the transcriptional dysregulation of <italic>Tns3-iKO</italic> O4<sup>+</sup> cells, representing the upregulation of the apoptosis pathway and the conflicting signals on cell cycle arrest/progression. Red and blue arrows represent gene upregulation and downregulation, respectively, in <italic>Tns3-iKO</italic> O4<sup>+</sup> cells compared to <italic>Ctrl</italic>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80273-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Transcriptomic analysis of acutely Tns3-deleted oligodendroglia.</title><p>(<bold>a</bold>) Diagram representing tamoxifen (Tam) injection at P5 and P8 Ctrl and <italic>Tns3-iKO</italic> pups followed by the MACSorting of O4<sup>+</sup> cells used for RNA-seq and plating. Cells were fixed 2 hr after and used to do immunostaining. (<bold>b</bold>) Immunostaining validating the loss of Tns3 protein in <italic>Tns3-iKO</italic> O4<sup>+</sup> cells compared to Ctrl. (<bold>c</bold>) Graph representing the count of exon 9 of Tns3 in the RNA-seq data. Note the reduction of floxed exon 9 in the <italic>Tns3-iKO</italic> O4<sup>+</sup> cells compared to control (<italic>Ctrl</italic>). (<bold>d</bold>) Immunostaining showing the composition in oligodendrocyte precursor cells (OPCs) (PDGFRα<sup>+</sup> cells) and immature oligodendrocytes (iOLs) (CNPase<sup>+</sup> cells) among <italic>Ctrl</italic> and <italic>Tns3-iKO</italic> O4<sup>+</sup> cells after MACS. (<bold>e</bold>) Graph indicating that the same amount of OPCs (PDGFRα<sup>+</sup> cells) and iOLs (CNPase<sup>+</sup> cells) was found in <italic>Ctrl</italic> and <italic>Tns3-iKO</italic> O4<sup>+</sup> cells after MACS. (<bold>f</bold>) Graph showing that the ratio of iOLs (CNPase<sup>+</sup> cells)/OPCs (PDGFRα<sup>+</sup> cells) was not altered in <italic>Tns3-iKO</italic> O4<sup>+</sup> cells compared to Ctrl. (<bold>g</bold>) Principal component analysis (PCA) of the RNA-seq data transcripts of <italic>Ctrl</italic> (CT) and <italic>Tns3-iKO</italic> (KO) O4<sup>+</sup> cells. (<bold>h</bold>) Volcano plot showing the upregulated (red) and downregulated (blue) in <italic>Tns3-iKO</italic> O4<sup>+</sup> cells compared to <italic>Ctrl</italic>. Some example of genes can be found. Scale bars: (<bold>b</bold>) 50 μm; (<bold>d</bold>) 10 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80273-fig7-figsupp1-v2.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The tight balance of OPCs between proliferation, survival, and differentiation ensures their capacity to respond to the myelination needs of the CNS by generating new OLs on demand, whilst avoiding the generation of brain gliomas through uncontrolled OPC proliferation. The observation that OPCs are present within demyelinating MS lesions but fail to efficiently differentiate into myelinating cells with age and disease progression (<xref ref-type="bibr" rid="bib14">Chang et al., 2002</xref>; <xref ref-type="bibr" rid="bib60">Neumann et al., 2019</xref>), together with the strong sensitivity of iOLs to survival/apoptotic signals (<xref ref-type="bibr" rid="bib31">Hughes and Stockton, 2021</xref>), suggests that efforts to foster OPC differentiation and survival of iOLs are a critical events for healthy aging and successful remyelination in MS patients. In this study, we combined the genome-wide binding profile of key regulators of OL differentiation, Olig2, Chd7, and Chd8 (<xref ref-type="bibr" rid="bib47">Lu et al., 2000</xref>; <xref ref-type="bibr" rid="bib87">Zhou et al., 2000</xref>; <xref ref-type="bibr" rid="bib48">Lu et al., 2002</xref>; <xref ref-type="bibr" rid="bib88">Zhou and Anderson, 2002</xref>; <xref ref-type="bibr" rid="bib29">He et al., 2016</xref>; <xref ref-type="bibr" rid="bib38">Küspert and Wegner, 2016</xref>; <xref ref-type="bibr" rid="bib50">Marie et al., 2018</xref>; <xref ref-type="bibr" rid="bib86">Zhao et al., 2018</xref>), to identify their common gene targets, and focused our analysis on Tensin3 (Tns3), whose expression matched the onset of OL differentiation. To study Tns3 expression and function, we generated several genetic tools, including CRISPR/Cas9 vectors, to induce <italic>Tns3</italic> mutations both in vivo and in vitro, a <italic>Tns3<sup>Tns3</sup></italic><sup>-V5</sup> knock-in mouse, two constitutive <italic>Tns3</italic> knockout mice, and finally an inducible knockout (<italic>Tns3<sup>Flox</sup></italic>) mouse. Using these tools, we provide several lines of evidence showing that Tns3 is upregulated in iOLs and required for normal OL differentiation. First, we show that Tns3 expression is strongly induced at the onset of OL differentiation, localized to the cytoplasm and main cell processes of iOLs, and downregulated in mature OLs both at the transcript and protein levels, thus constituting a novel marker for iOLs, for which we provide an optimal immunofluorescence protocol with a commercial antibody (Sigma, Ct). Second, we show that during remyelination Tns3 is also expressed in newly formed OLs and thus could be used as a hallmark for ongoing remyelination. Third, analyzing both <italic>Tns3<sup>βgeo</sup></italic> gene trap mice and two <italic>Tns3<sup>KO</sup></italic> mice, we show that constitutive <italic>Tns3</italic> deletion is detrimental for normal development and that the predicted loss of Tns3 full-length transcript and protein is bypassed in the oligodendroglia of surviving homozygous animals, paralleling the intolerance for <italic>TNS3</italic> loss-of-function variants found in the human population. Fourth, in vivo CRISPR-mediated <italic>Tns3</italic> deletion in neonatal NSCs from the SVZs leads to a twofold reduction of OLs without changes in OPC generation, proliferation, and numbers. Fifth, in vivo Tns3-induced knockout (<italic>Tns3-iKO</italic>) in postnatal OPCs leads to a twofold reduction of differentiating OLs without reducing the overall OPC population, both in gray and white matter brain regions. Finally, we provide evidence, by immunodetection in vivo and video microscopy of primary OPC differentiation cultures, that <italic>Tns3-iKO</italic> differentiating oligodendroglia upregulate p53, key sensor of cell stress, and present a four- to fivefold increase in apoptosis compared to control oligodendroglia, suggesting that mechanistically Tns3 function is likely required for normal OL differentiation at least in part by mediating integrin-β1 survival signaling in differentiating oligodendroglia.</p><sec id="s3-1"><title>Tns3 is a novel marker for immature oligodendrocytes</title><p>Recent studies have started to uncover genes enriched in iOLs, such as <italic>Itpr2</italic> (<xref ref-type="bibr" rid="bib84">Zeisel et al., 2015</xref>; <xref ref-type="bibr" rid="bib51">Marques et al., 2016</xref>), <italic>Enpp6</italic> (<xref ref-type="bibr" rid="bib79">Xiao et al., 2016</xref>), and <italic>Bcas1</italic> (<xref ref-type="bibr" rid="bib24">Fard et al., 2017</xref>), that could be used as markers for these transient cell populations, particularly interesting to label areas of active (re)myelination in the context of OL and myelin pathology, such as preterm brain injury and MS. Here, we report for the first time that Tns3 is a hallmark of iOLs (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Tns3 is expressed at high levels in iOLs and downregulated as OLs mature into myelinating cells, showing a complete overlap with Itpr2 transcript and protein. We found that a commercial Tns3 antibody (Millipore) also recognizes another nuclear protein that, like Tns3 in the cytoplasm, also labels at high levels iOLs, paralleling the case of CC1 antibody, which recognizes both APC and Quaking-7 proteins in OLs (<xref ref-type="bibr" rid="bib40">Lang et al., 2013</xref>; <xref ref-type="bibr" rid="bib6">Bin et al., 2016</xref>). Upon testing several antibodies, we found one (Sigma Ct) optimally labeling iOLs by immunofluorescence in brain sections and oligodendroglial cell cultures, whereas the Itpr2 commercial antibody we tried did not match this high-quality iOLs immunolabeling. An optimized protocol for immunodetection using Bcas1-recognizing antibodies has been shown to label iOLs (<xref ref-type="bibr" rid="bib24">Fard et al., 2017</xref>). Finally, Enpp6 is very specific for iOLs at the transcript level (<xref ref-type="bibr" rid="bib79">Xiao et al., 2016</xref>), but to our knowledge, no Enpp6-recognizing antibodies producing good quality immunodetection are yet available. Therefore, Tns3 protein expression in the CNS is a hallmark of iOLs, and the Tns3 Sigma Ct antibody is an optimal reagent to label iOLs during both myelination and remyelination.</p></sec><sec id="s3-2"><title>Tns3 is required for oligodendroglial differentiation</title><p>OL differentiation involves substantial generation of new membrane and cell processes composing the 40–60 myelin segments formed by mature OLs (<xref ref-type="bibr" rid="bib30">Hughes et al., 2018</xref>). Actin cytoskeleton remodeling is an important driver of the OL morphological changes undergone during their differentiation (<xref ref-type="bibr" rid="bib59">Nawaz et al., 2015</xref>; <xref ref-type="bibr" rid="bib89">Zuchero et al., 2015</xref>). Tensin proteins, linking the extracellular signals received by transmembrane integrins with the actin cytoskeleton in different cell types (<xref ref-type="bibr" rid="bib45">Liao and Lo, 2021</xref>), are well placed to play an important role in these morphological changes. At the molecular level, it has been shown that the phosphotyrosine-binding domains of Tensins interact with the NPXY motifs present in the cytoplasmic tails of integrin-β1 in a pTyr-insensitive fashion (<xref ref-type="bibr" rid="bib9">Calderwood et al., 2003</xref>; <xref ref-type="bibr" rid="bib35">Katz et al., 2007</xref>; <xref ref-type="bibr" rid="bib53">McCleverty et al., 2007</xref>), allowing Tensins to bring actin filaments, through their actin binding domain, to focal adhesion sites (<xref ref-type="bibr" rid="bib45">Liao and Lo, 2021</xref>). Given that the extension of OL cell processes’ growth cone is guided by the sequential activation of Fyn, FAK, and RhoGAP (<xref ref-type="bibr" rid="bib74">Thomason et al., 2020</xref>), and that high levels of Tns3 protein are detected in the cell body and processes of iOLs coinciding with their large enlargement, Tns3 is thus well placed to mediate integrin signaling to the actin cytoskeleton and play an active role in this large cellular remodeling. Moreover, integrin-β1, FAK/Ptk2, Fyn, p130Cas/Bcar1, and Tns3 are all highly expressed in iOLs (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Here, using three independent approaches, we show that loss of Tns3 in iOLs reduces by half the numbers of OLs in the postnatal brain. It is therefore very likely that Tns3 act as a mediator of integrin α6β1 signaling to promote OL survival and differentiation by mediating actin cytoskeletal remodeling. Finally, through its additional ability to bind to EGFR (<xref ref-type="bibr" rid="bib21">Cui et al., 2004</xref>), whose activation is another driver of oligodendroglial differentiation, Tns3 could also be required for mediation of signaling downstream of growth factor receptor activation in early iOLs; this could also explain the increased death in OLs lacking Tns3.</p></sec><sec id="s3-3"><title>Tns3’s role in immature oligodendrocyte survival</title><p>Programmed cell death regulates developmental oligodendrogenesis, with a large proportion of iOLs degenerating before the fourth week of postnatal life in mice (<xref ref-type="bibr" rid="bib3">Barres et al., 1992</xref>; <xref ref-type="bibr" rid="bib75">Trapp et al., 1997</xref>). Also in the adult mouse brain, differentiating OPCs remain in the iOL stage for roughly 2 days with many of them undergoing programmed cell death (<xref ref-type="bibr" rid="bib30">Hughes et al., 2018</xref>), indicating that this immature stage is very dependent on survival signals. Apoptotic pathways involving BCL-2 family members have been shown to regulate this oligodendroglial programmed cell death (reviewed in <xref ref-type="bibr" rid="bib31">Hughes and Stockton, 2021</xref>). One study has shown that the transcription factor TFEB, involved in autophagy and lysosomal biogenesis, ensures the spatial and temporal specificity of developmental myelination by promoting the expression of ER stress genes and PUMA, a pro-apoptotic factor inducing Bax-Bak-dependent programmed cell death in differentiating oligodendroglia (<xref ref-type="bibr" rid="bib72">Sun et al., 2018</xref>). Another recent study showed that during both during homeostasis and remyelination the activity of the primary sensor of cellular stress, nuclear factor (erythroid-derived 2)-like 2 (Nrf2), induces the expression of Gsta4, a scavenger of lipid peroxidation, which in turn controls apoptosis of iOLs via the mitochondria-associated Fas-Casp8-Bid-axis (<xref ref-type="bibr" rid="bib11">Carlström et al., 2020</xref>).</p><p>Several studies have shown that integrin-β1 signaling is required for iOL survival. Neuronal-derived signals, including neuregulin and laminin-2, are received by iOLs through integrin-β1 signaling that would enhance the function of neuroligin as a survival factor by inducing a survival-dependence switch from the phosphatidylinositol 3-kinase-Akt pathway to the mitogen-activated protein kinase (MAPK) pathway, with enhanced MAPK signaling inactivating the pro-apoptotic molecule BAD (<xref ref-type="bibr" rid="bib18">Colognato et al., 2002</xref>; <xref ref-type="bibr" rid="bib4">Benninger et al., 2006</xref>). Also, PDGF survival signaling in OPCs and myelin formation have been shown to depend on integrin α6β1 binding to Fyn (<xref ref-type="bibr" rid="bib19">Colognato et al., 2004</xref>). Tensins typically reside at focal adhesions, which connect the extracellular matrix (ECM) to the cytoskeletal networks through integrins and their associated protein complexes (<xref ref-type="bibr" rid="bib37">Kumar, 1998</xref>; <xref ref-type="bibr" rid="bib45">Liao and Lo, 2021</xref>), with focal adhesions mediating both outside-in and inside-out signaling pathways that regulate cellular events, such as cell attachment, migration, proliferation, apoptosis, and differentiation (<xref ref-type="bibr" rid="bib45">Liao and Lo, 2021</xref>). In this study, we show that Tns3 expression timing during oligodendrogenesis parallels that of integrin-β1, and we provided evidence of Tns3 and integrin-β1 co-localization in dotted structures resembling nascent and focal adhesion in the cytoplasm and processes of iOLs. Moreover, Tns3-deleted oligodendroglia have a 1.4-fold downregulation of <italic>Fyn</italic> transcripts, Src family kinase that associates with α6β1 and is required to amplify PDGF survival signaling (<xref ref-type="bibr" rid="bib19">Colognato et al., 2004</xref>), accompanied by the upregulation of transcripts of other integrin family members normally not expressed in OPCs and iOLs (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>), suggesting cellular changes to compensate the integrin signaling impairment of <italic>Tns3</italic>-deleted cells. Remarkably, knockout mice for <italic>integrin-α6</italic> present a 50% reduction in brainstem MBP<sup>+</sup> OLs at E18.5, just before they die at birth, accompanied by an increase in TUNEL<sup>+</sup> dying OLs (<xref ref-type="bibr" rid="bib18">Colognato et al., 2002</xref>), while conditional deletion of <italic>integrin-β1</italic> in iOLs by <italic>Cnp-Cre</italic> also leads to a 50% reduction in cerebellar OLs at P5, with a parallel increase in TUNEL<sup>+</sup> dying OLs (<xref ref-type="bibr" rid="bib4">Benninger et al., 2006</xref>). Therefore, given that <italic>Tns3</italic>-induced deletion in postnatal OPCs also leads to a 40–50% reduction in OLs in both gray and white matter regions of the postnatal telencephalon (this study), paralleled by a similar increase in TUNEL<sup>+</sup> apoptotic oligodendroglia, we suggest that Tns3 is required for integrin-β1-mediated survival signal in iOLs. Moreover, we suggest that this would lead to cellular stress of <italic>Tns3</italic>-deleted differentiating oligodendroglia and to the upregulation of p53, master regulator of cellular stress and apoptosis, which has been previously been shown to be involved in the apoptosis of human OLs in the context of MS (<xref ref-type="bibr" rid="bib39">Ladiwala et al., 1999</xref>; <xref ref-type="bibr" rid="bib78">Wosik et al., 2003</xref>) and in the cuprizone demyelination mouse model (<xref ref-type="bibr" rid="bib43">Li et al., 2008</xref>; <xref ref-type="bibr" rid="bib49">Luo et al., 2021</xref>).</p><p>In summary, here we have generated powerful genetic tools allowing to assess for the first time the role of Tns3 in the CNS, showing that Tns3 protein is found at high levels in the cytoplasm and main processes of iOLs, thus constituting a new marker of this oligodendroglial stage, and demonstrated by different genetic approaches that Tns3 deletion leads to a twofold reduction in differentiating OLs, explained at least in part by their increased apoptosis due to p53 upregulation and likely the loss of integrin-β1-mediated survival signaling. Follow-up studies using these tools should unravel with more detail the molecular mechanisms mediated by Tns3 not only in iOLs during developmental myelination but also in pathological contexts such as preterm birth dysmyelination, adult demyelination in MS and glioblastoma, this last one recently associated with reduced levels of Tns3 (<xref ref-type="bibr" rid="bib16">Chen et al., 2017</xref>).</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Tns3</italic><sup>β<italic>geo</italic></sup></td><td align="left" valign="bottom">Su Hao Lo lab (UC Davis, USA)</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Tn3<sup>Flox</sup></italic></td><td align="left" valign="bottom">Our lab</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Available as collaboration</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Tns3<sup>Tns3-V5</sup></italic></td><td align="left" valign="bottom">Our lab</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Available as collaboration</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Tns3<sup>KO</sup></italic></td><td align="left" valign="bottom">Our lab</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Lost in the Covid-19</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Tamoxifen</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">T5648</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">32% PFA solution</td><td align="left" valign="bottom">Electron Microscopy Sciences</td><td align="char" char="hyphen" valign="bottom">50-980-495</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Neural tissue dissociation kit (P)</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="char" char="ndash" valign="bottom">130-093-231</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Debris removal kit</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="char" char="hyphen" valign="bottom">130-090-101</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Anti-PDGFRα coupled-beads</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="char" char="hyphen" valign="bottom">130-094-543</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Anti-O4 coupled-beads</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="char" char="hyphen" valign="bottom">130-096-670</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Normal goat serum</td><td align="left" valign="bottom">Eurobio</td><td align="left" valign="bottom">CAECHVOO-OU</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">DAPI</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">D9542</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Fluoromount-G</td><td align="left" valign="bottom">SouthernBiotech</td><td align="char" char="." valign="bottom">15586276</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">In Situ Cell Death detection kit</td><td align="left" valign="bottom">Roche</td><td align="char" char="." valign="bottom">12156792910</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">RIPA buffer</td><td align="left" valign="bottom">Thermo Fisher</td><td align="char" char="." valign="bottom">89901</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Halt Protease Inhibitor Cocktail</td><td align="left" valign="bottom">Thermo Fisher</td><td align="char" char="." valign="bottom">87786</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Pierce Detergent Compatible Bradford Assay Kit</td><td align="left" valign="bottom">Thermo Fisher</td><td align="char" char="." valign="bottom">23246</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Bolt LDS Sample Buffer</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">B0007</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">4–12% polyacrylamide gradient gels</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">NW04122BOX</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Bolt MOPS SDS Running Buffer</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">B0001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Mini Gel Tank and Blot Module Set</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">NW2000</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Precision Plus Protein All Blue protein standards</td><td align="left" valign="bottom">Bio-Rad</td><td align="char" char="." valign="bottom">1610373EDU</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Amersham Protran 0.2 μm nitrocellulose membrane</td><td align="left" valign="bottom">Dutscher</td><td align="char" char="." valign="bottom">10600001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">NuPAGE Transfer Buffer</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">NP0006-1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Pierce ECL Western Blotting Substrate</td><td align="left" valign="bottom">Thermo Fisher</td><td align="char" char="." valign="bottom">32109</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Poly-<sc>l</sc>-ornithine</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">P4957</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">DMEM/F12</td><td align="left" valign="bottom">Life Technologies</td><td align="char" char="." valign="bottom">31331028</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">HEPES buffer</td><td align="left" valign="bottom">Life Technologies</td><td align="char" char="." valign="bottom">15630056</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Glucose</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">G8769</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Penicillin/streptomycin</td><td align="left" valign="bottom">Life Technologies</td><td align="char" char="." valign="bottom">15140122</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">N2 supplement</td><td align="left" valign="bottom">Life Technologies</td><td align="char" char="." valign="bottom">17502048</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">B27 supplement</td><td align="left" valign="bottom">Life Technologies</td><td align="char" char="." valign="bottom">17504044</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">EGF</td><td align="left" valign="bottom">PeproTech</td><td align="left" valign="bottom">AF-100-15</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">FGF-basic</td><td align="left" valign="bottom">PeproTech</td><td align="char" char="hyphen" valign="bottom">100-18B</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">PDGF-AA</td><td align="left" valign="bottom">PeproTech</td><td align="char" char="ndash" valign="bottom">100-13A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Insulin</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">I6634</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">iDeal ChIPseq kit for Transcription Factors</td><td align="left" valign="bottom">Diagenode</td><td align="left" valign="bottom">C01010055</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Tensin1 (rabbit)</td><td align="left" valign="bottom">Su Hao Lo, UC Davis</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Tensin2 (rabbit)</td><td align="left" valign="bottom">Su Hao Lo, UC Davis</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Tensin3 (rabbit)</td><td align="left" valign="bottom">Sassan Hafizi, University of Portsmouth</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Tensin3 (rabbit)</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">AB229</td><td align="char" char="." valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Tensin3 (rabbit)</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">PA5-116022</td><td align="char" char="." valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Tensin3 (mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotech</td><td align="left" valign="bottom">sc-376367</td><td align="char" char="." valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Tns3 (rabbit) (C-terminal)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">SAB4200205</td><td align="char" char="." valign="bottom">1:200</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Tns3 (rabbit) (TN-17)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">SAB4200416</td><td align="char" char="." valign="bottom">1:400</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-V5 tag (rabbit)</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">AB3792</td><td align="char" char="." valign="bottom">1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-V5 tag (mouse monoclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">R960-25</td><td align="char" char="." valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-PDGFRα (rat)</td><td align="left" valign="bottom">BD Biosciences</td><td align="char" char="." valign="bottom">558774</td><td align="char" char="." valign="bottom">1:250</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Olig1 (mouse monoclonal)</td><td align="left" valign="bottom">NeuroMab</td><td align="char" char="ndash" valign="bottom">75-180</td><td align="char" char="." valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Olig2 (mouse monoclonal)</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">MABN50</td><td align="char" char="." valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CNPase (mouse monoclonal)</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">MAB326R</td><td align="char" char="." valign="bottom">1:250</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-IP3 receptor 2 (rabbit) (Itpr2)</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">AB3000</td><td align="char" char="." valign="bottom">1:40</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Nkx2.2 (mouse polyclonal)</td><td align="left" valign="bottom">Developmental Studies Hybridoma Bank</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">1:4</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-CC1 (mouse monoclonal) (Quaking 7)</td><td align="left" valign="bottom">Calbiochem</td><td align="left" valign="bottom">OP80</td><td align="char" char="." valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-MOG (mouse monoclonal)</td><td align="left" valign="bottom">ICM, Paris Hybridoma</td><td align="left" valign="bottom">AA3</td><td align="char" char="." valign="bottom">1:20</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Opalin (mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotech</td><td align="left" valign="bottom">sc-374490</td><td align="char" char="." valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GFP (chicken polyclonal)</td><td align="left" valign="bottom">Aves Labs</td><td align="left" valign="bottom">GFP-1020</td><td align="char" char="." valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GFP (rabbit)</td><td align="left" valign="bottom">Life Technologies</td><td align="left" valign="bottom">A6455</td><td align="char" char="." valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-MCM2 (mouse)(BM28)</td><td align="left" valign="bottom">BD Biosciences</td><td align="char" char="." valign="bottom">610701</td><td align="char" char="." valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-p53 (rabbit)</td><td align="left" valign="bottom">Leica</td><td align="left" valign="bottom">P53-CM5P-L</td><td align="char" char="." valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-F4/80 (rat)</td><td align="left" valign="bottom"> Abd Serotec</td><td align="left" valign="bottom">MCA497</td><td align="char" char="." valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-beta-galactosidase (mouse monoclonal)</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">Z3783</td><td align="char" char="." valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">HRP-conjugated anti-rabbit</td><td align="left" valign="bottom">Bio-Rad</td><td align="char" char="." valign="bottom">1706515</td><td align="char" char="." valign="bottom">1:5000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">HRP-conjugated anti-mouse</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">NA931-1ML</td><td align="char" char="." valign="bottom">1:5000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">HRP-conjugated anti-rat</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">A10549</td><td align="char" char="." valign="bottom">1:5000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-H3K4me3 (rabbit)</td><td align="left" valign="bottom">Active Motif</td><td align="char" char="." valign="bottom">39060</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-H3K27Ac (rabbit)</td><td align="left" valign="bottom">Active Motif</td><td align="char" char="." valign="bottom">39034</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-H3K27me3 (mouse)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab6002</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-H3K4me1 (rabbit)</td><td align="left" valign="bottom">Ozyme</td><td align="char" char="." valign="bottom">5326T</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Plasmid</td><td align="left" valign="bottom"><italic>gRNA-pCMV-Cas9-2A-GFP</italic></td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Plasmid</td><td align="left" valign="bottom"><italic>gRNA-pCMV-Cas9-2A-Puro</italic></td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Plasmid</td><td align="left" valign="bottom"><italic>Tol2-gRNA-pCMV-Cas9-2A-GFP</italic></td><td align="left" valign="bottom">Our lab</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Plasmid</td><td align="left" valign="bottom"><italic>Tol2-gRNA-pCMV-Cas9-2A-Puro</italic></td><td align="left" valign="bottom">Our lab</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Plasmid</td><td align="left" valign="bottom"><italic>Tol2-gRNA-pCAG-Cas9-2A-GFP</italic></td><td align="left" valign="bottom">Our lab</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Plasmid</td><td align="left" valign="bottom"><italic>Tol2-gRNA-pCAG-Cas9-2A-Puro</italic></td><td align="left" valign="bottom">Our lab</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Plasmid</td><td align="left" valign="bottom"><italic>Tol2-Tns3gRNA2-pCAG-Cas9-2A-GFP</italic></td><td align="left" valign="bottom">Our lab</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Animals</title><p>All animal procedures were performed according to the guidelines and regulations of the Inserm ethical committees (authorization #A75-13-19) and animal experimentation license A75-17-72 (CP). Both males and females were included in the study. Mice were maintained in standard conditions with food and water ad libitum in the ICM animal facilities. <italic>Tensin3</italic> gene trap mouse line (<italic>Tns3<sup>βgeo</sup></italic>) was from Su Hao Lo lab (UC Davis, USA). Mice used for ChIP-seq analysis were wild-type Swiss obtained from Janvier Labs. <italic>Tns3<sup>flox</sup></italic> were crossed with <italic>Pdgfra-CreER<sup>T</sup></italic> (<xref ref-type="bibr" rid="bib32">Kang et al., 2010</xref>) and <italic>Rosa26<sup>stop-floxed-YFP</sup></italic> mice to generate <italic>Tns3<sup>flox</sup>; Pdgfra-CreER<sup>T</sup>; Rosa26<sup>stop-floxed-YFP</sup></italic> mice line. <italic>Pdgfra-CreER<sup>T</sup>; Rosa26<sup>stop-floxed-YFP</sup></italic> mice were used as controls.</p></sec><sec id="s4-2"><title>Generation of <italic>Tns3<sup>Tns3-V5</sup></italic> knock-in mice</title><p><italic>Tns3<sup>Tns3-V5</sup></italic> mice were generated at the Curie Institute mouse facility. Briefly, the Cas9 protein, the crRNA, the tracrRNA, and an ssODN targeting vector for the <italic>Tns3</italic> gene had been microinjected into a mouse egg cell, which was transplanted into a C57BL/6J-BALB/cJ female surrogate. Pups presenting HDR insertion of the V5 tag were selected after genotyping.</p></sec><sec id="s4-3"><title>Generation of <italic>Tns3<sup>4del</sup></italic> and <italic>Tns3<sup>14del</sup></italic> knockout mice</title><p><italic>Tns3<sup>KO</sup></italic> mice were generated at the ICM mice facility. Briefly, the Cas9 protein, the crRNA, the tracrRNA, and a targeting vector for the <italic>Tns3</italic> gene had been microinjected into a mouse egg cell transplanted into a C57BL/6J female surrogate. Pups with NHEJ mutations inducing a gene frameshift were selected after genotyping and Sanger sequencing verification. Finally, only two lines containing indels of 4 and 14 nucleotide deletions were maintained and studied.</p></sec><sec id="s4-4"><title>Generation of <italic>Tns3<sup>Flox</sup></italic> mice and tamoxifen administration</title><p>We designed a <italic>Tns3</italic> conditional knockout allele by flanking with LoxP sites exon 9 (LoxP-Exon9-LoxP; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1a</xref>). In this <italic>Tns3</italic>-floxed allele (<italic>Tns3<sup>flox</sup></italic>), Cre-mediated recombination induces a transcription frame shift translated into an early stop codon, leading to a putative small peptide of 109 aa instead of the full-length Tns3 protein (1442 aa; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1b and c</xref>). <italic>Tns3<sup>flox</sup></italic> mice were generated at the Transgenic Core Facility of the University of Copenhagen. The repair template contained homology arms of 771 bp and 759 bp length and <italic>loxP</italic> sequences flanking exon 9, was synthesized by Invitrogen, and verified by Sanger sequencing. Two gRNAs were designed at the Transgenic Core Facility that target a DNA sequence in the proximity of each <italic>loxP</italic> site. The gRNAs were designed in a fashion where the insertion of the <italic>loxP</italic> disrupts the targeting site, thus preventing retargeting of the repaired DNA. Mouse embryonic stem cell (mESC) method was used for the generation of this mouse model by transfecting ESCs with the repair construct (dsDNA) together with two plasmids – each containing each gRNA. Identification of the positive mESC clones was done via a combination of a PCR genotyping and Sanger sequencing confirmation. Mouse ESCs were transfected with a plasmid expressing <italic>Cas9, GFP</italic>, and gRNAs flanking <italic>Tns3</italic> exon 9, and a <italic>Tns3</italic>-floxed targeting vector (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1d</xref>), in order to induce CRISPR/Cas9-mediated homologous recombination. After verifying the presence of <italic>Tns3</italic>-floxed allele in <italic>Tns3</italic> locus by Sanger sequencing, positive ESC clones were injected into blastocysts to generate <italic>Tns3</italic>-floxed (<italic>Tns3<sup>flox</sup></italic>) mice.</p><p>Tamoxifen (Sigma, T5648) was dissolved in corn oil (Sigma, C-8267) and injected subcutaneously at 20 mg/ml concentration at P7 (30 µl) in <italic>Ctrl</italic> and <italic>Tns3-iKO</italic> animals. Brains were then collected at P21.</p></sec><sec id="s4-5"><title>Postnatal electroporation</title><p>Postnatal brain electroporation (<xref ref-type="bibr" rid="bib7">Boutin et al., 2008</xref>) was adapted to target the dorsal SVZ. Briefly, postnatal day 1 (P1) pups were cryoanesthetized for 2 min on ice and 1.5 μl of plasmid was injected into their left ventricle using a glass capillary. Plasmids were injected at a concentration of 2–2.5 μg/μl. Electrodes (Nepagene CUY650P10) coated with highly conductive gel (Signagel, signa250) were positioned in the dorsoventral axis with the positive pole dorsal. Five electric pulses of 100 V, 50 ms pulse ON, 850 ms pulse OFF were applied using a Nepagene CUY21-SC electroporator. Pups were immediately warmed up in a heating chamber and brought to their cages at the end of the experiment.</p></sec><sec id="s4-6"><title>Demyelinating lesions</title><p>Before surgery, adult (2–3 months) WT mice were weighed, and an analgesic (buprenorphine, 30 mg/g) was administered to prevent postsurgical pain. The mice were anesthetized by induction of isoflurane (ISO-VET). Ocrygel (Tvm) was put on their eye to prevent dryness and lidocaine in cream (Anesderm 5%) was put on the ear bars to prevent pain. After cutting of the skin, a few drops of liquid lidocaine were put to prevent pain. Focal demyelinating lesions were induced by stereotaxic injection of 1 µl of lysolecithin solution (LPC, Sigma, 1% in 0.9% NaCl) into the corpus callosum (CC; at coordinates: 1 mm lateral, 1.3 mm rostral to bregma, 1.7 mm deep) using a glass-capillary connected to a 10 µl Hamilton syringe. Animals were left to recover in a warm chamber before being returned into their housing cages.</p></sec><sec id="s4-7"><title>Tissue processing</title><p>Postnatal mice were transcardially perfused with 15 ml (P14) or 25 ml (&gt;P21) of 2% PFA freshly prepared from 32% PFA solution (Electron Microscopy Sciences, 50-980-495). Perfused brains were dissected out, dehydrated in 10% sucrose, followed by 20% sucrose overnight, and embedded in OCT (BDH) before freezing and sectioning (16 µm thickness) in a sagittal plane with a cryostat microtome (Leica).</p></sec><sec id="s4-8"><title>Magnetic-assisted cell sorting (MACS)</title><p>Dissociation of cortex and corpus callosum from mice brain was done using neural tissue dissociation kit (P) (Miltenyi Biotec; ref 130-093-231). Briefly, cortices were dissected from P7, P12, P14, or P21 mice and dissociated using a MACS dissociator (Miltenyi Biotec; ref 130-096-427) followed by filtration through a 70 μm cell strainer (Smartstainer; Miltenyi Biotec; ref 130-098-462). Myelin residues were eliminated from P12, P14, and P21 mice cortices during an additional step using the debris removal kit (Miltenyi Biotec; ref 130-090-101). Cells were suspended in a 0.5% NGS solution, then incubated with anti-PDGFRα or anti-O4 coupled-beads (Miltenyi Biotec; ref 130-094-543 and 130-096-670). Unbound bead-coupled antibodies were washed away by centrifugation, leaving bound cells that were sorted using MultiMACS Cell24 Separator Plus (Miltenyi Biotec; ref 130-098-637). Sorted cells were either plated in culture plates for in vitro cell study or centrifuged at 1200 rpm and used for Western blot analysis or ChIP-seq.</p></sec><sec id="s4-9"><title>Immunofluorescence staining and microscopy</title><p>Postnatal mouse brain cryosections were dried for 20 min at room temperature (RT), before adding the blocking solution (10% normal goat serum [NGS, Eurobio, CAECHVOO-OU] and 0.1% Triton X-100 in PBS) for 1 hr at RT. Primary antibodies were diluted (dilutions indicated in the Key ressource table) in the same blocking solution and incubated on the slices overnight at 4°C. After washing with 0.05% Triton X-100 in PBS, sections were incubated with secondary antibodies conjugated to Alexa Fluor-488, Alexa Fluor-594, and Alexa Fluor-647 (Thermo, 1:1000). Finally, cell nuclei were labeled with DAPI (1/10,000, Sigma-Aldrich, D9542-10MG), and slices mounted in Fluoromount-G (SouthernBiotech, Inc 15586276).</p><p>In Situ Cell Death detection kit (Roche, 12156792910) was used to do TUNEL experiment on P21 mouse brains. Briefly, tissues were processed as mentioned above with anti-GFP and anti-CC1 and fixed in fixation solution for 20 min at RT. After washing, slices were permeabilized for 2 min in permeabilization solution (0.1% Triton X-100; 0.1% sodium citrate) and TUNEL reaction mixture was put on samples for 1 hr at 37°C. Tissues were then mounted in Fluoromount-G.</p><p>Fixed coverslips were blocked in blocking solution (10% NGS [Eurobio, CAECHVOO-OU] and 0.1% Triton X-100 in PBS) for 30 min at RT, incubated in the primary antibodies for 45 min at RT, and washed three times in 1× PBS. Secondary antibodies were applied for 45 min at RT and washed three times in 1× PBS. Coverslips were then incubated with DAPI solution for 5 min at RT. A final washing was done before mounting the coverslips on slides to be visualized under the microscope.</p><p>Immunofluorescence was visualized with Zeiss Axio Imager.M2 microscope with Zeiss Apotome system. Pictures were taken as stacks of 5–10 µm with 0.5 µm between sections. Image acquisition and processing were achieved by ZEN Microscopy and Imaging Software. Z-projections and orthogonal projections were done in ImageJ and processed with Adobe Photoshop. Figures were created using Adobe Illustrator.</p></sec><sec id="s4-10"><title>Western blot</title><p>Proteins from MACsorted cells were extracted during 30 min at 4°C in RIPA buffer (Thermo Fisher; 50 µl per million cells, 89901) supplemented with Halt Protease Inhibitor Cocktail (100×; Thermo Fisher, 87786). Protein concentration in the supernatant was estimated using the Pierce Detergent Compatible Bradford Assay Kit (Thermo Fisher, 23246). For each Western blot, we used 50 µg of proteins denaturated for 10 min at 95°C with added β-mercaptoethanol (from 24× stock) and Bolt LDS Sample Buffer (4×) (Thermo Fisher, B0007). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed using precast 4–12% polyacrylamide gradient gels (Thermo Fisher, NW04122BOX), submerged at 4°C in Bolt MOPS SDS Running Buffer (Thermo Fisher, B0001) using Mini Gel Tank and Blot Module Set (Thermo Fisher, NW2000). Precision Plus Protein All Blue protein standards (Bio-Rad, 1610373EDU) were run alongside the samples as a protein migration control. Proteins were separated for 90 min at 90 V, after which gels were transferred onto Amersham Protran 0.2 µm nitrocellulose membrane (Dutscher, 10600001) immersed at 4°C in NuPAGE Transfer Buffer (Thermo Fisher, NP0006-1) for 90 min at 60 V. Following transfer, membranes were incubated for 1 hr in TBS-T, 10% dry milk to aid blocking of nonspecific binding by the antibodies. Primary antibodies diluted in TBS-T were incubated with the membrane overnight at 4°C with shaking. After three washes in TBS-T, membranes were incubated with HRP-conjugated secondary antibodies diluted in TBS-T for 1 hr at 4°C with shaking, then developed using Pierce ECL Western Blotting Substrate (Thermo Fisher, 32109) and imaged with the ChemiDoc Touch Imaging System (Bio-Rad, 1708370). Western blot detection of actin was performed as loading control.</p></sec><sec id="s4-11"><title>Videomicroscopy</title><p>Tamoxifen was administered to P5 <italic>Tns3<sup>flox</sup>; Pdgfrα-CreER<sup>T</sup>; Rosa26<sup>stop-floxed-YFP</sup></italic> and <italic>Tns3<sup>flox</sup>; Pdgfrα-WT; Rosa26<sup>stop-floxed-YFP</sup></italic> littermates. Brains were dissected out at P7 in order to MACSort OPCs using an anti-PDGFRα antibody coupled to magnetic beads. OPCs were plated in poly-<sc>l</sc>-ornithine (Sigma, P4957)-coated µ-Slide 8 Well Glass Bottom slide (ibidi, 80827) at 40,000 cells/mm<sup>2</sup> in OPC proliferative medium: DMEM/F12 (Life Technologies, 31331028), 5 mM HEPES buffer (Life Technologies, 15630056), 0.6% glucose (Sigma, G8769), 1× penicillin/streptomycin (Life Technologies, 15140122), N2 supplement (Life Technologies, 17502048), B27 supplement (Life Technologies, 17504044), 20 ng/µl EGF (PeproTech, AF-100-15), 10 ng/µl FGF-basic (PeproTech, 100-18B), 10 ng/µl PDGF-AA (PeproTech, 100-13A), and 20 μg/ml insulin (Sigma, I6634). After 3 days of proliferation, medium was replaced by growth factor-depleted medium. Cell differentiation was tracked for 3 days using time-lapse video recording. Cells were put in to a videomicroscope (Zeiss AxioObserver 7, provided by ICM-quant and CELIS facilities) with a humidified incubator at 37°C with a constant 5% CO<sub>2</sub> supply. Images for both FITC and bright field were acquired every 10 min.</p></sec><sec id="s4-12"><title>Chromatin immunoprecipitation (ChIP)</title><p>ChIP-seq assays were performed as described previously (<xref ref-type="bibr" rid="bib50">Marie et al., 2018</xref>) using iDeal ChIP-seq kit for Transcription Factors (Diagenode, C01010055). Briefly, O4<sup>+</sup> MACSorted cells were fixed in 1% formaldehyde (EMS, 15714) for 10 min at RT and the reaction was quenched with 125 mM glycine for 5 min at RT. Lysates were sonicated with a Bioruptor Pico sonicator (Diagenode, total time 8 min) and 4 μg of antibodies were added to sheared chromatin (from 4 million cells for Olig2 and from 1 million cells for histone marks) and incubated at 4°C overnight on 10 rpm rotation. Antibodies used were mouse anti-Olig2 antibody (Millipore, MABN50), rabbit anti-H3K4me3 antibody (Active Motif, 39060), rabbit anti-H3K27Ac antibody (Active Motif, 39034), rabbit anti-H3K4me1 antibody (Ozyme, 5326T), and mouse anti-H3K27me3 antibody (Abcam, ab6002). Mock (rabbit IgG) was used as negative control. Chromatin-protein complexes were immunoprecipitated with protein A/G magnetic beads and washed sequentially according to the manufacturer (Diagenode, C01010055). DNA fragments were then purified using IPure beads v2 (Diagenode, C01010055). Input (non-immunoprecipitated chromatin) was used as control in each individual experiment. The ChIP-seq libraries were prepared using Illumina TruSeq ChIP preparation kit and sequenced with Illumina NextSeq 500 platform.</p></sec><sec id="s4-13"><title>ChIP-seq analysis</title><p>All ChIP-seq analyses were done using the Galaxy Project (<ext-link ext-link-type="uri" xlink:href="https://usegalaxy.org/">https://usegalaxy.org/</ext-link>). Reads were trimmed using Cutadapt (--max-n 4) and Trimmomatic (TRAILING 1; SLIDINGWINDOW 4 and cutoff 20; LEADING 20; MINLEN 50) and mapped using Bowtie2 onto mm10 mouse reference genome (-X 600; -k 2; <monospace>--sensitive</monospace>). PCR-derived duplicates were removed using PICARD MarkDuplicates. Bigwig files were generated with bamCoverage (binsize = 1). Peak calling was performed using MACS2 callpeak with Input as control and with options: <monospace>--qvalue 0.05</monospace>; <monospace>--nomodel</monospace>; <monospace>--keep-dup 1</monospace>; <monospace>--broad</monospace> (only for histone marks). Blacklisted regions were then removed using bedtools Intersect intervals.</p><p>Visualization of coverage and peaks was done using IGV (<xref ref-type="bibr" rid="bib68">Robinson et al., 2011</xref>; <ext-link ext-link-type="uri" xlink:href="http://software.broadinstitute.org/software/igv/home">http://software.broadinstitute.org/software/igv/home</ext-link>). Intersection and analysis of bound genes were done using Genomatix (<ext-link ext-link-type="uri" xlink:href="https://www.genomatix.de/">https://www.genomatix.de/</ext-link>). Chd7, Chd8, and Mock ChIP-seq datasets are from <xref ref-type="bibr" rid="bib50">Marie et al., 2018</xref>. Heatmap was done using R (4.0) and pheatmap package. GO analysis was done using Enrichr GO Biological Process 2021.</p><p>Two replicates were done for Olig2, with one of them of better quality (53,960 peaks for replicate 1 and 14,242 peaks for replicate 2). Only the peaks found in both replicates (6781) and the peaks from replicate 1 found in regulatory elements (13,948) were considered (16,578 in total). Three replicates were done for H3K4me3, two replicates were done for H3K27me3 and one replicate was done for H3K27Ac and H3K4me1. Intersection of these datasets was done using bedtools Intersect intervals.</p><p>Peaks overlapping with regions between 1000 bp upstream of transcription start site (TSS) and 10 bp downstream of TSS were identified as ‘promoters’ (Genomatix). ‘Active promoters’ were marked by peaks for H3K4me3 and H3K27Ac; ‘Repressed promoters’ by peaks for H3K27me3 and no active marks; ‘Poised promoters’ by peaks for H3K4me1 and no active or repressed marks. Regions outside promoters containing histone marks were considered as ‘enhancers.’ ‘Active enhancers’ were marked by peaks for H3K27Ac; ‘Repressed enhancers’ by peaks for H3K27me3 and no active marks; ‘Poised enhancers’ by peaks for H3K4me1 and no active or repressed marks. Genes were considered associated if the peaks were present in the promoter or within a range of 100 kb from the middle of the promoter and the gene expression was medium to high (‘active’), low (‘poised’), or not (‘repressed’) expressed (based on control RNA-seq dataset in GSE116601).</p></sec><sec id="s4-14"><title>RNA-seq analysis</title><p>Raw data were downloaded from GEO datasets GSE107919 and GSE116601 and processed through the Galaxy Project (<ext-link ext-link-type="uri" xlink:href="https://usegalaxy.org/">https://usegalaxy.org/</ext-link>) using RNAstar for alignment on mm10 reference genome and featureCounts to obtain counts. Count per million (CPM), FPKM, and statistical analysis were done with R (4.0) using edgeR quasi-likelihood pipeline. Using control RNA-seq dataset in GSE116601, genes were classified based on their expression as not (below first quartile), low (between first quartile and mean), medium (between mean and third quartile), and high (above third quartile).</p></sec><sec id="s4-15"><title>scRNA-seq analysis</title><p>For mouse oligodendroglial cell analyses, counts per gene were downloaded from GEO datasets GSE75330 and GSE95194, and processed in R (4.0) using the following packages using de R-scripts deposited in <ext-link ext-link-type="uri" xlink:href="https://github.com/ParrasLab/Tns3_paper_eLife_2022">https://github.com/ParrasLab/Tns3_paper_eLife_2022</ext-link>; <xref ref-type="bibr" rid="bib65">ParrasLab, 2022</xref> and summarized here: <italic>Seurat</italic> (3.0) for data processing, <italic>sctransform</italic> for normalization, and <italic>ggplot2</italic> for graphical plots. Seurat objects were first generated for each dataset independently using <italic>CreateSeuratObject</italic> function (min.cells = 5, min.features = 100). Cell neighbors and clusters were found using <italic>FindNeighbors</italic> (dims = 1:30) and <italic>FindClusters</italic> (resolution = 0.4) functions. Clusters were manually annotated based on the top 50 markers obtained by the <italic>FindAllMarkers</italic>, adopting mainly the nomenclature from <xref ref-type="bibr" rid="bib51">Marques et al., 2016</xref>. Using the <italic>subset</italic> function, we selected only the clusters containing neural progenitors and oligodendroglia cells. Using the <italic>merge</italic> function, we combined both oligodendroglial datasets into a single Seurat object (OLgliaDevPost). The new object was subjected to <italic>NormalizeData</italic>, <italic>FindVariableFeatures</italic>, <italic>ScaleData</italic>, <italic>RunPCA</italic>, and <italic>RunUMAP</italic> functions with default parameters. Different OPC clusters were fused into a single one keeping apart the cycling OPC cluster. For DimPlots and dot plots, clusters were ordered by stages of oligodendrogenesis from NSCs to myelinating OLs.</p></sec><sec id="s4-16"><title><italic>Tns3<sup>βgeo</sup></italic> mice analysis</title><p>To explore the role of Tns3 in OL differentiation, we first analyzed a <italic>Tns3</italic> gene trap mouse line (<italic>Tns3<sup>βgeo</sup></italic>) previously studied outside the CNS (<xref ref-type="bibr" rid="bib17">Chiang et al., 2005</xref>), where the <italic>βgeo</italic> cassette is inserted after <italic>Tns3</italic> exon 4 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1a</xref>) driving <italic>LacZ</italic> transcription and by inserting a stop poly-A sequence, predicted to be a <italic>Tns3</italic> loss-of-function mutation. Despite the original report of postnatal growth retardation in <italic>Tns3<sup>βgeo/βgeo</sup></italic> mice, these mice were kept in homozygosity for several generations in C57BL/6 genetic background (Su-Hao Lo, UC Davis). We thus analyzed the impact in oligodendrogenesis in the postnatal brain of <italic>Tns3<sup>βgeo</sup></italic> animals. We first immunodetected βgalactosidase in OLs (Olig2<sup>+</sup>/CC1<sup>+</sup> and Olig2<sup>+</sup>/PDGFRα− cells) of <italic>Tns3<sup>βgeo</sup></italic> postnatal brains at P21 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1b and c</xref>), paralleling our characterization of Tns3 expression with V5 and Tns3 antibodies. We then quantified the density of PDGFRα<sup>+</sup> OPCs or CC1<sup>+</sup> OLs in <italic>Tns3<sup>βgeo/βgeo</sup></italic> and <italic>Tns3<sup>βgeo/+</sup></italic> littermates at P21, finding similar number of OPCs and OLs in two main white matter areas (corpus callosum and fimbria; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1d, d', e</xref>). Moreover, quantification of three different stages of OL differentiation (iOL1, iOL2, and mOL) by Olig2/CC1/Olig1 immunofluorescence did not reveal changes in the rate of OL differentiation (proportion of each stage) in <italic>Tns3<sup>βgeo/βgeo</sup></italic> mice compared to control littermates (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1f, f', g</xref>). We verified the homozygosity of <italic>Tns3<sup>βgeo</sup></italic> allele in <italic>Tns3<sup>βgeo/βgeo</sup></italic> mice by PCR amplification from genomic DNA of P21 brains finding that primers recognizing intron 4 and βgeo only produced PCR amplicons in <italic>Tns3<sup>βgeo/βgeo</sup></italic> mice but not when using intron 4 flanking primers that only produced PCR amplicons in wild-type mice (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1h</xref>). We then checked for <italic>Tns3</italic> full-length transcripts using cDNA generated from P21 brains, and to our surprise, primers flanking exons 17 and 31 were similarly amplified from cDNA of <italic>Tns3<sup>βgeo/βgeo</sup></italic> and wild-type brains (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1i</xref>), suggesting that in the brain of <italic>Tns3<sup>βgeo/βgeo</sup></italic> mice <italic>Tns3</italic> full-length transcripts coding for Tns3 protein are still produced. Altogether, these results suggested that, unlike in other tissues (<xref ref-type="bibr" rid="bib17">Chiang et al., 2005</xref>), the <italic>Tns3<sup>βgeo</sup></italic> allele does not lead to <italic>Tns3</italic> loss of function in the brain, likely through the generation of alternative spliced <italic>Tns3</italic> variants, and is thus not suitable for assessing <italic>Tns3</italic> function in the CNS.</p></sec><sec id="s4-17"><title>Analyses of <italic>TNS3</italic> alleles in the human population based in gnomAD project</title><p>To assess whether TNS3 is potentially required during human development, we explore for the presence of <italic>TNS3</italic> gene variants in the human population using the gnomAD database containing 125,748 exomes and 15,708 whole-genome sequences from unrelated individuals (<xref ref-type="bibr" rid="bib33">Karczewski et al., 2020</xref>; <xref ref-type="bibr" rid="bib42">Lek et al., 2016</xref>). Homozygous predicted loss-of-function (pLoF) alleles of <italic>TNS3</italic> were not found, and heterozygous pLoF were greatly below the expected frequency (0.1 observed/expected ratio, with 90% CI of 0.05–0.19; and LOEUF of 0.19; <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2a</xref>; <ext-link ext-link-type="uri" xlink:href="https://gnomad.broadinstitute.org">https://gnomad.broadinstitute.org</ext-link>), meaning that heterozygous loss-of-function variants of <italic>TNS3</italic> cause ~80% developmental mortality, a rate similarly high to key neurodevelopmental genes such as <italic>SOX10</italic> (LOEUF = 0.21; <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2b</xref>), <italic>CHD7</italic> (LOEUF = 0.08; <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2c</xref>), and <italic>CHD8</italic> (LOEUF = 0.08; <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2d</xref>), contrary to less broadly required factors such as <italic>NKX2-2</italic> (LOEUF = 0.67; <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2e</xref>) and <italic>OLIG1</italic> (LOEUF = 1.08; <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2f</xref>). Therefore, <italic>TNS3</italic> loss-of-function variants are badly tolerated in both mouse and human development.</p></sec><sec id="s4-18"><title>CRISPR/Cas9 tools development</title><p>CRISPOR software (<ext-link ext-link-type="uri" xlink:href="http://crispor.tefor.net/">http://crispor.tefor.net/</ext-link>) was used to design gRNAs with predicted cutting efficiency and minimal off-target and PCR amplification primers. The validation of <italic>Tns3</italic>-targeting CRISPR/Cas9 system was performed in 3T3 cells by transfection with Lipofectamine 3000 of <italic>PX459</italic> plasmids containing four different sgRNA sequences. After 2 days incubation, puromycin was added to medium for 4 days allowing survival of cells containing the <italic>PX459</italic> plasmid. Three days after proliferation in fresh medium without puromycin, DNA was extracted using DNeasy blood &amp; tissue kit (QIAGEN). The target DNA for 5′ <italic>Tns3</italic> region was amplified by PCR using primers with the following sequences: forward: 5′-<named-content content-type="sequence">AGG TGG CCT TCA GCT CAGT</named-content>-3′, reverse: 5′-<named-content content-type="sequence">GCT ATC ATC CCC ACT CAC CA</named-content>-3′; annealing temperature of 64°C, with the PCR product expected to be 326 bp. DNA from 3′ <italic>Tns3</italic> target region was amplified using primer with the following sequences: forward: 5′-<named-content content-type="sequence">CCA GTC AGT GGT GAC ATT GTTT</named-content>-3′, reverse: 5′-<named-content content-type="sequence">ACT GTT CCC AGG TTG CTA TCAT</named-content>-3′, annealing temperature of 58°C, with the PCR product expected to be 419 bp. Cutting efficiency of sgRNA was verified by T7 endonuclease I, following the beta protocol of IDTE synthetic biology for amplification of genomic DNA and detecting mutations (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3c</xref>), and using PAGE (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3d</xref>). In order to generate plasmids that will insert CRISPR tools into the genome of the transfected cells and lead to permanent expression of the targeting tools, the <italic>PX458</italic> (GFP) or <italic>PX459</italic> (Puromycin) plasmids were subcloned into a <italic>Tol2</italic>-containing sequence backbone (obtained from <italic>Tol2-mCherry</italic>-expressing plasmid kindly provided by Jean Livet, Institut de la Vision, Paris). Finally, to induce more robust expression of the Cas9 protein and reporter genes, we substitute the CMV promoter for the stronger CAG promoter.</p></sec><sec id="s4-19"><title><italic>Tns3<sup>4del</sup></italic> and <italic>Tns3<sup>14del</sup></italic> mice generation by CRISPR and analyses</title><p>To generate new <italic>Tns3</italic> knockout mouse using CRISPR/Cas9 technology by introducing loss-of-function mutations (indels) at the beginning of <italic>Tns3</italic> full-length coding sequence. We generated CRISPR integrative plasmids (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3a</xref>) driving Cas9 expression and gRNAs targeting <italic>Tns3</italic> exon 6 at the levels of the first coding ATG using as control plasmids without the <italic>Tns3</italic>-targeting sequence of the gRNA. Strong cutting efficiency of two gRNAs was validated by lipofection of neural progenitors (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3b–f</xref>). We then used these optimized tools to induce CRISPR-mediated <italic>Tns3</italic> mutations in mouse zygotes, generating and characterizing two mouse lines having small deletions (4-deletion and 14-deletion) after the first coding ATG of <italic>Tns3</italic> (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1j</xref>), expected to cause frame shifts leading to <italic>Tns3</italic> loss of function. Remarkably, homozygous animals were found in reduced numbers compared to Mendelian ratios with many of them dying during embryonic development (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1k</xref>) with most homozygous animals showing major growth retardation by the second postnatal week compared with their littermates (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1l</xref>), similar to the original report of <italic>Tns3<sup>βgeo</sup></italic> mice (<xref ref-type="bibr" rid="bib17">Chiang et al., 2005</xref>). Furthermore, we could still immunodetect Tns3 protein in CC1<sup>+</sup> OLs of these homozygous mice at P21 with at least two different Tns3 antibodies (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1m and n</xref>) and detect <italic>Tns3</italic> exons corresponding to <italic>Tns3</italic> full-length transcript by qPCR (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1o</xref>). Further analysis of these mice was prevented by the Covid-19 lockdown, leading to the loss of these <italic>Tns3</italic> knockout mouse lines. Altogether, these results suggest that mice carrying constitutive <italic>Tns3</italic> loss-of-function mutations seems to escape the full <italic>Tns3</italic> loss of function in the brain by generating alternative spliced variants containing the main <italic>Tns3</italic> full-length exons, and thus we considered these animals not suitable to study <italic>Tns3</italic> function in oligodendrogenesis.</p></sec><sec id="s4-20"><title>RNA sequencing and analysis</title><p>Cortices from 3 to 4 animals for each group were dissected and frozen in liquid nitrogen for further processing. Total RNA was isolated with the TRIzol Reagent protocol (Thermo Fisher) and RNeasy Mini Kit (QIAGEN) according to the instructions of the provider. The RNA-seq libraries were prepared using either the NEBNext Ultra II Directional RNA Library Prep Kit (NEB) and sequenced with the NovaSeq 6000 platform (Illumina, 32 * 106 100-bp pair-end reads per sample). Quality of raw data was evaluated with FastQC. Poor quality sequences were trimmed or removed with fastp tool, with default parameters, to retain only good quality paired reads. Illumina DRAGEN bio-IT Plateform (v3.6.3) was used for mapping on mm10 reference genome and quantification with gencode vM25 annotation gtf file. Library orientation, library composition, and coverage along transcripts were checked with Picard tools. The following analysis was conducted with R software. Data were normalized with edgeR (v3.28.0) bioconductor packages prior to differential analysis with glm framework likelihood ratio test from edgeR package workflow. Multiple hypothesis-adjusted p-values were calculated with the Benjamini–Hochberg procedure to control FDR. For the differential expression analyses, low-expressed genes were filtered, sex was used as covariable (when relevant), and the cutoffs applied were FDR &lt; 0.05. Finally, GO enrichment analysis of biological processes of the DEGs was conducted with clusterProfiler R package (v3.14.3).</p></sec><sec id="s4-21"><title>Statistical analysis</title><p>Experimental data is the result of optimization and analyses of several experiments done for each section of the study. Biological replicates (one sample comes from one animal) were used. Some quantifications concerning comparisons between <italic>Tns3</italic> loss-of-function genotypes and controls were done blindly.</p><p>Statistical parameters including the exact value of n, the definition of center, dispersion, and precision measures (mean ± SEM) and statistical significance are reported in the figures, figure legends, and <xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref>. ‘n’ represents the number of animals in histological studies and number of samples in RNA-seq, ChIP-seq, and ATAC-seq studies. Data distribution was assumed to be normal, but this was not formally tested. Statistical significance was determined using two-tailed Student’s <italic>t</italic>-tests. One-way ANOVA test was performed for multiple comparisons or pairwise comparisons following Turkey’s ranking tests when comparing multiple groups. Data are judged to be statistically significant when p&lt;0.05. In figures, asterisks denote statistical significance as calculated by Student’s <italic>t</italic>-test (*p&lt;0.05; **,p&lt;0.01; ***p&lt;0.001). No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those generally employed in the field to balance experimental robustness with the 3R rule for animal experimentation. Quantifications were performed from at least three independent experiments. No randomization was used to collect all the data, but they were quantified blindly. Statistical analysis was performed in Prism software.</p></sec><sec id="s4-22"><title>Data resources</title><p>Raw data files generated in this study have been deposited in the NCBI Gene Expression Omnibus under accession number GEO GSE203295 (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE203293">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE203293</ext-link>).</p><p>R-scripts used to treat RNA-seq data are deposited in GitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/ParrasLab/Tns3_paper_eLife_2022">https://github.com/ParrasLab/Tns3_paper_eLife_2022</ext-link>, copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:dc6c5659b5cec4cb5063f5604bd9edc00c80bc16;origin=https://github.com/ParrasLab/Tns3_paper_eLife_2022;visit=swh:1:snp:253a792d27c6ae851511abbaf4dd995bf7c19bc0;anchor=swh:1:rev:fa63c93277571bd0fe113242e4929ea5a1957fad">swh:1:rev:fa63c93277571bd0fe113242e4929ea5a1957fad</ext-link>; <xref ref-type="bibr" rid="bib65">ParrasLab, 2022</xref>).</p></sec><sec id="s4-23"><title>Contact for reagent and resource sharing</title><p>Further information and reasonable requests for reagents may be directed to and fulfilled by the corresponding author Carlos Parras (<ext-link ext-link-type="uri" xlink:href="https://institutducerveau-icm.org/en/member/?user=1349">carlos.parras@icm-institute.org</ext-link>).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Formal analysis, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Formal analysis, Visualization, Methodology</p></fn><fn fn-type="con" id="con3"><p>Data curation, Visualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con8"><p>Conceptualization</p></fn><fn fn-type="con" id="con9"><p>Investigation</p></fn><fn fn-type="con" id="con10"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con11"><p>Methodology</p></fn><fn fn-type="con" id="con12"><p>Methodology</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Methodology</p></fn><fn fn-type="con" id="con14"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con15"><p>Funding acquisition, Writing - review and editing</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animal procedures were performed according to the guidelines and regulations of the Inserm ethical committees (authorization #A75-13-19) and animal experimentation license A75-17-72.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-80273-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Statistics summary table.</title></caption><media xlink:href="elife-80273-data1-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Tables containing Olig2/Chd7/Chd8 ChIP-seq analyses and Tns3-iKO RNAseq analyses.</title></caption><media xlink:href="elife-80273-supp1-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Sequencing data have been deposited in GEO under accession code GSE203295.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Merour</surname><given-names>E</given-names></name><name><surname>Marie</surname><given-names>C</given-names></name><name><surname>Parras</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Transient regulation of focal adhesion via Tensin3 is required for nascent oligodendrocyte differentiation</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE203295">GSE203295</pub-id></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset2"><person-group person-group-type="author"><name><surname>Marques</surname><given-names>S</given-names></name><name><surname>Castello-Branco</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><data-title>scRNA-seq postnatal oligodendroglia</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE75330">GSE75330</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset3"><person-group person-group-type="author"><name><surname>Marques</surname><given-names>S</given-names></name><name><surname>Castello-Branco</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>scRNA-seq developmental oligodendroglia</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE95194">GSE95194</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset4"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>snRNA-seq human midgestation cerbellum</data-title><source>dbGaP</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001908.v2.p1">phs001908.v2.p1</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset5"><person-group person-group-type="author"><name><surname>Zack</surname><given-names>DJ</given-names></name><name><surname>Chamling</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>scRNA-seq from iPSC-derived Human Oligodendrocyte Progenitor Cells</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE146373">GSE146373</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Dwight Bergles for the <italic>PDGFRα::CreER<sup>T</sup></italic> mice and Jean Livet for Tol2-mCherry plasmid. Mathilde Bertrand for sharing ChIP-seq analysis pipeline. All animal work was conducted at the ICM PHENOPARC Core Facility. Data generated relied on ICM Core Facilities: PHENO ICMice, iGenSeq, DAC, iVector, CELIS, Histomics, and ICM Quant, and we thank all personnel involved for their contribution and help. The Core Facilities were supported by the 'Investissements d’avenir' (ANR-10-IAIHU-06 and ANR-11-INBS-0011-NeurATRIS) and the 'Fondation pour la Recherche Médicale.' This work was supported by funding by grants from the National Multiple Sclerosis Society (NMSS RG-1501-02851), and the Fondation pour l’Aide à la Recherche sur la Sclérose en Plaques (ARSEP 2014, 2015, 2018, 2019, 2020). EM, HH, and CM were supported by funding from Sorbonne Université. CM was also supported by Fondation pour la Recherche Médicale (FRM, FDT20160435662) and ARSEP grant 2018-2020.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aldinger</surname><given-names>KA</given-names></name><name><surname>Thomson</surname><given-names>Z</given-names></name><name><surname>Phelps</surname><given-names>IG</given-names></name><name><surname>Haldipur</surname><given-names>P</given-names></name><name><surname>Deng</surname><given-names>M</given-names></name><name><surname>Timms</surname><given-names>AE</given-names></name><name><surname>Hirano</surname><given-names>M</given-names></name><name><surname>Santpere</surname><given-names>G</given-names></name><name><surname>Roco</surname><given-names>C</given-names></name><name><surname>Rosenberg</surname><given-names>AB</given-names></name><name><surname>Lorente-Galdos</surname><given-names>B</given-names></name><name><surname>Gulden</surname><given-names>FO</given-names></name><name><surname>O’Day</surname><given-names>D</given-names></name><name><surname>Overman</surname><given-names>LM</given-names></name><name><surname>Lisgo</surname><given-names>SN</given-names></name><name><surname>Alexandre</surname><given-names>P</given-names></name><name><surname>Sestan</surname><given-names>N</given-names></name><name><surname>Doherty</surname><given-names>D</given-names></name><name><surname>Dobyns</surname><given-names>WB</given-names></name><name><surname>Seelig</surname><given-names>G</given-names></name><name><surname>Glass</surname><given-names>IA</given-names></name><name><surname>Millen</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Spatial and cell type transcriptional landscape of human cerebellar development</article-title><source>Nature Neuroscience</source><volume>24</volume><fpage>1163</fpage><lpage>1175</lpage><pub-id pub-id-type="doi">10.1038/s41593-021-00872-y</pub-id><pub-id pub-id-type="pmid">34140698</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aubrey</surname><given-names>BJ</given-names></name><name><surname>Kelly</surname><given-names>GL</given-names></name><name><surname>Janic</surname><given-names>A</given-names></name><name><surname>Herold</surname><given-names>MJ</given-names></name><name><surname>Strasser</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?</article-title><source>Cell Death and Differentiation</source><volume>25</volume><fpage>104</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1038/cdd.2017.169</pub-id><pub-id pub-id-type="pmid">29149101</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barres</surname><given-names>BA</given-names></name><name><surname>Hart</surname><given-names>IK</given-names></name><name><surname>Coles</surname><given-names>HS</given-names></name><name><surname>Burne</surname><given-names>JF</given-names></name><name><surname>Voyvodic</surname><given-names>JT</given-names></name><name><surname>Richardson</surname><given-names>WD</given-names></name><name><surname>Raff</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Cell death and control of cell survival in the oligodendrocyte lineage</article-title><source>Cell</source><volume>70</volume><fpage>31</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(92)90531-g</pub-id><pub-id pub-id-type="pmid">1623522</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benninger</surname><given-names>Y</given-names></name><name><surname>Colognato</surname><given-names>H</given-names></name><name><surname>Thurnherr</surname><given-names>T</given-names></name><name><surname>Franklin</surname><given-names>RJM</given-names></name><name><surname>Leone</surname><given-names>DP</given-names></name><name><surname>Atanasoski</surname><given-names>S</given-names></name><name><surname>Nave</surname><given-names>K-A</given-names></name><name><surname>Ffrench-Constant</surname><given-names>C</given-names></name><name><surname>Suter</surname><given-names>U</given-names></name><name><surname>Relvas</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Beta1-Integrin signaling mediates premyelinating oligodendrocyte survival but is not required for CNS myelination and remyelination</article-title><source>The Journal of Neuroscience</source><volume>26</volume><fpage>7665</fpage><lpage>7673</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0444-06.2006</pub-id><pub-id pub-id-type="pmid">16855094</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergles</surname><given-names>DE</given-names></name><name><surname>Richardson</surname><given-names>WD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Oligodendrocyte development and plasticity</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>8</volume><elocation-id>a020453</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a020453</pub-id><pub-id pub-id-type="pmid">26492571</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bin</surname><given-names>JM</given-names></name><name><surname>Harris</surname><given-names>SN</given-names></name><name><surname>Kennedy</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The oligodendrocyte-specific antibody “CC1” binds quaking 7</article-title><source>Journal of Neurochemistry</source><volume>139</volume><fpage>181</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1111/jnc.13745</pub-id><pub-id pub-id-type="pmid">27454326</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boutin</surname><given-names>C</given-names></name><name><surname>Diestel</surname><given-names>S</given-names></name><name><surname>Desoeuvre</surname><given-names>A</given-names></name><name><surname>Tiveron</surname><given-names>MC</given-names></name><name><surname>Cremer</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Efficient in vivo electroporation of the postnatal rodent forebrain</article-title><source>PLOS ONE</source><volume>3</volume><elocation-id>e1883</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0001883</pub-id><pub-id pub-id-type="pmid">18382666</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryois</surname><given-names>J</given-names></name><name><surname>Skene</surname><given-names>NG</given-names></name><name><surname>Hansen</surname><given-names>TF</given-names></name><name><surname>Kogelman</surname><given-names>LJA</given-names></name><name><surname>Watson</surname><given-names>HJ</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><collab>Eating Disorders Working Group of the Psychiatric Genomics Consortium</collab><collab>International Headache Genetics Consortium</collab><collab>23andMe Research Team</collab><name><surname>Brueggeman</surname><given-names>L</given-names></name><name><surname>Breen</surname><given-names>G</given-names></name><name><surname>Bulik</surname><given-names>CM</given-names></name><name><surname>Arenas</surname><given-names>E</given-names></name><name><surname>Hjerling-Leffler</surname><given-names>J</given-names></name><name><surname>Sullivan</surname><given-names>PF</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson’s disease</article-title><source>Nature Genetics</source><volume>52</volume><fpage>482</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1038/s41588-020-0610-9</pub-id><pub-id pub-id-type="pmid">32341526</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calderwood</surname><given-names>DA</given-names></name><name><surname>Fujioka</surname><given-names>Y</given-names></name><name><surname>de Pereda</surname><given-names>JM</given-names></name><name><surname>García-Alvarez</surname><given-names>B</given-names></name><name><surname>Nakamoto</surname><given-names>T</given-names></name><name><surname>Margolis</surname><given-names>B</given-names></name><name><surname>McGlade</surname><given-names>CJ</given-names></name><name><surname>Liddington</surname><given-names>RC</given-names></name><name><surname>Ginsberg</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Integrin beta cytoplasmic domain interactions with phosphotyrosine-binding domains: a structural prototype for diversity in integrin signaling</article-title><source>PNAS</source><volume>100</volume><fpage>2272</fpage><lpage>2277</lpage><pub-id pub-id-type="doi">10.1073/pnas.262791999</pub-id><pub-id pub-id-type="pmid">12606711</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Kaneko</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>JS</given-names></name><name><surname>Liu</surname><given-names>AD</given-names></name><name><surname>Voss</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>SSC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A phosphorylation switch controls the spatiotemporal activation of Rho GTPases in directional cell migration</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>7721</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms8721</pub-id><pub-id pub-id-type="pmid">26166433</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlström</surname><given-names>KE</given-names></name><name><surname>Zhu</surname><given-names>K</given-names></name><name><surname>Ewing</surname><given-names>E</given-names></name><name><surname>Krabbendam</surname><given-names>IE</given-names></name><name><surname>Harris</surname><given-names>RA</given-names></name><name><surname>Falcão</surname><given-names>AM</given-names></name><name><surname>Jagodic</surname><given-names>M</given-names></name><name><surname>Castelo-Branco</surname><given-names>G</given-names></name><name><surname>Piehl</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Gsta4 controls apoptosis of differentiating adult oligodendrocytes during homeostasis and remyelination via the mitochondria-associated fas-casp8-bid-axis</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>4071</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-17871-5</pub-id><pub-id pub-id-type="pmid">32792491</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castelijns</surname><given-names>B</given-names></name><name><surname>Baak</surname><given-names>ML</given-names></name><name><surname>Timpanaro</surname><given-names>IS</given-names></name><name><surname>Wiggers</surname><given-names>CRM</given-names></name><name><surname>Vermunt</surname><given-names>MW</given-names></name><name><surname>Shang</surname><given-names>P</given-names></name><name><surname>Kondova</surname><given-names>I</given-names></name><name><surname>Geeven</surname><given-names>G</given-names></name><name><surname>Bianchi</surname><given-names>V</given-names></name><name><surname>de Laat</surname><given-names>W</given-names></name><name><surname>Geijsen</surname><given-names>N</given-names></name><name><surname>Creyghton</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Hominin-specific regulatory elements selectively emerged in oligodendrocytes and are disrupted in autism patients</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>301</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-14269-w</pub-id><pub-id pub-id-type="pmid">31949148</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chamling</surname><given-names>X</given-names></name><name><surname>Kallman</surname><given-names>A</given-names></name><name><surname>Fang</surname><given-names>W</given-names></name><name><surname>Berlinicke</surname><given-names>CA</given-names></name><name><surname>Mertz</surname><given-names>JL</given-names></name><name><surname>Devkota</surname><given-names>P</given-names></name><name><surname>Pantoja</surname><given-names>IEM</given-names></name><name><surname>Smith</surname><given-names>MD</given-names></name><name><surname>Ji</surname><given-names>Z</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Kaushik</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Whartenby</surname><given-names>KA</given-names></name><name><surname>Calabresi</surname><given-names>PA</given-names></name><name><surname>Mao</surname><given-names>HQ</given-names></name><name><surname>Ji</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>TH</given-names></name><name><surname>Zack</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Single-Cell transcriptomic reveals molecular diversity and developmental heterogeneity of human stem cell-derived oligodendrocyte lineage cells</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>652</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-20892-3</pub-id><pub-id pub-id-type="pmid">33510160</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>A</given-names></name><name><surname>Tourtellotte</surname><given-names>WW</given-names></name><name><surname>Rudick</surname><given-names>R</given-names></name><name><surname>Trapp</surname><given-names>BD</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis</article-title><source>The New England Journal of Medicine</source><volume>346</volume><fpage>165</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa010994</pub-id><pub-id pub-id-type="pmid">11796850</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Lun</surname><given-names>ATL</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>From reads to genes to pathways: differential expression analysis of RNA-seq experiments using rsubread and the edger quasi-likelihood pipeline</article-title><source>F1000Research</source><volume>5</volume><elocation-id>1438</elocation-id><pub-id pub-id-type="doi">10.12688/f1000research.8987.1</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Lin</surname><given-names>LT</given-names></name><name><surname>Wang</surname><given-names>ML</given-names></name><name><surname>Laurent</surname><given-names>B</given-names></name><name><surname>Hsu</surname><given-names>CH</given-names></name><name><surname>Pan</surname><given-names>CM</given-names></name><name><surname>Jiang</surname><given-names>WR</given-names></name><name><surname>Chen</surname><given-names>PY</given-names></name><name><surname>Ma</surname><given-names>HI</given-names></name><name><surname>Chen</surname><given-names>YW</given-names></name><name><surname>Huang</surname><given-names>PI</given-names></name><name><surname>Chiou</surname><given-names>A</given-names></name><name><surname>Chiou</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Musashi-1 enhances glioblastoma cell migration and cytoskeletal dynamics through translational inhibition of tensin3</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>09504-7</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-09504-7</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>MK</given-names></name><name><surname>Liao</surname><given-names>YC</given-names></name><name><surname>Kuwabara</surname><given-names>Y</given-names></name><name><surname>Lo</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Inactivation of tensin3 in mice results in growth retardation and postnatal lethality</article-title><source>Developmental Biology</source><volume>279</volume><fpage>368</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2004.12.027</pub-id><pub-id pub-id-type="pmid">15733665</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colognato</surname><given-names>H</given-names></name><name><surname>Baron</surname><given-names>W</given-names></name><name><surname>Avellana-Adalid</surname><given-names>V</given-names></name><name><surname>Relvas</surname><given-names>JB</given-names></name><name><surname>Baron-Van Evercooren</surname><given-names>A</given-names></name><name><surname>Georges-Labouesse</surname><given-names>E</given-names></name><name><surname>ffrench-Constant</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Cns integrins switch growth factor signalling to promote target-dependent survival</article-title><source>Nature Cell Biology</source><volume>4</volume><fpage>833</fpage><lpage>841</lpage><pub-id pub-id-type="doi">10.1038/ncb865</pub-id><pub-id pub-id-type="pmid">12379866</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colognato</surname><given-names>H</given-names></name><name><surname>Ramachandrappa</surname><given-names>S</given-names></name><name><surname>Olsen</surname><given-names>IM</given-names></name><name><surname>ffrench-Constant</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Integrins direct Src family kinases to regulate distinct phases of oligodendrocyte development</article-title><source>The Journal of Cell Biology</source><volume>167</volume><fpage>365</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1083/jcb.200404076</pub-id><pub-id pub-id-type="pmid">15504915</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Compston</surname><given-names>A</given-names></name><name><surname>Coles</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Multiple sclerosis</article-title><source>Lancet</source><volume>359</volume><fpage>1221</fpage><lpage>1231</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(02)08220-X</pub-id><pub-id pub-id-type="pmid">11955556</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Liao</surname><given-names>YC</given-names></name><name><surname>Lo</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Epidermal growth factor modulates tyrosine phosphorylation of a novel tensin family member, tensin3</article-title><source>Molecular Cancer Research</source><volume>2</volume><fpage>225</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.225.2.4</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elsesser</surname><given-names>O</given-names></name><name><surname>Fröb</surname><given-names>F</given-names></name><name><surname>Küspert</surname><given-names>M</given-names></name><name><surname>Tamm</surname><given-names>ER</given-names></name><name><surname>Fujii</surname><given-names>T</given-names></name><name><surname>Fukunaga</surname><given-names>R</given-names></name><name><surname>Wegner</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Chromatin remodeler ep400 ensures oligodendrocyte survival and is required for myelination in the vertebrate central nervous system</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>6208</fpage><lpage>6224</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz376</pub-id><pub-id pub-id-type="pmid">31081019</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emery</surname><given-names>B</given-names></name><name><surname>Lu</surname><given-names>QR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Transcriptional and epigenetic regulation of oligodendrocyte development and myelination in the central nervous system</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>7</volume><elocation-id>a020461</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a020461</pub-id><pub-id pub-id-type="pmid">26134004</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fard</surname><given-names>MK</given-names></name><name><surname>van der Meer</surname><given-names>F</given-names></name><name><surname>Sánchez</surname><given-names>P</given-names></name><name><surname>Cantuti-Castelvetri</surname><given-names>L</given-names></name><name><surname>Mandad</surname><given-names>S</given-names></name><name><surname>Jäkel</surname><given-names>S</given-names></name><name><surname>Fornasiero</surname><given-names>EF</given-names></name><name><surname>Schmitt</surname><given-names>S</given-names></name><name><surname>Ehrlich</surname><given-names>M</given-names></name><name><surname>Starost</surname><given-names>L</given-names></name><name><surname>Kuhlmann</surname><given-names>T</given-names></name><name><surname>Sergiou</surname><given-names>C</given-names></name><name><surname>Schultz</surname><given-names>V</given-names></name><name><surname>Wrzos</surname><given-names>C</given-names></name><name><surname>Brück</surname><given-names>W</given-names></name><name><surname>Urlaub</surname><given-names>H</given-names></name><name><surname>Dimou</surname><given-names>L</given-names></name><name><surname>Stadelmann</surname><given-names>C</given-names></name><name><surname>Simons</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions</article-title><source>Science Translational Medicine</source><volume>9</volume><elocation-id>eaam7816</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aam7816</pub-id><pub-id pub-id-type="pmid">29212715</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ffrench-Constant</surname><given-names>C</given-names></name><name><surname>Raff</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>The oligodendrocyte-type-2 astrocyte cell lineage is specialized for myelination</article-title><source>Nature</source><volume>323</volume><fpage>335</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1038/323335a0</pub-id><pub-id pub-id-type="pmid">3531873</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fünfschilling</surname><given-names>U</given-names></name><name><surname>Supplie</surname><given-names>LM</given-names></name><name><surname>Mahad</surname><given-names>D</given-names></name><name><surname>Boretius</surname><given-names>S</given-names></name><name><surname>Saab</surname><given-names>AS</given-names></name><name><surname>Edgar</surname><given-names>J</given-names></name><name><surname>Brinkmann</surname><given-names>BG</given-names></name><name><surname>Kassmann</surname><given-names>CM</given-names></name><name><surname>Tzvetanova</surname><given-names>ID</given-names></name><name><surname>Möbius</surname><given-names>W</given-names></name><name><surname>Diaz</surname><given-names>F</given-names></name><name><surname>Meijer</surname><given-names>D</given-names></name><name><surname>Suter</surname><given-names>U</given-names></name><name><surname>Hamprecht</surname><given-names>B</given-names></name><name><surname>Sereda</surname><given-names>MW</given-names></name><name><surname>Moraes</surname><given-names>CT</given-names></name><name><surname>Frahm</surname><given-names>J</given-names></name><name><surname>Goebbels</surname><given-names>S</given-names></name><name><surname>Nave</surname><given-names>K-A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity</article-title><source>Nature</source><volume>485</volume><fpage>517</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1038/nature11007</pub-id><pub-id pub-id-type="pmid">22622581</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Georgiadou</surname><given-names>M</given-names></name><name><surname>Lilja</surname><given-names>J</given-names></name><name><surname>Jacquemet</surname><given-names>G</given-names></name><name><surname>Guzmán</surname><given-names>C</given-names></name><name><surname>Rafaeva</surname><given-names>M</given-names></name><name><surname>Alibert</surname><given-names>C</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Sahgal</surname><given-names>P</given-names></name><name><surname>Lerche</surname><given-names>M</given-names></name><name><surname>Manneville</surname><given-names>JB</given-names></name><name><surname>Mäkelä</surname><given-names>TP</given-names></name><name><surname>Ivaska</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Ampk negatively regulates tensin-dependent integrin activity</article-title><source>The Journal of Cell Biology</source><volume>216</volume><fpage>1107</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.1083/jcb.201609066</pub-id><pub-id pub-id-type="pmid">28289092</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grubman</surname><given-names>A</given-names></name><name><surname>Chew</surname><given-names>G</given-names></name><name><surname>Ouyang</surname><given-names>JF</given-names></name><name><surname>Sun</surname><given-names>G</given-names></name><name><surname>Choo</surname><given-names>XY</given-names></name><name><surname>McLean</surname><given-names>C</given-names></name><name><surname>Simmons</surname><given-names>RK</given-names></name><name><surname>Buckberry</surname><given-names>S</given-names></name><name><surname>Vargas-Landin</surname><given-names>DB</given-names></name><name><surname>Poppe</surname><given-names>D</given-names></name><name><surname>Pflueger</surname><given-names>J</given-names></name><name><surname>Lister</surname><given-names>R</given-names></name><name><surname>Rackham</surname><given-names>OJL</given-names></name><name><surname>Petretto</surname><given-names>E</given-names></name><name><surname>Polo</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A single-cell atlas of entorhinal cortex from individuals with Alzheimer’s disease reveals cell-type-specific gene expression regulation</article-title><source>Nature Neuroscience</source><volume>22</volume><fpage>2087</fpage><lpage>2097</lpage><pub-id pub-id-type="doi">10.1038/s41593-019-0539-4</pub-id><pub-id pub-id-type="pmid">31768052</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>D</given-names></name><name><surname>Marie</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Clavairoly</surname><given-names>A</given-names></name><name><surname>Frah</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Hmidan</surname><given-names>H</given-names></name><name><surname>Jones</surname><given-names>BV</given-names></name><name><surname>Witte</surname><given-names>D</given-names></name><name><surname>Zalc</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Choo</surname><given-names>DI</given-names></name><name><surname>Martin</surname><given-names>DM</given-names></name><name><surname>Parras</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>QR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Chd7 cooperates with sox10 and regulates the onset of CNS myelination and remyelination</article-title><source>Nature Neuroscience</source><volume>19</volume><fpage>678</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1038/nn.4258</pub-id><pub-id pub-id-type="pmid">26928066</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>EG</given-names></name><name><surname>Orthmann-Murphy</surname><given-names>JL</given-names></name><name><surname>Langseth</surname><given-names>AJ</given-names></name><name><surname>Bergles</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Myelin remodeling through experience-dependent oligodendrogenesis in the adult somatosensory cortex</article-title><source>Nature Neuroscience</source><volume>21</volume><fpage>696</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1038/s41593-018-0121-5</pub-id><pub-id pub-id-type="pmid">29556025</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>EG</given-names></name><name><surname>Stockton</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Premyelinating oligodendrocytes: mechanisms underlying cell survival and integration</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>9</volume><elocation-id>714169</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2021.714169</pub-id><pub-id pub-id-type="pmid">34368163</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>SH</given-names></name><name><surname>Fukaya</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>JK</given-names></name><name><surname>Rothstein</surname><given-names>JD</given-names></name><name><surname>Bergles</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>NG2+ CNS glial progenitors remain committed to the oligodendrocyte lineage in postnatal life and following neurodegeneration</article-title><source>Neuron</source><volume>68</volume><fpage>668</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2010.09.009</pub-id><pub-id pub-id-type="pmid">21092857</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karczewski</surname><given-names>KJ</given-names></name><name><surname>Francioli</surname><given-names>LC</given-names></name><name><surname>Tiao</surname><given-names>G</given-names></name><name><surname>Cummings</surname><given-names>BB</given-names></name><name><surname>Alföldi</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Collins</surname><given-names>RL</given-names></name><name><surname>Laricchia</surname><given-names>KM</given-names></name><name><surname>Ganna</surname><given-names>A</given-names></name><name><surname>Birnbaum</surname><given-names>DP</given-names></name><name><surname>Gauthier</surname><given-names>LD</given-names></name><name><surname>Brand</surname><given-names>H</given-names></name><name><surname>Solomonson</surname><given-names>M</given-names></name><name><surname>Watts</surname><given-names>NA</given-names></name><name><surname>Rhodes</surname><given-names>D</given-names></name><name><surname>Singer-Berk</surname><given-names>M</given-names></name><name><surname>England</surname><given-names>EM</given-names></name><name><surname>Seaby</surname><given-names>EG</given-names></name><name><surname>Kosmicki</surname><given-names>JA</given-names></name><name><surname>Walters</surname><given-names>RK</given-names></name><name><surname>Tashman</surname><given-names>K</given-names></name><name><surname>Farjoun</surname><given-names>Y</given-names></name><name><surname>Banks</surname><given-names>E</given-names></name><name><surname>Poterba</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Seed</surname><given-names>C</given-names></name><name><surname>Whiffin</surname><given-names>N</given-names></name><name><surname>Chong</surname><given-names>JX</given-names></name><name><surname>Samocha</surname><given-names>KE</given-names></name><name><surname>Pierce-Hoffman</surname><given-names>E</given-names></name><name><surname>Zappala</surname><given-names>Z</given-names></name><name><surname>O’Donnell-Luria</surname><given-names>AH</given-names></name><name><surname>Minikel</surname><given-names>EV</given-names></name><name><surname>Weisburd</surname><given-names>B</given-names></name><name><surname>Lek</surname><given-names>M</given-names></name><name><surname>Ware</surname><given-names>JS</given-names></name><name><surname>Vittal</surname><given-names>C</given-names></name><name><surname>Armean</surname><given-names>IM</given-names></name><name><surname>Bergelson</surname><given-names>L</given-names></name><name><surname>Cibulskis</surname><given-names>K</given-names></name><name><surname>Connolly</surname><given-names>KM</given-names></name><name><surname>Covarrubias</surname><given-names>M</given-names></name><name><surname>Donnelly</surname><given-names>S</given-names></name><name><surname>Ferriera</surname><given-names>S</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Gentry</surname><given-names>J</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Jeandet</surname><given-names>T</given-names></name><name><surname>Kaplan</surname><given-names>D</given-names></name><name><surname>Llanwarne</surname><given-names>C</given-names></name><name><surname>Munshi</surname><given-names>R</given-names></name><name><surname>Novod</surname><given-names>S</given-names></name><name><surname>Petrillo</surname><given-names>N</given-names></name><name><surname>Roazen</surname><given-names>D</given-names></name><name><surname>Ruano-Rubio</surname><given-names>V</given-names></name><name><surname>Saltzman</surname><given-names>A</given-names></name><name><surname>Schleicher</surname><given-names>M</given-names></name><name><surname>Soto</surname><given-names>J</given-names></name><name><surname>Tibbetts</surname><given-names>K</given-names></name><name><surname>Tolonen</surname><given-names>C</given-names></name><name><surname>Wade</surname><given-names>G</given-names></name><name><surname>Talkowski</surname><given-names>ME</given-names></name><name><surname>Neale</surname><given-names>BM</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>MacArthur</surname><given-names>DG</given-names></name><collab>Genome Aggregation Database Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>The mutational constraint spectrum quantified from variation in 141,456 humans</article-title><source>Nature</source><volume>581</volume><fpage>434</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2308-7</pub-id><pub-id pub-id-type="pmid">32461654</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kastenhuber</surname><given-names>ER</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Putting p53 in context</article-title><source>Cell</source><volume>170</volume><fpage>1062</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.08.028</pub-id><pub-id pub-id-type="pmid">28886379</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>M</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name><name><surname>Citri</surname><given-names>A</given-names></name><name><surname>Shay</surname><given-names>T</given-names></name><name><surname>Carvalho</surname><given-names>S</given-names></name><name><surname>Lavi</surname><given-names>S</given-names></name><name><surname>Milanezi</surname><given-names>F</given-names></name><name><surname>Lyass</surname><given-names>L</given-names></name><name><surname>Amariglio</surname><given-names>N</given-names></name><name><surname>Jacob-Hirsch</surname><given-names>J</given-names></name><name><surname>Ben-Chetrit</surname><given-names>N</given-names></name><name><surname>Tarcic</surname><given-names>G</given-names></name><name><surname>Lindzen</surname><given-names>M</given-names></name><name><surname>Avraham</surname><given-names>R</given-names></name><name><surname>Liao</surname><given-names>Y-C</given-names></name><name><surname>Trusk</surname><given-names>P</given-names></name><name><surname>Lyass</surname><given-names>A</given-names></name><name><surname>Rechavi</surname><given-names>G</given-names></name><name><surname>Spector</surname><given-names>NL</given-names></name><name><surname>Lo</surname><given-names>SH</given-names></name><name><surname>Schmitt</surname><given-names>F</given-names></name><name><surname>Bacus</surname><given-names>SS</given-names></name><name><surname>Yarden</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration</article-title><source>Nature Cell Biology</source><volume>9</volume><fpage>961</fpage><lpage>969</lpage><pub-id pub-id-type="doi">10.1038/ncb1622</pub-id><pub-id pub-id-type="pmid">17643115</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kessaris</surname><given-names>N</given-names></name><name><surname>Fogarty</surname><given-names>M</given-names></name><name><surname>Iannarelli</surname><given-names>P</given-names></name><name><surname>Grist</surname><given-names>M</given-names></name><name><surname>Wegner</surname><given-names>M</given-names></name><name><surname>Richardson</surname><given-names>WD</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Competing waves of oligodendrocytes in the forebrain and postnatal elimination of an embryonic lineage</article-title><source>Nature Neuroscience</source><volume>9</volume><fpage>173</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1038/nn1620</pub-id><pub-id pub-id-type="pmid">16388308</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>CC</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Signaling by integrin receptors</article-title><source>Oncogene</source><volume>17</volume><fpage>1365</fpage><lpage>1373</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1202172</pub-id><pub-id pub-id-type="pmid">9779984</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Küspert</surname><given-names>M</given-names></name><name><surname>Wegner</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Something 2 talk about-transcriptional regulation in embryonic and adult oligodendrocyte precursors</article-title><source>Brain Research</source><volume>1638</volume><fpage>167</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2015.07.024</pub-id><pub-id pub-id-type="pmid">26232072</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ladiwala</surname><given-names>U</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Antel</surname><given-names>JP</given-names></name><name><surname>Nalbantoglu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>P53 induction by tumor necrosis factor-alpha and involvement of p53 in cell death of human oligodendrocytes</article-title><source>Journal of Neurochemistry</source><volume>73</volume><fpage>605</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.1999.0730605.x</pub-id><pub-id pub-id-type="pmid">10428056</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>J</given-names></name><name><surname>Maeda</surname><given-names>Y</given-names></name><name><surname>Bannerman</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Horiuchi</surname><given-names>M</given-names></name><name><surname>Pleasure</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Adenomatous polyposis coli regulates oligodendroglial development</article-title><source>The Journal of Neuroscience</source><volume>33</volume><fpage>3113</fpage><lpage>3130</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3467-12.2013</pub-id><pub-id pub-id-type="pmid">23407966</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Morrison</surname><given-names>BM</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Lengacher</surname><given-names>S</given-names></name><name><surname>Farah</surname><given-names>MH</given-names></name><name><surname>Hoffman</surname><given-names>PN</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Tsingalia</surname><given-names>A</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>PW</given-names></name><name><surname>Pellerin</surname><given-names>L</given-names></name><name><surname>Magistretti</surname><given-names>PJ</given-names></name><name><surname>Rothstein</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Oligodendroglia metabolically support axons and contribute to neurodegeneration</article-title><source>Nature</source><volume>487</volume><fpage>443</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1038/nature11314</pub-id><pub-id pub-id-type="pmid">22801498</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lek</surname><given-names>M</given-names></name><name><surname>Karczewski</surname><given-names>KJ</given-names></name><name><surname>Minikel</surname><given-names>EV</given-names></name><name><surname>Samocha</surname><given-names>KE</given-names></name><name><surname>Banks</surname><given-names>E</given-names></name><name><surname>Fennell</surname><given-names>T</given-names></name><name><surname>O’Donnell-Luria</surname><given-names>AH</given-names></name><name><surname>Ware</surname><given-names>JS</given-names></name><name><surname>Hill</surname><given-names>AJ</given-names></name><name><surname>Cummings</surname><given-names>BB</given-names></name><name><surname>Tukiainen</surname><given-names>T</given-names></name><name><surname>Birnbaum</surname><given-names>DP</given-names></name><name><surname>Kosmicki</surname><given-names>JA</given-names></name><name><surname>Duncan</surname><given-names>LE</given-names></name><name><surname>Estrada</surname><given-names>K</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Pierce-Hoffman</surname><given-names>E</given-names></name><name><surname>Berghout</surname><given-names>J</given-names></name><name><surname>Cooper</surname><given-names>DN</given-names></name><name><surname>Deflaux</surname><given-names>N</given-names></name><name><surname>DePristo</surname><given-names>M</given-names></name><name><surname>Do</surname><given-names>R</given-names></name><name><surname>Flannick</surname><given-names>J</given-names></name><name><surname>Fromer</surname><given-names>M</given-names></name><name><surname>Gauthier</surname><given-names>L</given-names></name><name><surname>Goldstein</surname><given-names>J</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Howrigan</surname><given-names>D</given-names></name><name><surname>Kiezun</surname><given-names>A</given-names></name><name><surname>Kurki</surname><given-names>MI</given-names></name><name><surname>Moonshine</surname><given-names>AL</given-names></name><name><surname>Natarajan</surname><given-names>P</given-names></name><name><surname>Orozco</surname><given-names>L</given-names></name><name><surname>Peloso</surname><given-names>GM</given-names></name><name><surname>Poplin</surname><given-names>R</given-names></name><name><surname>Rivas</surname><given-names>MA</given-names></name><name><surname>Ruano-Rubio</surname><given-names>V</given-names></name><name><surname>Rose</surname><given-names>SA</given-names></name><name><surname>Ruderfer</surname><given-names>DM</given-names></name><name><surname>Shakir</surname><given-names>K</given-names></name><name><surname>Stenson</surname><given-names>PD</given-names></name><name><surname>Stevens</surname><given-names>C</given-names></name><name><surname>Thomas</surname><given-names>BP</given-names></name><name><surname>Tiao</surname><given-names>G</given-names></name><name><surname>Tusie-Luna</surname><given-names>MT</given-names></name><name><surname>Weisburd</surname><given-names>B</given-names></name><name><surname>Won</surname><given-names>HH</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Altshuler</surname><given-names>DM</given-names></name><name><surname>Ardissino</surname><given-names>D</given-names></name><name><surname>Boehnke</surname><given-names>M</given-names></name><name><surname>Danesh</surname><given-names>J</given-names></name><name><surname>Donnelly</surname><given-names>S</given-names></name><name><surname>Elosua</surname><given-names>R</given-names></name><name><surname>Florez</surname><given-names>JC</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Glatt</surname><given-names>SJ</given-names></name><name><surname>Hultman</surname><given-names>CM</given-names></name><name><surname>Kathiresan</surname><given-names>S</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name><name><surname>McCarroll</surname><given-names>S</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>McGovern</surname><given-names>D</given-names></name><name><surname>McPherson</surname><given-names>R</given-names></name><name><surname>Neale</surname><given-names>BM</given-names></name><name><surname>Palotie</surname><given-names>A</given-names></name><name><surname>Purcell</surname><given-names>SM</given-names></name><name><surname>Saleheen</surname><given-names>D</given-names></name><name><surname>Scharf</surname><given-names>JM</given-names></name><name><surname>Sklar</surname><given-names>P</given-names></name><name><surname>Sullivan</surname><given-names>PF</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Tsuang</surname><given-names>MT</given-names></name><name><surname>Watkins</surname><given-names>HC</given-names></name><name><surname>Wilson</surname><given-names>JG</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>MacArthur</surname><given-names>DG</given-names></name><collab>Exome Aggregation Consortium</collab></person-group><year iso-8601-date="2016">2016</year><article-title>Analysis of protein-coding genetic variation in 60,706 humans</article-title><source>Nature</source><volume>536</volume><fpage>285</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1038/nature19057</pub-id><pub-id pub-id-type="pmid">27535533</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Ghiani</surname><given-names>CA</given-names></name><name><surname>Kim</surname><given-names>JY</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name><name><surname>Sandoval</surname><given-names>J</given-names></name><name><surname>DeVellis</surname><given-names>J</given-names></name><name><surname>Casaccia-Bonnefil</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Inhibition of p53 transcriptional activity: a potential target for future development of therapeutic strategies for primary demyelination</article-title><source>The Journal of Neuroscience</source><volume>28</volume><fpage>6118</fpage><lpage>6127</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0184-08.2008</pub-id><pub-id pub-id-type="pmid">18550754</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Y-C</given-names></name><name><surname>Si</surname><given-names>L</given-names></name><name><surname>deVere White</surname><given-names>RW</given-names></name><name><surname>Lo</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1</article-title><source>The Journal of Cell Biology</source><volume>176</volume><fpage>43</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1083/jcb.200608015</pub-id><pub-id pub-id-type="pmid">17190795</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>YC</given-names></name><name><surname>Lo</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Tensins - emerging insights into their domain functions, biological roles and disease relevance</article-title><source>Journal of Cell Science</source><volume>134</volume><elocation-id>jcs254029</elocation-id><pub-id pub-id-type="doi">10.1242/jcs.254029</pub-id><pub-id pub-id-type="pmid">33597154</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Sage</surname><given-names>JC</given-names></name><name><surname>Miller</surname><given-names>MR</given-names></name><name><surname>Verhaak</surname><given-names>RGW</given-names></name><name><surname>Hippenmeyer</surname><given-names>S</given-names></name><name><surname>Vogel</surname><given-names>H</given-names></name><name><surname>Foreman</surname><given-names>O</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Nishiyama</surname><given-names>A</given-names></name><name><surname>Luo</surname><given-names>L</given-names></name><name><surname>Zong</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Mosaic analysis with double markers reveals tumor cell of origin in glioma</article-title><source>Cell</source><volume>146</volume><fpage>209</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.06.014</pub-id><pub-id pub-id-type="pmid">21737130</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>QR</given-names></name><name><surname>Yuk</surname><given-names>D</given-names></name><name><surname>Alberta</surname><given-names>JA</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Pawlitzky</surname><given-names>I</given-names></name><name><surname>Chan</surname><given-names>J</given-names></name><name><surname>McMahon</surname><given-names>AP</given-names></name><name><surname>Stiles</surname><given-names>CD</given-names></name><name><surname>Rowitch</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Sonic hedgehog -- regulated oligodendrocyte lineage genes encoding bHLH proteins in the mammalian central nervous system</article-title><source>Neuron</source><volume>25</volume><fpage>317</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1016/s0896-6273(00)80897-1</pub-id><pub-id pub-id-type="pmid">10719888</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>QR</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Ma</surname><given-names>N</given-names></name><name><surname>Garcia</surname><given-names>M</given-names></name><name><surname>Stiles</surname><given-names>CD</given-names></name><name><surname>Rowitch</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Common developmental requirement for olig function indicates a motor neuron/oligodendrocyte connection</article-title><source>Cell</source><volume>109</volume><fpage>75</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(02)00678-5</pub-id><pub-id pub-id-type="pmid">11955448</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Differential role of p53 in oligodendrocyte survival in response to various stresses: experimental autoimmune encephalomyelitis, cuprizone intoxication or white matter stroke</article-title><source>International Journal of Molecular Sciences</source><volume>22</volume><elocation-id>12811</elocation-id><pub-id pub-id-type="doi">10.3390/ijms222312811</pub-id><pub-id pub-id-type="pmid">34884611</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marie</surname><given-names>C</given-names></name><name><surname>Clavairoly</surname><given-names>A</given-names></name><name><surname>Frah</surname><given-names>M</given-names></name><name><surname>Hmidan</surname><given-names>H</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Van Steenwinckel</surname><given-names>J</given-names></name><name><surname>Daveau</surname><given-names>R</given-names></name><name><surname>Zalc</surname><given-names>B</given-names></name><name><surname>Hassan</surname><given-names>B</given-names></name><name><surname>Thomas</surname><given-names>JL</given-names></name><name><surname>Gressens</surname><given-names>P</given-names></name><name><surname>Ravassard</surname><given-names>P</given-names></name><name><surname>Moszer</surname><given-names>I</given-names></name><name><surname>Martin</surname><given-names>DM</given-names></name><name><surname>Lu</surname><given-names>QR</given-names></name><name><surname>Parras</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Oligodendrocyte precursor survival and differentiation requires chromatin remodeling by CHD7 and CHD8</article-title><source>PNAS</source><volume>115</volume><elocation-id>35</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.1802620115</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marques</surname><given-names>S</given-names></name><name><surname>Zeisel</surname><given-names>A</given-names></name><name><surname>Codeluppi</surname><given-names>S</given-names></name><name><surname>van Bruggen</surname><given-names>D</given-names></name><name><surname>Mendanha Falcão</surname><given-names>A</given-names></name><name><surname>Xiao</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Häring</surname><given-names>M</given-names></name><name><surname>Hochgerner</surname><given-names>H</given-names></name><name><surname>Romanov</surname><given-names>RA</given-names></name><name><surname>Gyllborg</surname><given-names>D</given-names></name><name><surname>Muñoz Manchado</surname><given-names>A</given-names></name><name><surname>La Manno</surname><given-names>G</given-names></name><name><surname>Lönnerberg</surname><given-names>P</given-names></name><name><surname>Floriddia</surname><given-names>EM</given-names></name><name><surname>Rezayee</surname><given-names>F</given-names></name><name><surname>Ernfors</surname><given-names>P</given-names></name><name><surname>Arenas</surname><given-names>E</given-names></name><name><surname>Hjerling-Leffler</surname><given-names>J</given-names></name><name><surname>Harkany</surname><given-names>T</given-names></name><name><surname>Richardson</surname><given-names>WD</given-names></name><name><surname>Linnarsson</surname><given-names>S</given-names></name><name><surname>Castelo-Branco</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Oligodendrocyte heterogeneity in the mouse juvenile and adult central nervous system</article-title><source>Science</source><volume>352</volume><fpage>1326</fpage><lpage>1329</lpage><pub-id pub-id-type="doi">10.1126/science.aaf6463</pub-id><pub-id pub-id-type="pmid">27284195</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martuszewska</surname><given-names>D</given-names></name><name><surname>Ljungberg</surname><given-names>B</given-names></name><name><surname>Johansson</surname><given-names>M</given-names></name><name><surname>Landberg</surname><given-names>G</given-names></name><name><surname>Oslakovic</surname><given-names>C</given-names></name><name><surname>Dahlbäck</surname><given-names>B</given-names></name><name><surname>Hafizi</surname><given-names>S</given-names></name><name><surname>Hoheisel</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Tensin3 is a negative regulator of cell migration and all four tensin family members are downregulated in human kidney cancer</article-title><source>PLOS ONE</source><volume>4</volume><elocation-id>e4350</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0004350</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCleverty</surname><given-names>CJ</given-names></name><name><surname>Lin</surname><given-names>DC</given-names></name><name><surname>Liddington</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Structure of the PTB domain of tensin1 and a model for its recruitment to fibrillar adhesions</article-title><source>Protein Science</source><volume>16</volume><fpage>1223</fpage><lpage>1229</lpage><pub-id pub-id-type="doi">10.1110/ps.072798707</pub-id><pub-id pub-id-type="pmid">17473008</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenzie</surname><given-names>IA</given-names></name><name><surname>Ohayon</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>de Faria</surname><given-names>JP</given-names></name><name><surname>Emery</surname><given-names>B</given-names></name><name><surname>Tohyama</surname><given-names>K</given-names></name><name><surname>Richardson</surname><given-names>WD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Motor skill learning requires active central myelination</article-title><source>Science</source><volume>346</volume><fpage>318</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1126/science.1254960</pub-id><pub-id pub-id-type="pmid">25324381</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>N</given-names></name><name><surname>Richter</surname><given-names>N</given-names></name><name><surname>Fan</surname><given-names>Z</given-names></name><name><surname>Siemonsmeier</surname><given-names>G</given-names></name><name><surname>Pivneva</surname><given-names>T</given-names></name><name><surname>Jordan</surname><given-names>P</given-names></name><name><surname>Steinhäuser</surname><given-names>C</given-names></name><name><surname>Semtner</surname><given-names>M</given-names></name><name><surname>Nolte</surname><given-names>C</given-names></name><name><surname>Kettenmann</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Oligodendrocytes in the mouse corpus callosum maintain axonal function by delivery of glucose</article-title><source>Cell Reports</source><volume>22</volume><fpage>2383</fpage><lpage>2394</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.02.022</pub-id><pub-id pub-id-type="pmid">29490274</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mount</surname><given-names>CW</given-names></name><name><surname>Monje</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Wrapped to adapt: experience-dependent myelination</article-title><source>Neuron</source><volume>95</volume><fpage>743</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2017.07.009</pub-id><pub-id pub-id-type="pmid">28817797</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nait-Oumesmar</surname><given-names>B</given-names></name><name><surname>Decker</surname><given-names>L</given-names></name><name><surname>Lachapelle</surname><given-names>F</given-names></name><name><surname>Avellana-Adalid</surname><given-names>V</given-names></name><name><surname>Bachelin</surname><given-names>C</given-names></name><name><surname>Baron-Van Evercooren</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Progenitor cells of the adult mouse subventricular zone proliferate, migrate and differentiate into oligodendrocytes after demyelination</article-title><source>The European Journal of Neuroscience</source><volume>11</volume><fpage>4357</fpage><lpage>4366</lpage><pub-id pub-id-type="doi">10.1046/j.1460-9568.1999.00873.x</pub-id><pub-id pub-id-type="pmid">10594662</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakatani</surname><given-names>H</given-names></name><name><surname>Martin</surname><given-names>E</given-names></name><name><surname>Hassani</surname><given-names>H</given-names></name><name><surname>Clavairoly</surname><given-names>A</given-names></name><name><surname>Maire</surname><given-names>CL</given-names></name><name><surname>Viadieu</surname><given-names>A</given-names></name><name><surname>Kerninon</surname><given-names>C</given-names></name><name><surname>Delmasure</surname><given-names>A</given-names></name><name><surname>Frah</surname><given-names>M</given-names></name><name><surname>Weber</surname><given-names>M</given-names></name><name><surname>Nakafuku</surname><given-names>M</given-names></name><name><surname>Zalc</surname><given-names>B</given-names></name><name><surname>Thomas</surname><given-names>JL</given-names></name><name><surname>Guillemot</surname><given-names>F</given-names></name><name><surname>Nait-Oumesmar</surname><given-names>B</given-names></name><name><surname>Parras</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Ascl1/mash1 promotes brain oligodendrogenesis during myelination and remyelination</article-title><source>The Journal of Neuroscience</source><volume>33</volume><fpage>9752</fpage><lpage>9768</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0805-13.2013</pub-id><pub-id pub-id-type="pmid">23739972</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nawaz</surname><given-names>S</given-names></name><name><surname>Sánchez</surname><given-names>P</given-names></name><name><surname>Schmitt</surname><given-names>S</given-names></name><name><surname>Snaidero</surname><given-names>N</given-names></name><name><surname>Mitkovski</surname><given-names>M</given-names></name><name><surname>Velte</surname><given-names>C</given-names></name><name><surname>Brückner</surname><given-names>BR</given-names></name><name><surname>Alexopoulos</surname><given-names>I</given-names></name><name><surname>Czopka</surname><given-names>T</given-names></name><name><surname>Jung</surname><given-names>SY</given-names></name><name><surname>Rhee</surname><given-names>JS</given-names></name><name><surname>Janshoff</surname><given-names>A</given-names></name><name><surname>Witke</surname><given-names>W</given-names></name><name><surname>Schaap</surname><given-names>IAT</given-names></name><name><surname>Lyons</surname><given-names>DA</given-names></name><name><surname>Simons</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Actin filament turnover drives leading edge growth during myelin sheath formation in the central nervous system</article-title><source>Developmental Cell</source><volume>34</volume><fpage>139</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2015.05.013</pub-id><pub-id pub-id-type="pmid">26166299</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>B</given-names></name><name><surname>Segel</surname><given-names>M</given-names></name><name><surname>Chalut</surname><given-names>KJ</given-names></name><name><surname>Franklin</surname><given-names>RJM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Remyelination and ageing: reversing the ravages of time</article-title><source>Multiple Sclerosis</source><volume>25</volume><fpage>1835</fpage><lpage>1841</lpage><pub-id pub-id-type="doi">10.1177/1352458519884006</pub-id><pub-id pub-id-type="pmid">31687878</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishino</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>N</given-names></name><name><surname>Chihara</surname><given-names>M</given-names></name><name><surname>Nagasaki</surname><given-names>K</given-names></name><name><surname>Torigoe</surname><given-names>D</given-names></name><name><surname>Kon</surname><given-names>Y</given-names></name><name><surname>Agui</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Distinct distribution of the tensin family in the mouse kidney and small intestine</article-title><source>Experimental Animals</source><volume>61</volume><fpage>525</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1538/expanim.61.525</pub-id><pub-id pub-id-type="pmid">23095816</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nott</surname><given-names>A</given-names></name><name><surname>Holtman</surname><given-names>IR</given-names></name><name><surname>Coufal</surname><given-names>NG</given-names></name><name><surname>Schlachetzki</surname><given-names>JCM</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Hu</surname><given-names>R</given-names></name><name><surname>Han</surname><given-names>CZ</given-names></name><name><surname>Pena</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Keulen</surname><given-names>Z</given-names></name><name><surname>Pasillas</surname><given-names>MP</given-names></name><name><surname>O’Connor</surname><given-names>C</given-names></name><name><surname>Nickl</surname><given-names>CK</given-names></name><name><surname>Schafer</surname><given-names>ST</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Rissman</surname><given-names>RA</given-names></name><name><surname>Brewer</surname><given-names>JB</given-names></name><name><surname>Gosselin</surname><given-names>D</given-names></name><name><surname>Gonda</surname><given-names>DD</given-names></name><name><surname>Levy</surname><given-names>ML</given-names></name><name><surname>Rosenfeld</surname><given-names>MG</given-names></name><name><surname>McVicker</surname><given-names>G</given-names></name><name><surname>Gage</surname><given-names>FH</given-names></name><name><surname>Ren</surname><given-names>B</given-names></name><name><surname>Glass</surname><given-names>CK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Brain cell type-specific enhancer-promoter interactome maps and disease-risk association</article-title><source>Science</source><volume>366</volume><fpage>1134</fpage><lpage>1139</lpage><pub-id pub-id-type="doi">10.1126/science.aay0793</pub-id><pub-id pub-id-type="pmid">31727856</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>S</given-names></name><name><surname>Mayoral</surname><given-names>SR</given-names></name><name><surname>Choi</surname><given-names>HS</given-names></name><name><surname>Chan</surname><given-names>JR</given-names></name><name><surname>Kheirbek</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Preservation of a remote fear memory requires new myelin formation</article-title><source>Nature Neuroscience</source><volume>23</volume><fpage>487</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1038/s41593-019-0582-1</pub-id><pub-id pub-id-type="pmid">32042175</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parras</surname><given-names>C</given-names></name><name><surname>Marie</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>QR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Chromatin remodelers in oligodendroglia</article-title><source>Glia</source><volume>68</volume><fpage>1604</fpage><lpage>1618</lpage><pub-id pub-id-type="doi">10.1002/glia.23837</pub-id><pub-id pub-id-type="pmid">32460418</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="software"><person-group person-group-type="author"><collab>ParrasLab</collab></person-group><year iso-8601-date="2022">2022</year><data-title>Tns3_paper_eLife_2022</data-title><version designator="swh:1:rev:fa63c93277571bd0fe113242e4929ea5a1957fad">swh:1:rev:fa63c93277571bd0fe113242e4929ea5a1957fad</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:dc6c5659b5cec4cb5063f5604bd9edc00c80bc16;origin=https://github.com/ParrasLab/Tns3_paper_eLife_2022;visit=swh:1:snp:253a792d27c6ae851511abbaf4dd995bf7c19bc0;anchor=swh:1:rev:fa63c93277571bd0fe113242e4929ea5a1957fad">https://archive.softwareheritage.org/swh:1:dir:dc6c5659b5cec4cb5063f5604bd9edc00c80bc16;origin=https://github.com/ParrasLab/Tns3_paper_eLife_2022;visit=swh:1:snp:253a792d27c6ae851511abbaf4dd995bf7c19bc0;anchor=swh:1:rev:fa63c93277571bd0fe113242e4929ea5a1957fad</ext-link></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phan</surname><given-names>BN</given-names></name><name><surname>Bohlen</surname><given-names>JF</given-names></name><name><surname>Davis</surname><given-names>BA</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>H-Y</given-names></name><name><surname>Mayfield</surname><given-names>B</given-names></name><name><surname>Sripathy</surname><given-names>SR</given-names></name><name><surname>Cerceo Page</surname><given-names>S</given-names></name><name><surname>Campbell</surname><given-names>MN</given-names></name><name><surname>Smith</surname><given-names>HL</given-names></name><name><surname>Gallop</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Thaxton</surname><given-names>CL</given-names></name><name><surname>Simon</surname><given-names>JM</given-names></name><name><surname>Burke</surname><given-names>EE</given-names></name><name><surname>Shin</surname><given-names>JH</given-names></name><name><surname>Kennedy</surname><given-names>AJ</given-names></name><name><surname>Sweatt</surname><given-names>JD</given-names></name><name><surname>Philpot</surname><given-names>BD</given-names></name><name><surname>Jaffe</surname><given-names>AE</given-names></name><name><surname>Maher</surname><given-names>BJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A myelin-related transcriptomic profile is shared by pitt-hopkins syndrome models and human autism spectrum disorder</article-title><source>Nature Neuroscience</source><volume>23</volume><fpage>375</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1038/s41593-019-0578-x</pub-id><pub-id pub-id-type="pmid">32015540</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>H</given-names></name><name><surname>Rao</surname><given-names>M</given-names></name><name><surname>Sussel</surname><given-names>L</given-names></name><name><surname>Rubenstein</surname><given-names>J</given-names></name><name><surname>Qiu</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Control of oligodendrocyte differentiation by the nkx2.2 homeodomain transcription factor</article-title><source>Development</source><volume>128</volume><fpage>2723</fpage><lpage>2733</lpage><pub-id pub-id-type="doi">10.1242/dev.128.14.2723</pub-id><pub-id pub-id-type="pmid">11526078</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>JT</given-names></name><name><surname>Thorvaldsdóttir</surname><given-names>H</given-names></name><name><surname>Winckler</surname><given-names>W</given-names></name><name><surname>Guttman</surname><given-names>M</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Integrative genomics viewer</article-title><source>Nature Biotechnology</source><volume>29</volume><fpage>24</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1038/nbt.1754</pub-id><pub-id pub-id-type="pmid">21221095</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steadman</surname><given-names>PE</given-names></name><name><surname>Xia</surname><given-names>F</given-names></name><name><surname>Ahmed</surname><given-names>M</given-names></name><name><surname>Mocle</surname><given-names>AJ</given-names></name><name><surname>Penning</surname><given-names>ARA</given-names></name><name><surname>Geraghty</surname><given-names>AC</given-names></name><name><surname>Steenland</surname><given-names>HW</given-names></name><name><surname>Monje</surname><given-names>M</given-names></name><name><surname>Josselyn</surname><given-names>SA</given-names></name><name><surname>Frankland</surname><given-names>PW</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Disruption of oligodendrogenesis impairs memory consolidation in adult mice</article-title><source>Neuron</source><volume>105</volume><fpage>150</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2019.10.013</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stolt</surname><given-names>CC</given-names></name><name><surname>Rehberg</surname><given-names>S</given-names></name><name><surname>Ader</surname><given-names>M</given-names></name><name><surname>Lommes</surname><given-names>P</given-names></name><name><surname>Riethmacher</surname><given-names>D</given-names></name><name><surname>Schachner</surname><given-names>M</given-names></name><name><surname>Bartsch</surname><given-names>U</given-names></name><name><surname>Wegner</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Terminal differentiation of myelin-forming oligodendrocytes depends on the transcription factor SOX10</article-title><source>Genes &amp; Development</source><volume>16</volume><fpage>165</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1101/gad.215802</pub-id><pub-id pub-id-type="pmid">11799060</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stuart</surname><given-names>T</given-names></name><name><surname>Butler</surname><given-names>A</given-names></name><name><surname>Hoffman</surname><given-names>P</given-names></name><name><surname>Hafemeister</surname><given-names>C</given-names></name><name><surname>Papalexi</surname><given-names>E</given-names></name><name><surname>Mauck</surname><given-names>WM</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Stoeckius</surname><given-names>M</given-names></name><name><surname>Smibert</surname><given-names>P</given-names></name><name><surname>Satija</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Comprehensive integration of single-cell data</article-title><source>Cell</source><volume>177</volume><fpage>1888</fpage><lpage>1902</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.05.031</pub-id><pub-id pub-id-type="pmid">31178118</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>LO</given-names></name><name><surname>Mulinyawe</surname><given-names>SB</given-names></name><name><surname>Collins</surname><given-names>HY</given-names></name><name><surname>Ibrahim</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Simon</surname><given-names>DJ</given-names></name><name><surname>Tessier-Lavigne</surname><given-names>M</given-names></name><name><surname>Barres</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Spatiotemporal control of CNS myelination by oligodendrocyte programmed cell death through the TFEB-PUMA axis</article-title><source>Cell</source><volume>175</volume><fpage>1811</fpage><lpage>1826</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.10.044</pub-id><pub-id pub-id-type="pmid">30503207</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>SO</given-names></name><name><surname>Goldman</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Multiple cell populations in the early postnatal subventricular zone take distinct migratory pathways: a dynamic study of glial and neuronal progenitor migration</article-title><source>The Journal of Neuroscience</source><volume>23</volume><fpage>4240</fpage><lpage>4250</lpage><pub-id pub-id-type="pmid">12764112</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomason</surname><given-names>EJ</given-names></name><name><surname>Escalante</surname><given-names>M</given-names></name><name><surname>Osterhout</surname><given-names>DJ</given-names></name><name><surname>Fuss</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The oligodendrocyte growth cone and its actin cytoskeleton: a fundamental element for progenitor cell migration and CNS myelination</article-title><source>Glia</source><volume>68</volume><fpage>1329</fpage><lpage>1346</lpage><pub-id pub-id-type="doi">10.1002/glia.23735</pub-id><pub-id pub-id-type="pmid">31696982</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapp</surname><given-names>BD</given-names></name><name><surname>Nishiyama</surname><given-names>A</given-names></name><name><surname>Cheng</surname><given-names>D</given-names></name><name><surname>Macklin</surname><given-names>W</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Differentiation and death of premyelinating oligodendrocytes in developing rodent brain</article-title><source>The Journal of Cell Biology</source><volume>137</volume><fpage>459</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1083/jcb.137.2.459</pub-id><pub-id pub-id-type="pmid">9128255</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Ren</surname><given-names>S-Y</given-names></name><name><surname>Chen</surname><given-names>J-F</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>R-X</given-names></name><name><surname>Li</surname><given-names>Z-F</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Niu</surname><given-names>J-Q</given-names></name><name><surname>Xiao</surname><given-names>L</given-names></name><name><surname>Chan</surname><given-names>JR</given-names></name><name><surname>Mei</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Myelin degeneration and diminished myelin renewal contribute to age-related deficits in memory</article-title><source>Nature Neuroscience</source><volume>23</volume><fpage>481</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1038/s41593-020-0588-8</pub-id><pub-id pub-id-type="pmid">32042174</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheeler</surname><given-names>NA</given-names></name><name><surname>Fuss</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Extracellular cues influencing oligodendrocyte differentiation and (re)myelination</article-title><source>Experimental Neurology</source><volume>283</volume><fpage>512</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2016.03.019</pub-id><pub-id pub-id-type="pmid">27016069</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wosik</surname><given-names>K</given-names></name><name><surname>Antel</surname><given-names>J</given-names></name><name><surname>Kuhlmann</surname><given-names>T</given-names></name><name><surname>Brück</surname><given-names>W</given-names></name><name><surname>Massie</surname><given-names>B</given-names></name><name><surname>Nalbantoglu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Oligodendrocyte injury in multiple sclerosis: a role for p53</article-title><source>Journal of Neurochemistry</source><volume>85</volume><fpage>635</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2003.01674.x</pub-id><pub-id pub-id-type="pmid">12694389</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>L</given-names></name><name><surname>Ohayon</surname><given-names>D</given-names></name><name><surname>McKenzie</surname><given-names>IA</given-names></name><name><surname>Sinclair-Wilson</surname><given-names>A</given-names></name><name><surname>Wright</surname><given-names>JL</given-names></name><name><surname>Fudge</surname><given-names>AD</given-names></name><name><surname>Emery</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Richardson</surname><given-names>WD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Rapid production of new oligodendrocytes is required in the earliest stages of motor-skill learning</article-title><source>Nature Neuroscience</source><volume>19</volume><fpage>1210</fpage><lpage>1217</lpage><pub-id pub-id-type="doi">10.1038/nn.4351</pub-id><pub-id pub-id-type="pmid">27455109</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xin</surname><given-names>W</given-names></name><name><surname>Chan</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Myelin plasticity: sculpting circuits in learning and memory</article-title><source>Nature Reviews. Neuroscience</source><volume>21</volume><fpage>682</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1038/s41583-020-00379-8</pub-id><pub-id pub-id-type="pmid">33046886</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>SM</given-names></name><name><surname>Michel</surname><given-names>K</given-names></name><name><surname>Jokhi</surname><given-names>V</given-names></name><name><surname>Nedivi</surname><given-names>E</given-names></name><name><surname>Arlotta</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Neuron class-specific responses govern adaptive myelin remodeling in the neocortex</article-title><source>Science</source><volume>370</volume><elocation-id>eabd2109</elocation-id><pub-id pub-id-type="doi">10.1126/science.abd2109</pub-id><pub-id pub-id-type="pmid">33335032</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>LMN</given-names></name><name><surname>Mao</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>JR</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>QR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Olig2 targets chromatin remodelers to enhancers to initiate oligodendrocyte differentiation</article-title><source>Cell</source><volume>152</volume><fpage>248</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.12.006</pub-id><pub-id pub-id-type="pmid">23332759</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaret</surname><given-names>KS</given-names></name><name><surname>Mango</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Pioneer transcription factors, chromatin dynamics, and cell fate control</article-title><source>Current Opinion in Genetics &amp; Development</source><volume>37</volume><fpage>76</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.gde.2015.12.003</pub-id><pub-id pub-id-type="pmid">26826681</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeisel</surname><given-names>A</given-names></name><name><surname>Muñoz-Manchado</surname><given-names>AB</given-names></name><name><surname>Codeluppi</surname><given-names>S</given-names></name><name><surname>Lönnerberg</surname><given-names>P</given-names></name><name><surname>La Manno</surname><given-names>G</given-names></name><name><surname>Juréus</surname><given-names>A</given-names></name><name><surname>Marques</surname><given-names>S</given-names></name><name><surname>Munguba</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Betsholtz</surname><given-names>C</given-names></name><name><surname>Rolny</surname><given-names>C</given-names></name><name><surname>Castelo-Branco</surname><given-names>G</given-names></name><name><surname>Hjerling-Leffler</surname><given-names>J</given-names></name><name><surname>Linnarsson</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Brain structure. Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq</article-title><source>Science</source><volume>347</volume><fpage>1138</fpage><lpage>1142</lpage><pub-id pub-id-type="doi">10.1126/science.aaa1934</pub-id><pub-id pub-id-type="pmid">25700174</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Sloan</surname><given-names>SA</given-names></name><name><surname>Bennett</surname><given-names>ML</given-names></name><name><surname>Scholze</surname><given-names>AR</given-names></name><name><surname>O’Keeffe</surname><given-names>S</given-names></name><name><surname>Phatnani</surname><given-names>HP</given-names></name><name><surname>Guarnieri</surname><given-names>P</given-names></name><name><surname>Caneda</surname><given-names>C</given-names></name><name><surname>Ruderisch</surname><given-names>N</given-names></name><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Liddelow</surname><given-names>SA</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Daneman</surname><given-names>R</given-names></name><name><surname>Maniatis</surname><given-names>T</given-names></name><name><surname>Barres</surname><given-names>BA</given-names></name><name><surname>Wu</surname><given-names>JQ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex</article-title><source>The Journal of Neuroscience</source><volume>34</volume><fpage>11929</fpage><lpage>11947</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1860-14.2014</pub-id><pub-id pub-id-type="pmid">25186741</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Dong</surname><given-names>C</given-names></name><name><surname>Frah</surname><given-names>M</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Marie</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Koenig</surname><given-names>S</given-names></name><name><surname>Nait-Oumesmar</surname><given-names>B</given-names></name><name><surname>Martin</surname><given-names>DM</given-names></name><name><surname>Wu</surname><given-names>LN</given-names></name><name><surname>Xin</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Parras</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>QR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Dual requirement of CHD8 for chromatin landscape establishment and histone methyltransferase recruitment to promote CNS myelination and repair</article-title><source>Developmental Cell</source><volume>45</volume><fpage>753</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2018.05.022</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Anderson</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Identification of a novel family of oligodendrocyte lineage-specific basic helix-loop-helix transcription factors</article-title><source>Neuron</source><volume>25</volume><fpage>331</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1016/s0896-6273(00)80898-3</pub-id><pub-id pub-id-type="pmid">10719889</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Anderson</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The bHLH transcription factors Olig2 and Olig1 couple neuronal and glial subtype specification</article-title><source>Cell</source><volume>109</volume><fpage>61</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(02)00677-3</pub-id><pub-id pub-id-type="pmid">11955447</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuchero</surname><given-names>JB</given-names></name><name><surname>Fu</surname><given-names>M-M</given-names></name><name><surname>Sloan</surname><given-names>SA</given-names></name><name><surname>Ibrahim</surname><given-names>A</given-names></name><name><surname>Olson</surname><given-names>A</given-names></name><name><surname>Zaremba</surname><given-names>A</given-names></name><name><surname>Dugas</surname><given-names>JC</given-names></name><name><surname>Wienbar</surname><given-names>S</given-names></name><name><surname>Caprariello</surname><given-names>AV</given-names></name><name><surname>Kantor</surname><given-names>C</given-names></name><name><surname>Leonoudakis</surname><given-names>D</given-names></name><name><surname>Leonoudakus</surname><given-names>D</given-names></name><name><surname>Lariosa-Willingham</surname><given-names>K</given-names></name><name><surname>Kronenberg</surname><given-names>G</given-names></name><name><surname>Gertz</surname><given-names>K</given-names></name><name><surname>Soderling</surname><given-names>SH</given-names></name><name><surname>Miller</surname><given-names>RH</given-names></name><name><surname>Barres</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cns myelin wrapping is driven by actin disassembly</article-title><source>Developmental Cell</source><volume>34</volume><fpage>152</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2015.06.011</pub-id><pub-id pub-id-type="pmid">26166300</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80273.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nave</surname><given-names>Klaus-Armin</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a7f6w43</institution-id><institution>Max Planck Institute of Experimental Medicine</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group></front-stub><body><p>This work provides a major contribution to the field of oligodendrogenesis. It is a comprehensive analysis of Tensin3 function and is conceptually novel as it links the fields of transcriptional control in oligodendrocyte lineage cells with morphogenetic changes and integrin signaling-mediated cell survival. Finally, it is also the discovery of a very useful marker for remyelinating oligodendrocytes in disease conditions.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80273.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Nave</surname><given-names>Klaus-Armin</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a7f6w43</institution-id><institution>Max Planck Institute of Experimental Medicine</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p>[Editors' note: this paper was reviewed by <ext-link ext-link-type="uri" xlink:href="https://www.reviewcommons.org/">Review Commons</ext-link>.]</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80273.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p>We thank all reviewers for their positive and encouraging comments and criticisms to improve our work. Here we present a reviewed version of the manuscript according to the comments risen.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Evidence, reproducibility and clarity (Required)):</p><p>This is an interesting paper that identifies Tns3 as a potential effector of oligodendrocytes differentiation based on an ingenious strategy comparing regulatory binding sites of known master regulators of differentiation, and then shows using in vivo genetics that this role is indeed correct. Next, a potential mechanism is identified by showing co-localization with β 1 integrin, known to regulate apoptosis of newly-formed oligodendrocytes. The results are well illustrated and the experiments performed with appropriate power using a broad range of techniques that combine in silico, in vitro and in vivo work to great effect.</p><p>I think this represents an important contribution that will be of significant interest to neuroscientists – the mechanisms regulating oligodendrocytes generation remain poorly understood and the evidence that this contributes to adult learning (adaptive myelination) and CNS regeneration makes this a key question. I would suggest that the following are considered before publication:</p></disp-quote><p>We thank the reviewer for this positive comments and critics to improve the manuscript.</p><disp-quote content-type="editor-comment"><p>The work describing the KO mice that were not used as they proved unsuitable need not be described – it breaks the logical flow.</p></disp-quote><p>In agreement with the reviewer comment, we have reduced this part to a sort paragraph indicating that our analyses of several Tns3 constitutive KO lines showed developmental lethality and possible genetic compensation in Tns3 expression, leading us to conclude them inappropriate tools to study Tns3 function in oligodendrogenesis. We have summarized the data in Figure S7 and the description in the method section.</p><disp-quote content-type="editor-comment"><p>It would be useful to compare the extent of cell death in the Tns3 cKO mice with that described in the alpha6 integrin KO and the integrin beta1 cKO (the Colognato and Benninger papers). Do they match? If not (and I suspect the Tns3 cKO death is greater) could other mechanisms be downstream of the Tns3?</p></disp-quote><p>In agreement with the reviewer comment, we have added the following paragraph to the discussion:</p><p>‘Knockout mice for <italic>integrin-</italic>α<italic>6</italic> present a 50% reduction in brainstem MBP<sup>+</sup> OLs at E18.5, just before they die at birth, accompanied by an increase in TUNEL<sup>+</sup> dying OLs (Colognato et al., 2002). Similarly, conditional deletion of <italic>integrin-</italic>β<italic>1</italic> in immature OLs by <italic>Cnp-Cre</italic> also leads to a 50% reduction in cerebellar OLs at P5, with a parallel increase in TUNEL<sup>+</sup> dying OLs (Benninger et al., 2006). Therefore, given that <italic>Tns3</italic>-induced deletion in postnatal OPCs also leads to 40-50% reduction in OLs in both grey and white matter regions of the postnatal telencephalon (this study), paralleled by similar increase in TUNEL<sup>+</sup> apoptotic oligodendroglia, we suggest that Tns3 is required for integrin-β1 mediated survival signal in immature oligodendrocytes.’</p><disp-quote content-type="editor-comment"><p>I'm not sure why the authors argue that the activation of β 1 would not be informative experiment? This will regulate actin dynamics just as it regulates other integrin signaling pathways.</p><p>Indeed, I would argue that an integrin activation experiments would be a neat way to prove mechanism (as it would be predicted to rescue the Tns3 cKO phenotype).</p></disp-quote><p>In agreement with the reviewer comment, we have removed this sentence: ‘If so, exogenous activation of integrin α6β1 in cultured OPCs by Mn<sup>2+</sup> (Colognato et al., 2004) would not be expected to increase oligodendrogenesis in Tns3-iKO oligodendroglia.’</p><p>In an effort, to understand Tns3 function by acute Tns3-deletion in postnatal OPCs, we have compared the transcriptome of <italic>Tns3-iKO</italic> oligodendroglia compared to control cells, and we present these results in figure 7 pinpointing deregulated genes leading to reduced oligodendroglial differentiation, integrin dysregulation, increase apoptosis, and conflicting cell cycle signaling, and leaving for further studies the full characterization how the loss of Tns3 leads to the deregulation of these processes.</p><disp-quote content-type="editor-comment"><p>Can the authors provide any data on GM oligos and their OPCs? Is the requirement for Tns3 the same, and if so what might the implications be in the adult where new oligodendrocytes are being generated throughout life?</p></disp-quote><p>Indeed, in our analyses of <italic>Tns3-iKO</italic> mice, we provide quantifications of the cortex as a grey matter territory, showing a similar 40-50% reduction in OLs as in white matter areas corpus callosum and fimbria, and mixed regions such as the striatum.</p><disp-quote content-type="editor-comment"><p>I note in S13 that integrin beta1 is not highly expressed in human oligos at the time in question. Does this call into question the relevance for human disease?</p></disp-quote><p>We realize that scRNAseq plots are never easy to interpret but it is important to note that the levels of expression are coded by the intensity of the color scale, while the surface of the dot plots indicate the experimental sensitivity to detect transcript expression in a larger or smaller proportion of the cells in a given cluster/cell type (due to the drop out limitation of current single cell RNA-seq technologies). Considering this, please note that beyond a stronger expression in neural progenitor cells (NPCs, blue color), integrin-b1 (<italic>Itgb1</italic>) transcripts are expressed at medium to high levels (green to blue) in human immature OLs (Figure S13B), similar to their pattern of expression in mouse oligodendroglia (Figure S13A).</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Significance (Required)):</p><p>See above</p><p>Reviewer #2 (Evidence, reproducibility and clarity (Required)):</p><p>In this article, the authors identify and characterise Tensin3 (Tns3) as a target of key oligodendroglial transcription factors driving differentiation in the mouse. They use multiple transgenic models to describe loss of function, and suggest Tns3's action through integrin B1 signalling, with the key function being oligodendroglial survival.</p><p>There is extensive and impressive work here, including identification of Tns3 by ChIPseq, expression of Tns3 in brain development, analysis of human (ES-derived) and mouse scRNAseq to infer timing of expression in the differentiation pathway, generation of V5-tagged Tns3-KI mice to overcome antibody limitations, identification of its expression in mouse remyelination, generation of a new Tns3KO mouse, in vivo Crispr Tns3KO in development, generation of a conditional KO, for deletion in adulthood, and finally some culture work to investigate potential mechanisms of actions.</p><p>The bottom line is that Tns3 is required for survival of OPCs and immature oligodendrocytes in development/remyelination in mouse at least, and loss leads to apoptosis (through p53 increase and loss of integrin-B1 signalling), leading to a failure of proper differentiation.</p><p>The experiments are carefully done, convincing and the tools generated impressive. There is clearly more to be done on clarifying the mechanism of action of Tns3, but I do not think further experiments on this topic are needed for this paper – they can wait for the next.</p></disp-quote><p>We thank the reviewer for the positive and encouraging reviewing comments. In an effort, to understand Tns3 function by acute Tns3-deletion in postnatal OPCs, we have compared the transcriptome of <italic>Tns3-iKO</italic> oligodendroglia compared to control cells, and we present these results in figure 7 pinpointing deregulated genes leading to reduced oligodendroglial differentiation, integrin dysregulation, increase apoptosis, and conflicting cell cycle signaling, and leaving for further studies the full characterization how the loss of Tns3 leads to the deregulation of these processes.</p><disp-quote content-type="editor-comment"><p>My only query is whether the expression of Tns3 is also in immature OLs in human brain (rather than human ES-derived OLs). This should be easily checked with interrogation of online Shiny apps from already published snRNAseq from various groups on human post mortem adult brain, but if not present then in also baby/fetal brain. This would be interesting and may well be different from the ES_derived cells which tend to be very immature and would add interest to the possible translational impact.</p></disp-quote><p>According to the suggestion of the reviewer, we analyzed 69,174 snRNAseq GW9-GW22 from fetal cerebellum,; Aldinger and Miller, 2021; https://doi-org.proxy.insermbiblio.inist.fr/10.1038/s41593-02100872-y, which we present now in Figure S3, finding a cluster of cells expressing iOL markers, including <italic>NKX2-2, TNS3, ITPR2,</italic> and <italic>BCAS1,</italic> similar to the hiPSCs-derived iOL1/iOL2 clusters and mouse iOL1/iOL2 clusters shown in Figure S2<italic>.</italic></p><p>We also analyzed other datasets without finding iOLs given their age or numbers, including:</p><p>– Immunopanned PDGFRA+ cells from human cortex GW20-GW24 (2690 cells, Huang and Kriegstein, Cell 2020) finding OPCs but not iOLs.</p><p>– The recently published dataset from GW8-GW10 human forebrain oligodendroglia (van Brugen and Castelo-Branco, Dev Cell 2022; https://doi.org/10.1016/j.devcel.2022.04.016<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.devcel.2022.04.016">)</ext-link> containing OPCs but not iOLs.</p><p>– The GW17 to GW18 human cortex (40,000 cells, Polioudakis and Geschwind, 2019, https://doi.org/10.1016/j.neuron.2019.06.011<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.neuron.2019.06.011">)</ext-link> containing OPCs but not iOLs.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Significance (Required)):</p><p>This work extends our knowledge of oligodendroglial differentiation, links it to the ECM and provides interest in manipulating this in diseases including glioma.</p><p>My expertise: myelin, oligodendroglia, remyelination, human neuropathology</p><p>Reviewer #3 (Evidence, reproducibility and clarity (Required)):</p><p>See below</p><p>Reviewer #3 (Significance (Required)):</p><p>Using purified oligodendrocytes target genes of key regulators of oligodendrocyte differentiation were analyzed, which led to the identification of Tensin-3. The authors performed a detail characterization of Tensin-3 expression. They found that Tensin-3 is highly expressed in immature mouse and human oligodendrocytes. Interestingly, Tensin-3 is selectively enriched in immature oligodendrocytes, and not present at detectable levels in OPCs and mature oligodendrocytes. Subsequently, the authors characterized Tensin-3 function by a series of knockdown approaches in vitro and in vivo. These series of experiments revealed an essential function of Tensin-3 in supporting oligodendrocytes survival. In the absence of Tensin-3 a large fraction of oligodendrocytes undergo apoptosis while differentiating to mature oligodendrocytes.</p><p>This is a remarkable study applying an impressive array of methods that led to an important discovery in the field of oligodendrocyte biology. The main advances for the field are: (1) identification of a novel marker for premyelinating oligodendrocytes, (2) elucidation of Tensin-3 as a pro-survival factor in oligodendrocytes differentiation, (3) evidence of link of Tensin-3-integrin signal in survival of oligodendrocytes.</p><p>The data is well presented and organized, and the paper well written. I recommend publication with only minor suggestions for a revision:</p></disp-quote><p>We thank the reviewer for this positive comments and critics to improve the manuscript.</p><disp-quote content-type="editor-comment"><p>In Figure 2, only images are shown, and the data is referred to as highly expressed or strong colocalization. Even if the data looks clear, the authors should provide some quantification of the data in the figure.</p></disp-quote><p>We thank the reviewer for his comment and we have now provided a quantification of the fraction of Tns3+ cells expressing different markers of oligodendrocyte lineage progression/stages, and the percentage of each stage expressing Tns3.</p><disp-quote content-type="editor-comment"><p>Figure 3 is given too much weight in the manuscript text. I would recommend to shorten the text in the result section, and to move this figure to the supplement as it does not advance the story. It mainly shows that the KO mice still express transcripts in the brain. Were the transcripts lost in peripheral tissue?</p></disp-quote><p>As mentioned above, in agreement with the reviewers #1 and #3 comments, we have reduced this part to a sort paragraph indicating that our analyses of several Tns3 constitutive KO lines showed developmental lethality and possible genetic compensation in Tns3 expression, leading us to conclude them inappropriate tools to study Tns3 function in oligodendrogenesis. We have summarized the data in Figure S7 and the description in the method section.</p><disp-quote content-type="editor-comment"><p>Page 11: the authors describe in the text how the floxed allele was generated. This should be shifted to the supplement.</p></disp-quote><p>According to reviewers suggestion, we have moved the description of Tns3 floxed allele generation to the Methods section.</p><disp-quote content-type="editor-comment"><p>Page 16: the authors refer to Bcas1 as a problematic marker for immature oligodendrocytes, because the transcript is also expressed in mature oligodendrocytes. The authors are correct that the transcript is expressed in mature oligodendrocytes. However, the proteins changes its localization when oligodendrocytes mature. On protein level, it is valuable and a selective marker, as antibodies only label pre-myelinating and actively myelinating cells. In mature oligodendrocytes, antibodies against Bcas1 do not label the cell, only myelin. The text is misleading and needs to be corrected.</p></disp-quote><p>In agreement with reviewers comment we have modified the text as follows: ‘An optimized protocol for immunodetection using Bcas1-recognizing antibodies has been shown to label iOLs (Fard et al., 2017).’</p></body></sub-article></article>